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THE ROLE OF PROLINE RICH 15 IN TROPHOBLAST CELL DEVELOPMENT 
Maintenance of pregnancy in eutherian mammals requires a sophisticated 
and tightly regulated program of gene expression in order to develop a fully 
functional placenta. This transient organ mediates nutrient and gas exchange 
between the mother and fetus while protecting the fetus from the maternal 
immune system. Deviations from the normal regulation of gene expression during 
early pregnancy can lead to early embryonic loss as well as dysfunctional 
placentation, which can cause significant maternal and fetal morbidity and 
mortality. Proline rich 15 (PRR15) is a low molecular weight nuclear protein 
expressed by the trophoblast during early gestation in several mammalian 
species, including humans, mice, cattle, sheep, and horses. 
Immunohistochemistry revealed localization of PRR15 to the trophectoderm and 
extraembryonic endoderm of day 15 sheep conceptuses. In humans, PRR15 is 
localized in the nuclei of both first and second trimester trophoblast cells. 
Additional research has shown increased PRR15 transcription in colorectal 
cancers with mutations in the adenomatous polyposis coli (Apc) protein, 
suggesting a link to the Wnt signaling pathway. PRR15 mRNA concentrations 
increase when trophoblast cells, both sheep (oTR) and human (ACH-3P), are 
cultured on Matrigel, a basement membrane matrix. The expression profile in the 
sheep conceptus during pregnancy revealed a rise in PRR15 mRNA 
concentrations during the period of conceptus elongation with a peak in 
expression at day 16 of gestation, followed by a decline to day 30 of gestation. 
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This peak coincides with a halt in elongation of the conceptus, and the initial 
period of apposition to the uterine luminal epithelium. Lentiviral-mediated 
knockdown of PRR15 in ovine trophectoderm at the blastocyst stage led to 
demise of the embryo by day 15 of gestation. This provides compelling evidence 
that PRR15 is a critical factor during this precarious window of development 
when initial attachment and implantation begin.  
The first aim of this research was to determine the effect of PRR15 
deficiency on trophoblast gene expression, as well as trophoblast proliferation 
and survival. The human first trimester trophoblast cell line, ACH-3P, was 
infected with control lentivirus (LL3.7) and lentivirus expressing a short hairpin 
(sh)RNA to target PRR15 mRNA for degradation, resulting in a 68% decrease in 
PRR15 mRNA (p<0.01). Microarray analysis of these cell lines revealed 
differential expression of genes related to cancer, focal adhesion, and p53 
signaling. We selected 21 genes for validation of mRNA levels by quantitative 
real-time RT-PCR, 18 (86%) of which gave results consistent with the microarray 
analysis, with similar direction and magnitude fold changes. This included 
significant up-regulation of GDF15, a cytokine increased in pregnancies with 
preeclampsia. GDF15 mRNA concentrations were examined more extensively 
during early ovine gestation, which revealed that GDF15 was low during peak 
PRR15 expression, then increased significantly at day 30 when PRR15 was 
nearly undetectable. Proliferation, as measured by cell metabolic activity and 
bromodeoxyuridine (BrdU) uptake, decreased in the PRR15-deficient cells, which 
was consistent with a decrease observed in cell cycle-related genes CCND1 and 
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CDK6, and an increase in CCNG2 and CDKN1A in the PRR15-deficient cells. 
TNFSF10, a tumor necrosis factor superfamily member known to induce 
apoptosis, and its receptor, TNFRSF10b, increased significantly in the PRR15-
deficient cells, suggesting trophoblast cells may be more susceptible to apoptosis 
when depleted of PRR15. Assays for caspase activity and annexin V staining 
revealed an increased population of apoptotic cells when treated with shRNA to 
target PRR15. These results suggest that PRR15 is required for driving 
trophoblast proliferation and survival during early development of the placenta, 
functions that are critical to early embryonic survival and successful placentation. 
The second experimental aim was to examine regions of the PRR15 
promoter that are necessary for regulating its expression in trophoblast cells and 
to identify the role of Wnt signaling in PRR15 transcription. The 5’-flanking 
sequences from -824, -640, -424, -326, and -284 bp to +7 bp relative to the 
annotated transcription start site were amplified by PCR and ligated into the 
pGL3-Basic plasmid. These vectors were co-transfected into the first trimester 
human trophoblast cell line, ACH-3P, HT29 (human colorectal carcinoma), oTR, 
and BHK-21 (hamster kidney fibroblast) cells with a RSV-β-galactosidase vector 
control. In ACH-3P cells, transactivation of the luciferase reporter was maximal 
following transfections with the -326 construct (15.4 ± 4.8-fold). Significant 
promoter activity was absent in the -284, -424, and -640 constructs, but regained 
with the -824 construct (14.8 ± 5.8-fold). These results suggest that cis-acting 
elements within the proximal promoter of the PRR15 gene are essential for 
expression in trophoblast cells, requiring the regions from -284 to -326 and -640 
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to -824. DNase I footprinting and electrophoretic mobility shift assays were 
performed to identify transcription factor binding sites within these regions. Due 
to the potential link to the Wnt signaling pathway, cells were treated with an 
inhibitor to GSK3β, the kinase responsible for phosphorylation and proteasomal 
degradation of β-catenin. Inhibition of GSK3β decreased PRR15 mRNA 
concentrations and decreased transactivation of the luciferase reporter in all 
proximal promoter reporter constructs; this effect was mediated through β-
catenin activity in the proximal 284 bases of the PRR15 5’-flanking region. 
Furthermore, trophoblast cell proliferation decreased after treatment with the 
GSK3β inhibitor. Electrophoretic mobility shift assays on the region from -98 to -
68 revealed differential binding of nuclear proteins derived from ACH-3P cells 
grown in the presence or absence of the GSK3β inhibitor. These results reveal 
that canonical Wnt signaling inhibits the transcription of PRR15, mediated in part 
through the -98 to -68 region of the 5’-flanking region, and decreases proliferation 
in trophoblast cells. This indicates that suppression of Wnt signaling may be 
crucial during early trophectoderm outgrowth in order to allow significant 
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CHAPTER I – Introduction 
Eutherian mammals have developed a unique system in which the 
placenta allows for prolonged intrauterine fetal growth and development. This 
transient yet vital organ develops from a single layer of cells on the outside of the 
early embryo, the trophectoderm. The placenta facilitates nutrient and waste 
exchange between the mother and fetus while protecting the allogeneic fetus 
from the maternal immune system. Though the morphology of this organ varies 
widely across species, these functions are conserved. The mature placenta 
represents an intimate and complex connection between cells of maternal and 
fetal origin. The development of this organ from a single layer of cells requires a 
tightly regulated program of gene expression from the differentiating 
trophectoderm. Deviations from this program during early placental development 
can lead to a variety of issues for both the mother and the developing embryo. 
The most dramatic consequence of dysfunctional placental development 
is early embryonic loss due to failed implantation. This is a common issue in both 
human and animal reproduction. Increasing cases of early pregnancy loss and 
recurrent miscarriage cause substantial emotional hardship for couples trying to 
conceive. In our food animal species, early embryonic losses lead to significant 
costs for producers, threatening the viability of the animal agriculture industry. 
Though complete failures of implantation lead to embryonic loss, dysfunctional 
trophoblast development during early placentation may cause placental 
insufficiency which can lead to intrauterine growth restriction or preeclampsia. 
Some cases of intrauterine growth restriction and preeclampsia are attributed to 
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dysfunctional placentation during the first trimester; these pregnancy 
complications not only cause increased maternal and fetal morbidity and 
mortality, but also increase the risk of adult-onset diseases in these children. 
Placental insufficiency in agricultural species leads to increased fetal losses as 
well as decreased viability and growth of offspring, again increasing costs for 
producers. Enhancing our understanding of the regulation of implantation and 
early placental development will pave the way for therapeutic interventions in 
cases of placental insufficiency. Furthermore, increasing reproductive efficiency 
in our agricultural species will help to maintain an affordable and sustainable food 
supply in the face of a growing world population. 
The focus of this research is the gene Proline rich 15 (PRR15), which 
appears to have a crucial function during early pregnancy. PRR15 is expressed 
by the trophectoderm of elongating sheep conceptuses, as well as first and 
second trimester human trophoblast cells. The mRNA and protein are well 
conserved among several mammals, suggesting a similar function across 
species. In the sheep, PRR15 expression increases during conceptus elongation, 
a period of rapid trophoblast outgrowth and proliferation. At the point of 
conceptus attachment, the mRNA concentration peaks and then diminishes while 
the trophoblast and endometrium begin to form intricate connections that will 
become functional placentomes. Its purpose during placental development is not 
known; however, deficiency of PRR15 in elongating sheep conceptuses leads to 
embryonic demise prior to conceptus attachment. The spatial and temporal 
pattern of expression and the dramatic consequence of PRR15 deficiency in vivo 
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suggest an essential function of PRR15 during early placental development. The 
aims of these experiments were two-fold. First, determine the effect of PRR15 
deficiency on trophoblast gene expression and function in order to elucidate the 
role of PRR15 during normal placental development. Second, determine the 
transcription factors and signaling pathways that regulate transcription of PRR15 
and lead to the strict window of expression during trophoblast elongation and 
attachment. Though focusing on a single gene may seem myopic, the 
demonstrated necessity for PRR15 during early embryonic growth suggests it 
plays a critical role in this developmental window. Understanding the upstream 
regulators of its transcription, as well as the downstream effects of its presence 




CHAPTER II – Review of Literature 
Placentation in the Human 
Placental Dysfunction 
Carrying a fetus to term requires an intimate connection between mother 
and fetus, which is mediated through the placenta. The period of implantation 
and early placental development is the most precarious time for the developing 
embryo. Only 50-60% of conceptions survive to twenty weeks of gestation; the 
majority of these early pregnancy losses are due to a failure of implantation.1 
Chromosomal abnormalities account for a portion of these spontaneous 
abortions, but leave a number of cases without an etiology.2 Recurrent 
miscarriage, defined as three or more consecutive spontaneous miscarriages, 
affects 1-3% of women of reproductive age.3 Risk factors for recurrent 
miscarriage include genetic and physiologic disorders that lead to deficient 
placental development.4 The control of trophoblast invasion into maternal tissues 
is crucial for a successful pregnancy outcome. Excessive trophoblast invasion 
can lead to attachment of the placenta to the myometrium, termed placenta 
accreta, or to invasion into the uterine serosa and adjacent organs, termed 
placenta percreta.5 Conversely, placental disorders such as preeclampsia and 
some cases of intrauterine growth restriction are attributed to insufficient 
trophoblast invasion.6,7  
Preeclampsia is a complication in 4-8% of pregnancies in the United 
States, and up to 10% of pregnancies in the developing world.8 The majority of 
cases occur in healthy nulliparous individuals, though mothers with diabetes, 
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chronic hypertension, or multi-fetal gestations are more likely to develop the 
disorder. It is a leading cause of maternal and perinatal morbidity and is 
associated with a 20-fold increase in perinatal mortality.9 Up to 20% of maternal 
deaths in the United States are attributed to complications from preeclampsia.10 
Severe preeclampsia is often associated with intrauterine growth restriction 
(IUGR), which itself is a cause of significant perinatal morbidity and increases the 
likelihood for development of adult disease.11 IUGR is the second leading cause 
of perinatal mortality and morbidity, affecting about 5% of all pregnancies.12 The 
only known cure for preeclampsia is delivery of the placenta and fetus. Preterm 
birth (birth prior to 37 weeks gestation) accounts for more than two thirds of 
perinatal deaths.13 Preterm delivery, often due to complications of preeclampsia, 
IUGR, or pregnancy-induced hypertension, costs the United States upwards of 
26.2 billion dollars per year.14 The rate of preeclampsia in the United States is 
increasing, possibly due to the rising incidence of predisposing causes such as 
chronic hypertension, obesity and diabetes.15 Increasing use of assisted 
reproductive technologies (ART) such as in vitro fertilization leads to 2.7 times 
higher risk of preeclampsia.16 Not only does preeclampsia increase maternal and 
prenatal morbidity and mortality, it is also an indicator of increased risk for future 
cardiovascular disease for the mother.17 The growing rates of obesity and 
diabetes and the rising rate of ART call for advancing our understanding of these 
costly and significant diseases. 
Preeclampsia is defined as the occurrence of hypertension and proteinuria 
during the second half of gestation. During normal placentation, trophoblast cells 
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invade the decidual segments of maternal spiral arteries, replacing maternal 
endothelium in the distal portions of the vessels, and extending into the 
myometrial segments.18 The definitive cause of preeclampsia is unknown, though 
preeclamptic placentas at term are characterized by incomplete invasion of 
maternal spiral arteries by trophoblast cells. Though clinical diagnosis of 
preeclampsia does not occur until mid-gestation, most researchers believe the 
disorder originates with deranged or incomplete placentation during the first 
trimester.  
Studying the pathogenesis of severe preeclampsia and intrauterine growth 
restriction presents three major challenges. First, the shallow trophoblast 
invasion characteristic of these disorders occurs during the first trimester, yet 
clinical signs are normally not apparent until after 20 weeks of gestation. 
Individuals destined to develop preeclampsia cannot be identified until after the 
critical period of trophoblast invasion and spiral artery remodeling. Identifying 
markers for predicting preeclampsia prior to the onset of clinical signs is the 
subject of much research.19,20,21,22 Identifying growth restricted fetuses requires 
repeated measurements by ultrasound to determine the fetal growth curve, which 
is not performed in standard cases. The second major challenge is that 
spontaneous preeclampsia does not occur in other species, including nonhuman 
primates. Though growth restriction has been observed in a number of 
mammalian species, the mechanisms that underlie this phenotype likely vary as 
do placental structures across species. A number of animal models have been 
developed, but the capacity of these models to embody all of the changes of 
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human preeclampsia and IUGR is not likely, especially considering the distinctive 
architecture of the human placenta. Though many models demonstrate some of 
the key features of preeclampsia, no animal model can truly recapitulate the 
pathogenesis of this specifically human disease. The final challenge is the 
heterogeneity of these disorders, and the frequency with which they appear in 
conjunction with other pregnancy complications. IUGR occurs in 5-18% of 
pregnancies complicated by preeclampsia, and most frequently in association 
with early-onset disease.23,24 Although women with obesity, diabetes, and 
multiple gestations are predisposed to develop preeclampsia, the majority of 
cases occur in healthy, nulliparous individuals. Pathologic changes specific to 
preeclampsia may be obscured by these complicating factors. Huppertz suggests 
that dysregulation of syncytiotrophoblast development leads to preeclampsia, 
while dysregulation of cytotrophoblast development leads to IUGR, and a 
combination of the two results from impaired early trophoblast development.25 
Clarifying the regulation of early trophoblast development may aid in our 
understanding of these disorders, and possibly reveal areas in which we can 
intervene clinically.  
From Fertilization to Implantation  
After fertilization, the trophectoderm is the first lineage to differentiate in 
the human embryo between the morula and blastocyst stage. The blastocyst, 
made up of the inner cell mass surrounded by a single layer of mononucleated 
trophoblast cells, hatches from the zona pellucida by day 6-7 post-conception 
and attaches to the uterine epithelium to initiate implantation.26 The trophoblast 
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cells in contact with the endometrium proliferate and fuse to form the early 
syncytiotrophoblast, a multinucleated syncytium. By day 8 after conception, 
vacuoles form within the syncytiotrophoblast layer, which later expand and form 
lacunae. The lacunae are separated by columns of syncytiotrophoblast called 
trabeculae. Cytotrophoblast cells continue to proliferate, expand, and branch 
from the trabeculae, forming primary villi.27 As early as day 12 post-conception, 
trophoblast cells erode maternal capillaries and release the first maternal blood 
cells into the lacunar space.28 From 3-6 weeks of pregnancy, the placenta 
outweighs the fetus by more than five times and acts as a surrogate for various 
fetal organs. The fetus does not outgrow the placenta until after the first trimester 
as the fetal organs develop and begin to function.29 During these initial weeks, 
maternal-fetal nutrient and gas exchange is at a minimum until a more dramatic 
remodeling of maternal vasculature occurs.  
As pregnancy progresses, cytotrophoblast cells continue to proliferate in 
the expanding placenta. Anchoring villi are derived from the initial trabeculae and 
stretch across the entire trophoblast layer. Clusters of proliferative extravillous 
trophoblast cells form trophoblastic cell columns at the terminal ends of 
anchoring villi.30,31,32,33 Spiral arterioles are plugged by clumps of extravillous 
trophoblast cells from 5-10 weeks of gestation, leading to a hypoxic state which 
promotes trophoblast proliferation.34 From 11-14 weeks, the endovascular plugs 
open up, leading to a rapid increase in placental oxygen tension which triggers 
trophoblast differentiation.35,36 A subpopulation of these cells differentiates into 
the invasive extravillous trophoblast. The type of invasion can be divided into two 
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categories: interstitial invasion, where trophoblast cells invade the entire 
endometrium and inner third of the myometrium, and endovascular invasion, 
where trophoblast cells invade maternal vasculature and replace maternal 
endothelium.37 Endovascular trophoblast cells aid in the transformation of spiral 
arterioles from low flow, high resistance to high flow, low resistance vessels 
which support the growing fetus.  
After the maternal vasculature has been remodeled, the lacunar spaces 
become the intervillous space. The intervillous space fills with maternal blood to 
bathe the syncytiotrophoblast layer, where nutrient and gas exchange occurs. 
The syncytiotrophoblast is also responsible for the production of hormones 
required for maintenance of pregnancy, such as human chorionic gonadotropin 
and progesterone. Maternal blood is separated from fetal blood by a layer of 
syncytiotrophoblast, the underlying regenerative cytotrophoblast, a basal lamina, 
connective tissue derived from the extraembryonic mesoderm, and the fetal 
endothelium.28 The surface area for maternal-fetal exchange is maximized by 
multiple branching villi which protrude into the intervillous space, known as 
floating villi.38 From the first trimester through the end of pregnancy, the placenta 
remains a dynamic and active organ. The dramatic architectural transformations, 
however, are by and large completed in the first trimester. The placenta grows in 
volume at a much slower rate than the fetus, which at birth outweighs the 
placenta by over seven times. The villous surface area per gram of placenta 
increases until term due to continuous growth and remodeling of the villous 
trees.39 During the third trimester, the number of intermediate and terminal villi 
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increases, increasing the surface area available for maternal-fetal exchange.40 
Proper placental development during the first trimester is crucial for maintenance 
of pregnancy to term as well as fetal and maternal health.  
Trophoblast Differentiation 
All trophoblast cell subtypes arise from the trophectoderm that first 
differentiates in the developing embryo (Figure 1). Both the syncytiotrophoblast 
and the extravillous trophoblast cells are derived from a progenitor population of 
cytotrophoblast cells. The non-proliferative, multinucleated syncytiotrophoblast 
develops from the fusion of cytotrophoblast cells, and grows throughout gestation 
by continued fusion of the underlying cytotrophoblast layer. The 
syncytiotrophoblast is in direct contact with maternal blood, and is responsible for 
placental hormone production as well as maternal-fetal exchange and immune 
tolerance.41 Extravillous trophoblast cells begin to invade the uterine stroma from 
the ends of anchoring villi. These cells exit the cell cycle and stop proliferating as 
they migrate away from the basal plate and into the maternal tissue.42 They are 
responsible for the remarkable remodeling of uterine vasculature that allows 





Figure II-1. Human trophoblast differentiation from trophectoderm. 
Differentiation into these trophoblast subtypes is controlled by a variety of 
factors, including oxygen tension, growth factors, cytokines, cell-to-cell and cell-
to-extracellular matrix interactions. From 8-10 weeks of gestation, oxygen tension 
in the placenta is low relative to endometrial levels as cytotrophoblast cell 
columns occlude spiral arteries. From 10-12 weeks, the spiral artery plugs open, 
causing a significant increase in placental partial pressure of oxygen.43 Oxygen 
tension influences the expression of transcription factors such as glial cell 
missing factor 1 (GCM1) and Hash-2, which stimulate or inhibit, respectively, 
syncytial fusion.44 These transcription factors and others initiate changes in gene 
expression required for trophoblast differentiation. Hypoxia inhibits trophoblast 
cell fusion, as assessed by staining for desmoplakin and E-cadherin, and 
differentiation, as measured by hCG secretion and hPL expression in vitro.45 In 
BeWo cells, decreased cell fusion and differentiation due to hypoxia led to 
significant changes in protein expression.46  
Two hypotheses exist in regards to the effect of hypoxia on differentiation 












hypoxia promotes trophoblast proliferation, both in vivo, measured by mitotic 
index, and in vitro in villous explants and first trimester trophoblast cells. A 
smaller body of research demonstrates increased trophoblast invasion in a low 
oxygen environment, suggesting differentiation into the extravillous subtype.47 
The differences observed may be attributed to a range of oxygen concentrations 
in hypoxic conditions as well as different cellular models, such as villous explants 
and transformed first trimester trophoblast. The interpretation of villous explant 
outgrowth has been attributed to both proliferation and invasion, giving conflicting 
results in these types of experiments.48,49 Immunostaining with proteins specific 
for proliferation or for extravillous trophoblast cells could help clarify the effect of 
hypoxia on this differentiation pathway. 
One of the initial steps toward syncytialization is the redistribution of 
phosphatidylserine from the inner to the outer leaflet of the plasma membrane.50 
Treating JAR cells with monoclonal antibodies against phosphatidylserine 
inhibited cell fusion, suggesting that externalization of these molecules is 
required for cell fusion.51 The initiation of this flip may be regulated by initiator 
caspases, proteases involved in apoptosis. Blocking caspase-8 activity using 
antisense oligonucleotides and peptide inhibitors decreased trophoblast fusion in 
villous explants.52 Expression of fusogenic proteins such as syncytin-1 (HERV-
W), syncytin-2 (HERV-FRD), connexin 43,53 cadherin 11,54 and CD9855 is also 
required for trophoblast cell fusion. Galectin-1 also stimulated BeWo and villous 
trophoblast cell fusion.56 The mechanism for determining which cells in the 
cytotrophoblast later will fuse into the growing syncytiotrophoblast and the 
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regulation thereof is not clear. It is evident that expression of specific fusogenic 
proteins and exit from the cell cycle are necessary for syncytialization. Syncytin-1 
expression is decreased in placentas and cultured trophoblasts from pregnancies 
complicated by preeclampsia and IUGR; in addition, these trophoblasts exhibit 
impaired cell fusion, increased apoptosis, and decreased expression of hCG.57 
Vargas et al. observed a correlation between decreased expression of syncytin-1 
and syncytin-2 and the severity of preeclampsia symptoms, with syncytin-2 being 
more severely impaired in preeclampsia.58 It is clear that activation of a specific 
repertoire of genes is required for the process of syncytialization. 
Differentiation into the invasive extravillous trophoblast requires increased 
expression of matrix metalloproteinases (MMPs) in order to degrade the maternal 
extracellular matrix. Increased expression of MMPs is commonly used as an 
indicator of differentiation into extravillous trophoblast cells. The precise 
regulation of extravillous trophoblast invasion is critical for successful 
placentation. Insufficient invasion can lead to placental oxidative stress and 
decreased nutrient exchange to the fetus, while unchecked invasion can lead to 
placenta accreta or choriocarcinoma. Cytokines expressed by placental stromal 
cells, trophoblast cells, and decidual cells influence trophoblast invasion. 
Treatment with hepatocyte growth factor (HGF) increased trophoblast invasion in 
vitro, while knocking out HGF in the mouse led to embryo demise due to 
impaired labyrinth development.59,60 Leukemia inhibitory factor (LIF) , originating 
primarily from the endometrium, increases trophoblast invasion by enhancing 
trophoblast adhesion to the extracellular matrix, though it does not affect MMP 
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expression.61 Treatment of extravillous trophoblast cells with human placental 
growth hormone stimulated invasiveness.62 Treatment with forskolin and 
epidermal growth factor (EGF) significantly increased invasiveness and secretion 
of matrix metalloproteinase (MMP)-2 and MMP-9 in primary first-trimester 
trophoblast cells.63 On the other hand, treatment of trophoblast cells with 
transforming growth factor beta (TGFβ1) promotes intercellular adhesion while 
decreasing invasion: expression of MMP-9 decreased with TGFβ1 treatment 
while E-cadherin and β-catenin were up-regulated.64,65 Inhibitor of DNA binding 
proteins (Id)-2 is down-regulated as trophoblast cells differentiate into the 
invasive subtype; cells that constitutively express Id-2 retain characteristics of 
undifferentiated cells, such as cyclin B expression.66 The regulation of 
trophoblast differentiation and invasion is clearly multifactorial and requires a 
complex repertoire of genes expressed in an ordered timeframe.  
Preeclampsia is characterized by shallow cytotrophoblast invasion, and 
has been associated with an increased population of immature, more proliferative 
trophoblast cells.67 The lack of invasion is correlated with impaired differentiation 
and decreased expression of markers of the invasive phenotype.68 As 
cytotrophoblasts differentiate into the invasive extravillous trophoblast, the 
expression of proliferation markers decreases.69,70 Low molecular weight heparin, 
used clinically for the prevention of pregnancy loss, enhances MMP expression 
and increases invasiveness of trophoblast cells.71 In addition, heparin and IGF-II 
decreased trophoblast apoptosis in primary first-trimester trophoblast cells and 
may contribute to trophoblast survival during this timeframe.72 Determining 
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additional factors and regulatory networks involved in trophoblast differentiation 
could aid in the treatment of placental disorders such as preeclampsia, IUGR, 
and recurrent miscarriage.  
In vitro Models of Trophoblast Function 
Manipulation of placental gene function in vivo is problematic, particularly 
in humans. Though methods for in vivo trophoblast-specific gene knockdown 
have been developed for rodents as well as ruminants, these types of 
experiments are not feasible in humans.73,74,75,76 Various approaches to 
circumvent these issues while still providing data relevant to the true physiologic 
state have been developed. Methods relevant to the first trimester of human 
pregnancy include the use of placental villous explants, chorionic villus samples, 
primary trophoblast cells and immortalized trophoblast cell lines.  
Founds et al. used chorionic villus (CV) samples to evaluate gene 
expression in normal and preeclamptic pregnancies by microarray analysis.77,78 
Forty percent of the differentially expressed genes were identified previously in 
susceptibility loci for preeclampsia.79 However, of the 36 genes found to be 
differentially expressed, none of them matched the eight differentially expressed 
genes identified in a nearly identical study of preeclamptic versus normal CV 
samples.80 This may be due to very small sample sizes in both studies, and the 
heterogeneity of the sample populations. Using CV samples to study first 
trimester trophoblast gene expression has several major drawbacks. First, CV 
sampling is not without risk, with a 0.33% rate of pregnancy loss, and is only 
indicated for women of advanced maternal age (>35 years).81 Because of the 
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risks, obtaining the required samples for an un-biased analysis is challenging and 
time-consuming. Second, there is a very limited amount of tissue obtained from 
the procedure, the majority of which is used for prenatal genetic screening of the 
fetus. Third, the tissue obtained from a CV sample is a mixture of cell types, 
including mesenchymal and trophoblast cells. A recent study suggests the cells 
obtained from CV samples represent the villus mesenchymal core originating 
from the inner cell mass rather than from the trophectoderm.82 Thus, gene and 
protein expression in CV samples may not be representative of trophoblast, and 
may simply reveal changes in mesenchymal cell expression. The limited sample 
size of this study warrants further testing of the embryonic origin of CV samples, 
but it illuminates an essential point about the heterogeneous cellular nature of the 
placenta. Although relevant to placental growth and development, fetal 
mesenchymal cells do not play a direct role in remodeling the maternal 
vasculature as do trophoblast cells.  
The in vitro models that likely best approach the in vivo condition are 
placental villous explants and primary trophoblast cells. First-trimester placental 
explants are obtained from elective pregnancy terminations. The cellular 
architecture of the villus is maintained with the presence of fetal stromal, 
endothelial, and immune cells in addition to villous trophoblast cells. When 
cultured on collagen I or Matrigel, an extracellular matrix, explants can be used to 
study the effects of oxygen tension and growth factors on trophoblast 
proliferation and invasive capacity.83,84 Hypoxic conditions which mimic the low 
blood flow prior to 10 weeks of gestation promote trophoblast proliferation in 
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villous explants.85 There is some evidence for successful manipulation of gene 
expression in placental explants by delivery of siRNA using electroporation with a 
nucleofector.86 Though they may closely mimic villous development in vivo, there 
are several disadvantages to explant culture. The observation of villous 
outgrowth on an extracellular matrix has been labeled as both invasion and 
proliferation, leading to mixed interpretations of these types of experiments. 
Differences in culture media, matrices or substrates, oxygen tension, and 
methods of collection make it difficult to accurately compare one experiment to 
the next. In addition, a number of placentas will not produce outgrowths87; these 
placentas may have spontaneously aborted or may have developed placental 
insufficiency if allowed to mature in vivo. The lack of early biomarkers for 
preeclampsia and intrauterine growth restriction makes differentiating normal 
from pathologic samples nearly impossible in the first trimester. 
Primary trophoblast cells can be isolated from first-trimester placentas and 
grown in culture for a limited amount of time due to replicative senescence. 
When grown on plastic, these cells rapidly exit the cell cycle, syncytialize, and 
degenerate within 5 days,88,89 whereas culturing on a basement membrane 
matrix stimulates differentiation into invasive extravillous trophoblast cells.90 High 
interplacental variability and diverse isolation and culture protocols lead to wide-
ranging and sometimes conflicting results from experiments with these cells.91 
Oxygen tension clearly plays a role in gene expression and behavior of primary 
trophoblast cells, just as in explants. While culturing primary trophoblasts in 
various levels of oxygenation, Oh et al. found that none of the conditions tested 
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mimicked the changes in gene expression observed in placentas from growth-
restricted pregnancies, suggesting significant weaknesses in this particular 
model system for studying intrauterine growth restriction.92 The methods of 
isolation, culture medium, and substrate have a profound impact on the 
differentiation of these cells in culture.93 The principal drawbacks of both primary 
cells and explants are the limited time they can be cultured, the diversity of 
culturing and experimental conditions, and the difficulty of manipulating gene 
expression using RNA interference. 
The use of trophoblast cell lines in vitro provides an alternative that can be 
easily manipulated and reproduced. Several trophoblast cell lines have been 
developed using various techniques; those commonly referenced are shown in 
Table 1.94 Cytokeratin-7 (CK-7) is commonly associated with trophoblast-specific 
expression, and is not normally expressed in other placental or uterine cells.95,96 
HTR-8/SVneo cells are a first trimester trophoblast transformed with SV40 large 
T antigen using electroporation; these cells stain positive for cytokeratin and 
express human chorionic gonadotropin (hCG).97 They have frequently been used 
for in vitro invasion assays, and are thought to represent extravillous trophoblast 
cells, though some debate this supposition. Though they express CK-7, there are 
mixed results as far as their expression of human leukocyte antigen G (HLA-G), 
discussed in more detail below. SGHPL-4 (MC4) cells were developed by 
transfecting primary first trimester trophoblast cells with SV40 large T antigen 
using poly-L-ornithine. Trophoblast origin was verified by the expression of 
placental lactogen, pregnancy specific protein, and hCG.98 ACH-3P cells 
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represent a fusion of primary first trimester trophoblasts (12 weeks) with a human 
choriocarcinoma cell line (AC1-1), which is a mutant derivate of the JEG-3 
choriocarcinoma.99 ACH-3P cells have a mixed population of human leukocyte 
antigen G (HLA-G) negative (60%) and HLA-G positive (40%) cells, which can be 
separated by flow cytometry; the HLA-G negative cells represent cytotrophoblast-
like cells, while the HLA-G positive cells represent a population of extravillous 
trophoblast-like cells.100 Swan-71 cells are a primary first trimester trophoblast 
infected with human telomerase reverse transcriptase (hTERT); they express 
cytokeratin-7, vimentin, and secrete low levels of hCG.101 There are mixed 
results as far as their positivity for HLA-G expression. HLA-G is a marker specific 
for extravillous trophoblast cells, often used for sorting these cells from a mixed 
population.102 Several antibodies are available for HLA-G, and some may cross-
react with additional members of HLA class I molecules, such as HLA-A and 
HLA-B which are ubiquitously expressed.103 When the specificity of HLA-G 
antibodies was validated, it appears both hTR-8 and Swan-71 cells do not 
express HLA-G, and thus may not be representative of extravillous 
trophoblast.103 TEV-1 cells are primary first-trimester cells that were transformed 
by lentiviral infection with human papillomavirus type 16 (HPV16) E6/E7 genes. 
They express cytokeratin-7 and secrete MMP-2 and MMP-9.104 BeWo cells were 
established from a cerebral metastasis of a human choriocarcinoma that was 
maintained in a hamster cheek pouch until Pattillo and Gey developed a method 
for sustaining these cells in culture.105 HLA-G transcripts are present in BeWo 
cells, although the protein was only detected in JEG cells, which represent a later 
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passage of this choriocarcinoma.106,107 An increase in cyclic AMP caused by 
treatment with forskolin causes BeWo cells to syncytialize in vitro; these cells 
have become a valuable and widely used model for the regulation of 
syncytialization.108 
Table II-1. Selection of human trophoblast cell lines.  
Blank cells indicate that data is not available. CK-7 = cytokeratin-7, hCG = 




CK-7 hCG HLA-G 
hTR-8 / SVneo + + +/- Graham et al. 1993 (97) 
SGHPL-4 - +  Choy & Manyonda 1998 (98) 
ACH-3P + + +/- Hiden et al. 2007 (100) 
Swan-71 + + +/- Straszewski-Chavez et al. 2009 (101) 
TEV-1 +  + Feng et al. 2005 (104) 
BeWo + + - Pattillo & Gey 1968 (105) 
The ability of any of these cell lines to recapitulate the in vivo condition 
has been called into question. A microarray analysis comparing several 
choriocarcinoma and SV40 large T antigen-transformed cells to primary villous 
and extravillous cytotrophoblasts revealed distinct gene expression profiles for 
the different cell types.109 In this comparison, the authors plated the extravillous 
cytotrophoblasts on a basement membrane matrix (Matrigel), while all other cell 
types were grown on plastic culture dishes. These culture conditions alone could 
cause a significant alteration of gene expression in any cell type, as evidence 
demonstrates that interaction with an extracellular matrix induces both 
phenotypic and gene expression changes in trophoblast cells.110,111,112 Novakovic 
et al. showed that DNA methylation increased in immortalized cell lines as 
compared to primary trophoblast cells, which correlated with decreased global 
gene expression after transformation.113 Unfortunately, culture substrates varied 
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with each cell type, which could confound any resulting changes in methylation 
status and gene expression. These studies demonstrate the difficulty of 
interpreting results of experiments with explants and trophoblast cells, with such 
a wide variety of techniques and cell lines available. Attempts have been made to 
isolate human trophoblast stem cells, with some recent success.114 The utility of 
these cells in culture and the similarity of their behavior to primary cells remain to 
be seen. 
In spite of many recent advances in trophoblast culture systems, every in 
vitro model lacks the capacity to fully mimic the complex interplay among the 
array of cell types interacting in vivo.115 Careful scrutiny of in vitro studies is 
necessary in order to decipher the changes most relevant to the true condition. 
Ideally, phenotypes observed in trophoblast cell lines would be validated in 
primary cells; however, restricted access to these cells limits their availability for 
study. The combination of animal models, cell culture experiments in 
immortalized and primary cells, and the occasional genetic mutation identified in 
a population will bring us closer to understanding this complex and critical period 
of development. 
Our current knowledge of human placental development is a result of data 
from sampling actual pregnancies to experiments on trophoblast cells in vitro to a 
plethora of animal models. Animal models are a valuable tool for assessing gene 
function in vivo. When it comes to placental development, understanding the 
similarities and differences between the model of choice and the human placenta 
are critical to interpreting resulting data. This transient yet essential organ 
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exhibits surprising diversity across all eutherian mammals. Rodents are the most 
commonly used model for research purposes due to the low cost of maintenance 
and the relative ease of genetic manipulations. As in the human placenta, the 
separation between maternal and fetal blood is described as hemochorial with 
trophoblast cells in direct contact with maternal blood.116 The disadvantages are 
that they are a litter-bearing species, they are too small to catheterize for 
repeated sampling, fetal growth is not complete until after birth, and implantation 
occurs within hours after fertilization.117,118 Certain non-human primates exhibit 
placentation very similar to humans, but the cost of maintenance and ethical 
concerns limit their use in research. Ruminants provide a larger and more easily 
maintained animal model in which catheters can be placed for repeated sampling 
during pregnancy, allowing for a more comprehensive analysis of placental and 
fetal physiology.119 Though on gross examination the ruminant placenta may 
appear very different from the human, on a cellular level it exhibits many 
similarities.  
Placentation in the Sheep 
Embryonic Loss and Placental Dysfunction 
Just as in humans, early pregnancy in the sheep is a period of significant 
embryonic loss. In the food animal industry, reproductive efficiency is critical to 
maintaining viability and profitability. Over the past 30 years, pregnancy rates 
have been decreasing up to 1% per year, particularly as producers select for 
qualities such as increased milk production in dairy cattle rather than 
reproductive traits.120,121 These reproductive inefficiencies cost producers 
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upwards of $1 billion annually in the United States alone.122 In cattle, early 
embryonic mortality, prior to day 20 of gestation, accounts for 75-80 percent of all 
embryonic and fetal losses.123 Losses from days 8 to 16 range from 24% to over 
30%, and up to 45% prior to day 35 of gestation.124,125,126,127 Early embryonic 
losses in sheep are estimated at 17-30%, with most losses occurring prior to day 
18 of gestation.128,129,130 The vast majority, up to 80%, of these embryonic losses 
are attributed to aberrant placentation.131 A ―critical period‖ was identified in cattle 
from day 15 to 17 of gestation during which the majority of embryonic losses 
occur.132 This coincides with the period where maternal recognition of pregnancy 
is required in order to prevent luteolysis, as well as the period of rapid conceptus 
outgrowth prior to attachment to the endometrium. In ruminants, the trophoblast 
produces interferon (IFN)-τ which prevents the production of prostaglandin F2α 
and allows for continued secretion of progesterone from the corpus luteum during 
pregnancy.133 Maintenance of pregnancy and successful implantation require a 
continuous reciprocal interaction between the conceptus and endometrium.  
In addition to significant embryonic losses, dysfunctional placentation is 
also observed in domestic ruminants, resulting in intrauterine growth restriction. 
IUGR is a significant concern in animal agriculture, and can have both genetic 
and environmental origins. Environmental effects include multi-fetal gestations, 
maternal over- or under-nutrition, and thermal stress. Consequences of IUGR 
include reduced meat quality, cardiovascular disease, reduced growth rates, 
hormonal imbalances, metabolic disorders, and increased perinatal morbidity and 
mortality.134 In addition to the significance of IUGR to the food animal industry, 
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sheep have been widely used as a model for human IUGR; their size allows for 
repeated sampling during pregnancy to measure placental oxygen and nutrient 
transfer.135,136 Though IUGR can have many etiologies, placental insufficiency is 
a frequent cause and the one most commonly studied.137 Furthering our 
understanding of early implantation and placentation in the sheep will not only 
illuminate analogous pathways in the human, but may also shed light on how to 
improve reproductive efficiency and profitability of animal agriculture.  
From Fertilization to Implantation 
Placentas may be classified by the distribution of chorionic villi and by the 
layers separating the maternal and fetal blood supply. In ruminants, the placenta 
is cotyledonary and made up of discrete attachments called placentomes, with a 
fetal cotyledon and a maternal caruncle. The attachment is classified as 
syndesmochorial because the chorionic epithelium is intermittently exposed to 
maternal stroma when the endometrial epithelium transiently erodes.116 Wooding 
suggests a more accurate designation of ―synepitheliochorial‖ to emphasize the 
role of cell fusion in the formation of a maternal-fetal hybrid layer containing 
binucleate cells fused to endometrial epithelial cells.138 Contrast this with the 
human placenta which is zonary, indicating a single area for maternal-fetal 
exchange, and hemochorial, meaning the chorionic epithelium is in direct contact 
with maternal blood.116 Despite these gross phenotypic differences between the 
two species, the trophoblast cells themselves exhibit many similarities.  
The sheep blastocyst hatches from the zona pellucida around day 7-8 
after fertilization and begins a period of dramatic elongation prior to attaching to 
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the endometrium around day 16. Binucleate cells, also known as trophoblast 
giant cells, first appear on day 14;139 these are thought to result from mitotic 
polyploidy, or consecutive nuclear divisions without cytokinesis.138 By day 16, 
these cells represent nearly one fifth of the population of trophoblast cells.140 
Over the next week, binucleate cells migrate and fuse with uterine epithelial cells 
to form fetomaternal hybrid trinucleate cells in syncytial plaques which cover the 
uterine caruncles at day 24.138 Binucleate cells are responsible for the synthesis 
and secretion of hormones into maternal circulation, including chorionic 
somatomammotropin hormone 1 (CSH-1 or placental lactogen) and 
progesterone.141 The process of elongation requires trophoblast cell proliferation, 
growth, and cytoskeletal remodeling.141,142 In porcine conceptuses, which have 
similar trophectoderm outgrowth prior to attachment, expression of Ki67 during 
the elongation phase indicated that cell division was active within the 
trophectoderm.143 Clearly significant trophoblast proliferation is required for this 
rapid and dramatic outgrowth prior to implantation.  
In order for initial conceptus adhesion to occur on day 16, the uterine 
luminal epithelium must be receptive to this interaction. This requires specific 
changes in gene expression and expression of cell surface proteins. Down-
regulation of progesterone receptor in the luminal epithelium is associated with 
decreased expression of MUC1 and coincides with initial conceptus adhesion.144 
This large transmembrane mucin glycoprotein may block access of integrin 
receptors on the conceptus to their ligands on the luminal epithelium.145 Integrin 
receptors and their ligands, such as osteopontin, are expressed by both the 
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luminal epithelium and trophoblast during the peri-implantation period, and have 
been shown to play a critical role during this interaction in several other 
species.146 Glycosylated cell adhesion molecule 1 (GlyCAM-1) expression 
increases in the luminal epithelium on day 15, and is abundantly expressed at 
day 17 and 19, as well as in the trophoblast from days 13-19; this timeframe of 
expression suggests it may be involved in conceptus-endometrial interactions 
during initial adhesion.146 In addition to adhesion molecules, growth factors and 
cytokines expressed by both the conceptus and endometrium are required for 
successful implantation in the sheep, just as in other species. Insulin-like growth 
factor I (IGF-I), epithelial growth factor, transforming growth factor (TGF) 1, 2 and 
3, IL-6 and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
expression has been demonstrated in the peri-implantation ovine conceptus and 
endometrium, though their specific functions have yet to be explained.147 The 
potential roles of specific cytokines and growth factors in early pregnancy can be 
inferred from the expression patterns of these proteins in vivo. Fibroblast growth 
factor (FGF) 2 is expressed by ovine endometrium and conceptus during early 
pregnancy; conceptuses at days 14-19 express the receptors FGFR 1, 2, and 3, 
which suggests a possible function for FGF signaling during initial conceptus 
attachment.148 FGF2 is involved in up-regulation of IFN-τ transcription in bovine 
trophoblast cells, and is likely required for maternal recognition of pregnancy.149 
Properly timed signaling between the conceptus and endometrium is critical 
during this initial phase of adhesion and implantation. 
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Though ruminant placentas do not have a continuous syncytiotrophoblast 
layer in direct contact with maternal blood as in the human placenta, they do 
exhibit cell fusion during the formation of multinucleated syncytial plaques. In 
sheep, trinucleate cells making up syncytial plaques completely replace the 
uterine epithelium within the placentomes.150 Like the syncytiotrophoblast of the 
human, post-mitotic binucleate cells are responsible for the synthesis and 
secretion of a number of hormones into maternal circulation, including placental 
lactogen, prolactin-related protein (PRP), pregnancy-associated glycoprotein 
(PAG), and C-type natriuretic peptide.151,152 The function of these placental 
hormones in pregnancy is not well understood. Placental lactogen may stimulate 
fetal growth, modify maternal metabolism, stimulate lactogenesis, and/or 
stimulate placental angiogenesis.153,154 Both ruminant BNCs and human 
cytotrophoblasts which fuse into the syncytiotrophoblast differentiate and exit the 
cell cycle while undergoing a significant change in the repertoire of expressed 
proteins; this requires specialized regulation of gene transcription in these cells. 
The specific mechanism of how a single trophoblast cell is selected for 
differentiation into a binucleate cell is not clear. Syncytial plaques undergo 
constant demise and renewal throughout gestation,155 just as observed in the 
human syncytiotrophoblast. The BNC lifespan is likely controlled by apoptotic 
factors whose activities determine each cell’s fate. Apoptotic pathways, 
discussed in more detail below, appear to play an important role in both human 
and ruminant placentation.  
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Additional similarities between human and sheep placentas exist in the 
factors which regulate trophoblast cell fusion. Evidence for the presence of 
endogenous retrovirus envelope elements in sheep and cattle was recently 
published. In cattle, endogenous retrovirus element-like transcript A (ERVE-A) 
has a similar sequence to human syncytin-1 and was specifically expressed in 
binucleate cells from day 20 increasing to day 70 of gestation.156 Whether this 
transcript is translated into a protein with a role in trophoblast fusion remains to 
be seen. The endogenous Jaagsiekte sheep retrovirus envelope gene 
(enJSRVs) is expressed in the trophectoderm of the elongating ovine conceptus 
from day 12 of gestation. In vivo knockdown of the protein inhibited binucleate 
cell differentiation and slowed trophectoderm outgrowth.157 Though BNCs are not 
a result of cell fusion158, they fuse to the uterine luminal epithelium to form a 
syncytium. These studies suggest a similarity in the function of endogenous 
retroviruses during fusion of both human and ovine trophoblast cells. 
In vivo loss- and gain-of-function studies as well as furthering our 
understanding of normal gene expression and regulation during the peri-
implantation period can help to improve pregnancy rates in domestic ruminants 
as well as other species. As in the human, developing in vitro models for 
ruminant placental development is the topic of much research, given the 
limitations of in vivo studies. A selection of trophoblast cell lines established with 
varying methods is discussed below. 
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In vitro models of ruminant trophoblast 
Ruminant-specific trophoblast cell lines are a relatively recent 
development in the study of placental function in these species. Prior to this, 
studying trophoblast development specific to cattle and sheep was limited to in 
vivo analysis or the use of trophoblast cells from other species. Altering placental 
gene expression in vivo has recently been reported by delivering morpholino 
oligonucleotides and lentiviruses to developing conceptuses.159,75 These types of 
experiments will provide substantial insight into placental development. However, 
trophoblast cell lines allow for a more rapid and less expensive approach to 
studying transcriptional regulation and trophoblast differentiation, with more 
readily available methods for modifying gene expression. 
Primary culture of bovine and ovine trophectoderm has been reported 
historically in the literature,160,161,162,163 but cell lines capable of continuous culture 
are a more contemporary development. Origins and features of cell lines 
developed from ruminant trophectoderm and placenta are shown in Table I-2. 
CT-1 cells represent outgrowths of gestational day 10 to 11 bovine hatched 
blastocysts.164 These cells have been used extensively to study the 
transcriptional regulation of IFN-τ,165,166,167 demonstrating the utility of ruminant-
specific cell lines for increasing our understanding of biological function. BT-1 
cells were developed from day 8 bovine blastocysts cultured on collagen, 
eliminating the need for a feeder cell layer as in the CT-1 cells.168 These cells 
form BNCs in culture and express PL.169 A custom cDNA microarray comparing 
BT-1 gene expression to in vivo-derived trophoblast cells showed more than one 
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third of the genes examined were differentially regulated, though trophoblast-
specific genes such as IFN-τ, PL, PAGs, and PRPs remained relatively 
constant.170 As with any cell line cultured over time, one must use caution when 
interpreting the results as increasing time in culture can modify gene expression. 
Most recently, Bovine F3 cells were developed from cotyledons at 5 months of 
gestation, with trophoblast cells isolated by trypsinization and centrifugation over 
a Percoll gradient.171 When treated with epidermal growth factor (EGF), 
proliferation and migration of F3 cells increased significantly, along with 
stimulating MMP-9 expression and activity.172 EGF also promotes survival and 
reduces apoptosis in primary human cytotrophoblast173 and increases outgrowth 
of mouse trophoblast cells in vitro174, suggesting a similar function of this growth 
factor in multiple trophoblast types. F3 cells were recently used to develop a 
three-dimensional spheroid culture system, which may better mimic in vivo 
properties than a cell monolayer.175  
Table II-2. Ruminant trophoblast cell lines.  
PL = placental lactogen or chorionic somatomammotropin, IFN-τ = 
interferon tau, IVF = in vitro fertilized 
Name Origin Features Reference 
CT-1 d10-11 IVF bovine blastocysts 
plated on fibroblast feeder layer 
IFN-τ mRNA & protein Talbot et al. 
2000 (164) 
BT-1 outgrowths from d8 IVF bovine 
blastocysts plated on collagen 
IFN-τ, PL mRNA & protein; 
cytokeratin; some BNCs 
Shimada et al. 
2001 (168) 
F3 bovine cotyledon at 5 months 
gestation 
PL only in early passages; 
cytokeratin later 
Hambruch et 
al. 2010 (171) 
oTr1, oTrF d15 ovine conceptus plated on 
plastic (1) and collagen (F) 
 Farmer et al. 
2008 (176) 
oTR d15 ovine conceptus  Anthony et al. 
2010 (76) 
 
In the sheep, oTr1 and oTrF cells were developed from plating elongating 
day 15 conceptuses on plastic and collagen-coated dishes, respectively.176 Both 
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oTr1 and the bovine CT-1 cells responded to FGF2 or FGF10 treatment by 
increasing migration.177 The analogous response of these two trophoblast cell 
lines derived from different species by different methods suggests a consistent 
phenotype, which supports their use for further studies on the regulation of 
trophoblast function. Our laboratory developed several lines of oTR cells from 
d15 conceptuses plated on plastic.77 One difficulty with the oTR cells is that the 
magnitude of expression of specific genes is altered from what is observed in 
conceptuses collected from the same day of gestation. The cells seem to 
differentiate rapidly when cultured on plastic; culturing on a substrate such as 
collagen or a basement membrane matrix may bring the transcriptome closer to 
that observed in vivo. As with human trophoblast cells, oTR cells undergo a 
phenotypic change that corresponds to changes in gene expression when 
cultured on a basement membrane matrix. oTR cells aggregate and appear to 
invade when cultured on Matrigel, similar to what is observed in ACH-3P cells, 
primary first trimester human cytotrophoblast, and mouse trophoblast stem 
cells.77,178,113 Though placentation in each of these species is quite distinct, the 
trophoblast cells appear to respond and behave very similarly in culture, 
strengthening the case for using them as a model. Identifying appropriate 
markers for ruminant uninucleate trophoblast and binucleate cells, as well as 
ideal culture media and substrates will help to provide a standardized system 
from which researchers can collect data and compare results. Reliable cell 
culture systems will allow for transfections, treatment with specific pathway 
inhibitors, and modification of gene expression using RNA interference; these 
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tools will help illuminate the pathways regulating trophoblast development during 
early pregnancy. 
Ruminants, specifically sheep, provide a valuable model for placental 
development. Furthering our understanding of early ovine placentation may offer 
tools to help to improve reproductive efficiency in our food animal species. 
Moreover, it will provide considerable insight into analogous pathways of human 
pregnancy in a model system that can be manipulated and assessed during 
pregnancy in vivo. Though significant morphological differences exist between 
ruminant and human placentas, we still have much to learn about the particular 
pathways regulating trophoblast proliferation and differentiation during early 
implantation in both species. These pathways are likely widely conserved across 
eutherian mammals, making the sheep a useful model for this particular subject. 
Disturbances in trophoblast proliferation, survival, and differentiation cause 
significant morbidity and mortality in humans, as well as increased production 
costs in food animal species. Advancing our understanding of the genes and 
signals that are critical during this period will have a substantial impact on 
maternal and fetal health and the agricultural industry.  
Apoptosis in the Placenta 
Cell turnover and renewal is a necessary process in most tissues; the 
placenta is no exception. Apoptosis, or programmed cell death, plays an 
important role in placental development as the syncytiotrophoblast layer 
undergoes continual shedding and renewal, and cytotrophoblast cells invade and 
signal to maternal cells. Apoptosis is initiated via two potential pathways: 
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extrinsic or intrinsic. The extrinsic or death receptor pathway is mediated by 
members of the tumor necrosis factor death receptor family, including Fas 
(CD95), TNF-R1 (CD120a), and TNF-related apoptosis inducing ligand receptors 
1 and 2 (TRAIL-R1, TRAIL-R2), while the intrinsic or mitochondrial pathway is 
initiated by cellular stresses which activate the mitochondrial pathway. Cysteine 
proteases, or caspases, are the effectors of apoptosis in both pathways; they are 
cleaved from inactive pro-caspases and activated upon initiation of programmed 
cell death. Caspase-8, an ―initiator‖ caspase, is exclusive to the extrinsic 
pathway, but both pathways converge on the activation of caspase-3 and 
caspase-7, the ―executioner‖ caspases.179  
Controversy exists regarding the localization and quantity of apoptotic 
cells in the placenta throughout gestation due to the varied methods of 
visualizing and quantifying apoptosis. When measured by terminal 
deoxynucleotidyl transferase-mediated deoxyuridine triphosphate marker nick 
end-labeling (TUNEL), apoptosis appears to increase from the first to the third 
trimester.180 When trophoblast apoptosis was assessed using the M30 antibody, 
which detects cleaved cytokeratin 18, an early event in apoptosis, they observed 
a significant decrease in apoptosis from first to second and third trimesters and a 
concomitant increase in Bcl2 expression, an anti-apoptotic protein.181 These 
conflicting results may be explained by recent evidence suggesting that early 
stages of apoptosis are evident in the process of trophoblast fusion.  
When differentiating into syncytiotrophoblast, cytotrophoblast cells 
undergo changes commonly associated with apoptosis, including externalization 
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of phosphatidylserine (PS), exit from the cell cycle, and rearrangement of 
cytoskeletal components.182 Initially, it was proposed that cytotrophoblast cells 
begin the apoptotic cascade prior to syncytial fusion, but continuation is inhibited 
by anti-apoptotic proteins such as Bcl-2; then the apoptotic cascade is completed 
in the syncytium with the formation and shedding of syncytial knots into maternal 
circulation.183 The mechanism of trophoblast apoptosis and its relationship to 
trophoblast fusion is widely debated. In BeWo cells, it appears that PS efflux can 
occur via a PKA-dependent pathway related to differentiation or a caspase-
dependent pathway related to apoptosis. The authors of this study suggest that 
the PS flip in cytotrophoblast cells is independent of caspase activation and 
apoptosis.184 Cleavage of caspase-8 was observed in a small number of first 
trimester villous cytotrophoblasts, but no signs of apoptosis were observed in the 
nuclei. Co-staining of cleaved caspase-8 with Ki-67 revealed that caspase-8 was 
only active in cells that had left the cell cycle, suggesting it may be involved in 
trophoblast fusion.185 However, inhibiting caspase activity did not block 
syncytialization of BeWo cells or explant cultures, suggesting caspase activity is 
not required for trophoblast fusion.186 Another recent study indicates that 
syncytialization of BeWo cells by treatment with cAMP is mediated in part by 
increased FasL expression and activation of caspase-3.187 This also suggests a 
link between apoptosis and trophoblast fusion. 
Mounting evidence suggests that apoptosis is increased in placentas from 
pregnancies complicated by preeclampsia and IUGR. Heazell et al. 
demonstrated increased apoptosis and decreased proliferation in term IUGR 
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placentas.188 This concurred with an earlier study by Smith et al., although 
another group found no difference in proliferation or apoptosis in idiopathic IUGR 
placentas.189,190 A number of studies have demonstrated increased trophoblast 
apoptosis in pregnancies complicated by preeclampsia.191,192,193 In preeclamptic 
placentas, apoptosis and the number of syncytial knots was significantly 
increased, while FasL expression was significantly less; no difference was 
observed in trophoblast proliferation between groups.194 A different study also 
demonstrated increased apoptosis in trophoblasts and a significant increase in 
FasL expression in the decidua from preeclamptic pregnancies, but no change in 
caspase-3 or p53 expression.195 Sokolov et al. found a similar degree of 
apoptosis by TUNEL in normal and preeclamptic placentas, but observed a 
significant decrease in Fas, Caspase-3, and Caspase-8 expression, a significant 
increase in TRAIL expression, while Caspase-2, Caspase-9 and FasL were 
unchanged.196 FasL was significantly increased in complete hydatidiform moles 
when compared to age-matched control placentas, although no change in 
trophoblast apoptosis was observed.197 These studies point to a role for 
increased programmed cell death in placentas characterized by insufficient 
trophoblast differentiation and invasion.  
Most recently, Longtine et al. found that induction of apoptosis with 
staurosporine in placental villous explants caused caspase-mediated apoptosis 
in cytotrophoblasts but not in the syncytiotrophoblast. The authors suggest that 
apoptotic cytotrophoblasts interdigitated in the syncytiotrophoblast may be 
mistaken for syncytiotrophoblast if specific markers are not used to distinguish 
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the two cell types.198 They followed up this study with an analysis of apoptosis in 
normal, preeclamptic and IUGR pregnancies, demonstrating increased caspase-
mediated apoptosis limited to the cytotrophoblast in pathologic pregnancies.199 
This brings into question the results of earlier studies demonstrating apoptosis in 
the syncytiotrophoblast layer, but confirms the enhanced apoptosis initially 
established.  
The ruminant placenta also demonstrates continuous turnover and 
renewal of syncytial plaques throughout gestation. The precise role of apoptotic 
factors in regulating this has not been explained. Bovine placentomes 
demonstrate increasing apoptosis, as detected by positive staining for TUNEL 
and CASP3, from day 60 of gestation to post-partum, with a concomitant 
increase in the expression of the anti-apoptotic family member BCL2A1.200 In 
early bovine pregnancy, FasL is highly expressed by day 18 conceptuses; there 
was no change in endometrial apoptosis between pregnant and non-pregnant 
animals, but the authors did not measure apoptosis in the conceptus.201 
In yak placentomes, FasL is expressed in binuclear, mononuclear, and 
trinuclear trophoblast giant cells through gestation, while its receptor Fas was 
expressed in the cotyledonary villous trophoblast primarily in early pregnancy. 
Apoptosis in this species, also detected by TUNEL, was highest in the middle of 
pregnancy in both caruncular epithelium and trophoblast cells.202 These limited 
data demonstrate the expression of apoptotic factors in ruminant trophoblast 
cells, but the function is not clear. It has been suggested that cell death also 
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plays a role early in gestation during the period of elongation, but this has not 
been confirmed as apoptosis.203 
Another role for apoptotic factors in the developing placenta is to 
communicate between the trophoblast and the maternal endometrium. 
Trophoblast cells migrate and invade into uterine spiral arteries, eventually 
replacing maternal endothelium, possibly via endothelial cell apoptosis. 
Trophoblast secretion of MMP-9 may contribute to endothelial cell apoptosis by 
increasing the release of FasL.204 James et al. demonstrated that FasL blocking 
antibodies significantly inhibited trophoblast-induced endothelial cell apoptosis, 
confirming that Fas/FasL interactions were involved.205 First-trimester trophoblast 
cells express membrane-bound TRAIL, which can induce smooth muscle cell 
apoptosis.206 Evidence for in vivo vascular smooth muscle cell apoptosis during 
spiral artery remodeling is conflicting. Bulmer et al. did not observe apoptosis in 
vascular smooth muscle cells in placentas from 8-20 weeks of gestation, but did 
identify apoptotic trophoblasts and leukocytes by double immunostaining.207 They 
suggest that extravillous trophoblast cells stimulate smooth muscle cell migration 
away from spiral artery walls, rather than causing apoptosis.208 In contrast, 
TUNEL staining of placentas at 8-20 weeks of gestation along with 
immunostaining for markers of smooth muscle cells and endothelial cells 
identified a proportion of apoptotic nuclei in both cell types during spiral artery 
remodeling.209 Whether apoptosis in maternal smooth muscle cells and 
endothelial cells plays a role in spiral artery remodeling remains to be seen. 
Apoptosis-inducing ligands secreted by trophoblast cells may bind to neighboring 
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trophoblast cells or bind to receptors on maternal endothelial or smooth muscle 
cells. Determining the definitive role of these ligands in the placenta will require 
additional in vivo analyses as well as in vitro analyses with trophoblast cells and 
co-culture systems of trophoblast cells with endometrial and smooth muscle 
cells. 
Signaling Pathways in the Placenta 
Growth factors and cytokines play an essential role in the development of 
the placenta and the modulation of maternal hemodynamics during pregnancy. 
Autocrine, paracrine and endocrine signaling allow for the coordinated and 
controlled growth of trophoblast cells into the fully-formed placenta. Two 
pathways with demonstrated effects on placental development include the 
transforming growth factor β superfamily of ligands and receptors and the Wnt 
signaling pathway. 
Transforming growth factor β (TGFβ), produced in the uterine decidua and 
to a lesser extent the trophoblast, is a key repressor of extravillous trophoblast 
proliferation and invasiveness.210 At the blastocyst stage, the actions of TGFβ 
appear to be pro-proliferative rather than inhibitory. Pre-implantation embryos 
express TGFβ receptors211 and exogenous TGF-β stimulates blastocyst 
proliferation and development and increases blastocyst cell numbers.212,213,214 
TGFβ secreted by the blastocyst induces apoptosis of uterine epithelial cells, 
perhaps aiding in implantation.215 After initial implantation, it appears the effects 
of TGFβ isoforms on proliferating and invading cytotrophoblast cells are 
antagonistic. Neutralization of endogenous TGFβ1, 2 and 3 increased the 
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invasive capacity of extravillous trophoblasts while exogenous administration of 
these growth factors inhibited invasion; this effect was mediated through a 
decreased secretion of matrix metalloproteinase 9 (MMP9) and urokinase 
plasminogen activator.216 MMP9 may also be involved in activation of latent 
stores of TGFβ through proteolytic cleavage.217 In contrast to studies on human 
cells, treatment of rat placental stem cells (HRP-1) with TGFβ1, 2 and 3 
significantly increased invasion; TGFβ3 administration significantly decreased 
apoptosis in RCHO-1 cells, a rat choriocarcinoma cell line, but had no effect on 
invasiveness.218 The differing effects of TGFβ on these cells may be explained by 
the differing placental physiology between humans and rodents.219 The majority 
of data indicate TGFβ isoforms inhibit the proliferative and invasive capacity of 
trophoblast cells, which is reflected in the expression pattern of these cytokines 
during dysfunctional placentation.  
The TGFβ family of proteins is also implicated in pathologic pregnancies. 
TGFβ1 was significantly up-regulated in the serum of preeclamptic women as 
compared to normotensive controls, as well as in CV samples from women 
destined to develop preeclampsia.220,221,222 In addition, TGFβ3 expression 
increased in preeclamptic placentas and blocking endogenous TGFβ activity 
stimulated extravillous trophoblast cell sprouting from villous explants.223 The 
elevation of TGFβ3 appears to be partially mediated by a parallel increase in 
hypoxia-inducible factor 1α (HIF1α) in preeclamptic placentas.224,225 Endoglin, a 
high affinity co-receptor for TGFβ1 and TGFβ3 (but not β2), appears to be 
required for the inhibitory effect of TGFβ on trophoblast differentiation.226 A 
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soluble form of endoglin (sEng) exists in circulation and increases in the serum of 
women with preeclampsia as well as normotensive IUGR, indicating it may be a 
circulating marker for placental insufficiency.227,228 Decreased expression of 
transmembrane endoglin resulted in increased invasiveness and motility of 
hTR8/SVneo cells.229  
Growth differentiation factor 15 (GDF15) is a non-canonical member of the 
TGFβ superfamily of cytokines. It is up-regulated in decidual cells and facilitates 
decidualization in vitro.230 As with other TGFβ superfamily members, it appears 
to be inhibitory to trophoblast invasion, causing anti-proliferative and pro-
apoptotic effects in vitro.231,232 GDF15 may have systemic and intrauterine 
immunosuppressive or anti-inflammatory actions due to high circulating 
concentrations during pregnancy.231 Its expression is confined to cytotrophoblast 
and decidual stromal cells, and does not appear in the syncytiotrophoblast.233 
Although GDF15 knockout mice produce viable and fertile offspring,234 it is 
possible that an alternative TGFβ superfamily member increases to compensate 
for the loss of GDF15, as is the case with activin βB knockout mouse, where 
activin βA is elevated.235 Furthermore, GDF15 may play a more important role in 
the modulation of maternal hemodynamics in human pregnancy than in the 
rodent. As with other TGFβ family members, GDF15 is elevated in the placenta 
and in maternal serum from preeclamptic pregnancies.236 TGFβ cytokines may 
play a causative role in placental insufficiency or they may be a downstream 
consequence of poor placental development. 
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Wnt signaling plays an important role in vertebrate development, as well 
as the progression of cancer and degenerative diseases. The multi-gene families 
of Wnt ligands and Frizzled (Fzd) receptors provide for a diverse array of 
interactions, with 19 Wnt genes and 10 Fzd receptors known in the human 
genome.237,238 The canonical Wnt signaling pathway involves activation of β-
catenin, which translocates to the nucleus to activate transcription of Wnt target 
genes in complex with T-cell factor/lymphoid enhancer factor (TCF/LEF) family 
proteins. In the absence of Wnt ligand, β-catenin is phosphorylated and targeted 
to the proteasome for destruction by a complex comprising axin, adenomatous 
polyposis coli (APC), glycogen synthase kinase 3β (GSK3β) and casein kinase I 
(CKI).239 Non-canonical Wnt signaling can be divided into two phenotypic 
categories: the planar-cell-polarity (PCP) pathway and the Wnt/Ca++ pathway. 
The PCP pathway is involved in epithelial cell polarity and motility through the 
control of actin remodeling via activation of the GTPases Rho and Rac. The 
Wnt/Ca++ pathway is characterized by Wnt-Fzd activation of phospholipase C 
(PLC) and a subsequent increase in cytoplasmic calcium concentrations. The 
latter pathway modulates cellular adhesion and cytoskeletal rearrangements.240 
To further complicate the canonical Wnt signaling pathway, β-catenin binds to a 
number of other nuclear proteins in addition to the TCF/LEF family, including 
androgen receptor, estrogen receptor, and cyclic AMP response element binding 
protein (CREB).241 The complexity of Wnt signaling is demonstrated by the array 
of proteins mediating these cascades and the diverse cellular responses to Wnt 
signals. The known functions of Wnt signaling in cell motility, cytoskeletal 
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remodeling, and proliferation support a function for this pathway in the 
developing placenta. 
The role of Wnt signaling in placental development and trophoblast 
differentiation remains to be elucidated. In the placenta, several Wnt ligands and 
Fzd receptors are expressed in both human and ovine trophectoderm. Wnt2, 
Wnt2B and Wnt4 were detected in ovine trophectoderm, as well as Fzd6/8, 
GSK3β, β-catenin, and Fzd co-receptor low density lipoprotein receptor-related 
proteins 5/6 (LRP5/6).242 Expression of Wnt7A in the luminal epithelium is 
induced by IFN-τ between days 12 and 16 of pregnancy.243 Wnt7A activates the 
canonical Wnt signaling pathway in ovine trophoblast cells and may regulate 
gene expression, proliferation, or differentiation into binucleate cells.245,244 It may 
also have autocrine actions on the luminal epithelium to influence uterine 
receptivity. In the human, Sonderegger et al. found 14 of the 19 known Wnt 
ligands expressed in first trimester placenta, as well as 8 of the 10 Fzd receptors. 
Expression of Wnt1, Wnt7b, Wnt10a, and Wnt10b was high in first trimester 
samples, but mostly absent from term placentas.245 This differential expression 
suggests a functional role for these Wnt ligands in early trophoblast proliferation 
or differentiation. TCF3 and TCF4 are highly expressed in first trimester placenta 
and extravillous trophoblasts. Treatment with Wnt3a increased nuclear β-catenin 
staining as well as canonical Wnt/TCF luciferase reporter activity in human 
trophoblast cells, suggesting increased transcriptional activation by β-catenin-
TCF complexes. Concurrently, invasion and migration of trophoblast cells 
increased upon Wnt3a treatment, and this increase disappeared with the addition 
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of Dickkopf 1 (Dkk1), an extracellular inhibitor of Wnt signaling.246 The 
expression pattern in vivo and effects of Wnt ligands in vitro demonstrates a 
probable function for this signaling pathway in early placental development. 
Successful navigation of early pregnancy in eutherian mammals requires 
coordinated communication and interaction between the uterus and the 
developing placenta. Properly timed and controlled expression of growth factors, 
cytokines, transcription factors, and other regulatory proteins in the endometrium 
and trophoblast will determine the pregnancy outcome. Though the pathways 
regulating placentation have many redundancies in order to favor the 
propagation of each species, certain factors are critical for placental development 
and embryonic survival. One such protein that is conserved across mammals as 
well as more primitive vertebrates is the small nuclear protein proline rich 15. 
Proline Rich 15 
Proline rich 15 (PRR15) is a small, well-conserved nuclear protein 
originally identified in murine intestinal epithelium.247 In situ hybridization analysis 
on sections of small and large intestine and testis showed that PRR15 (G90) 
transcripts were present primarily in post-mitotic cells.247 Further studies of its 
expression during mouse embryonic development were consistent with this, 
showing a correlation between PRR15 expression and the absence of 
proliferation.248 A recent finding that stimulation of proliferation of rat pancreatic 
islet β and acinar cells led to significant down-regulation of PRR15 further 
suggests that it could play a role in differentiation or cell cycle arrest.249 However, 
Meunier et al. observed PRR15 expression in mouse gastrointestinal tumors 
44 
caused by mutations in the Apc gene, as well as in several human colorectal 
cancers and suggested that PRR15 is linked to the Wnt signaling pathway.250 In 
Apc mutants, the complex which binds and phosphorylates β-catenin cannot 
form, resulting in accumulation of β-catenin and activation of Wnt target genes. 
Though only supported by in situ hybridization analysis, these data suggest that 
Wnt signaling could activate transcription of PRR15. 
Glover and Seidel251 independently identified PRR15 in elongating bovine 
embryos by mRNA differential display analysis. In silico analysis of this cDNA 
confirmed an open reading frame encoding a 126 amino acid protein with four 
putative protein kinase C (PKC) phosphorylation sites, two casein kinase II 
phosphorylation sites and a nuclear targeting sequence.251 The expression 
profile in the sheep conceptus during pregnancy revealed a peak in expression at 
day 16 of gestation,75 which coincides with a halt in elongation of the conceptus, 
and the period of apposition to the uterine epithelium.252 Immunohistochemistry 
localized PRR15 to the trophectoderm and extraembryonic endoderm of day 15 
sheep conceptuses, suggesting a role in early placental development. Lentiviral-
mediated knockdown of PRR15 in ovine trophectoderm at the blastocyst stage 
led to demise of the embryo by gestational day 15.75 This provides compelling 
evidence that PRR15 is a critical factor during this window of development where 
proliferation gives way to differentiation of trophoblast cells. 
In humans, PRR15 immunolocalized to the nuclei of both first and second 
trimester placental sections, predominantly in cytotrophoblast cells.253 PRR15 
mRNA expression increased when trophoblast cells, both sheep (oTR) and 
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human (ACH3P), were cultured on Matrigel, a basement membrane matrix. 
During this time, cells cluster together and appear to invade into the extracellular 
matrix.76 First trimester cytotrophoblasts grown on an extracellular matrix 
differentiate into an invasive phenotype, characterized by the same phenotypic 
changes observed in our trophoblast cell lines.179 It is generally believed that 
proliferation ceases once trophoblasts differentiate into the invasive extravillous 
subtype. These data support the hypothesis that PRR15 could function in 
trophoblast differentiation or regulation of the cell cycle.  
In view of the fact that PRR15 expression increases upon induction of the 
invasive, more differentiated phenotype, it could be involved in the pathogenesis 
of placental disorders demonstrating disturbed trophoblast growth. Lentiviral-
mediated delivery of shRNA provided robust evidence for the necessity of 
PRR15 during early embryonic development in the sheep. PRR15 does not 
contain any known DNA binding motifs, and may not have a direct effect on gene 
transcription. Due to its nuclear localization, it may act as a co-activator or co-
repressor of transcription or influence mRNA processing. Understanding the 
effect of PRR15 on trophoblast gene expression will help to illuminate the 
function it may play in placental development. 
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CHAPTER III – Effect of PRR15-deficiency on Trophoblast Proliferation and 
Survival 
Introduction 
Maintenance of early pregnancy in eutherian mammals requires an 
intricate coordination of events between the embryo and endometrium in order to 
develop a fully functional placenta. The period of early pregnancy when the 
embryo begins to attach, adhere to and invade into the endometrium is the most 
precarious time for the developing embryo. In humans, it is estimated that nearly 
half of all conceptions are lost, with the majority of these losses occurring during 
early pregnancy.254,255 Additionally, common disorders of pregnancy, such as 
early-onset preeclampsia and intrauterine growth restriction, originate with 
defective placentation during the first trimester.256 Ruminants experience early 
embryonic losses similar to humans, with 30% loss during the period of 
conceptus elongation prior to gestational day 16.125 Appropriate proliferation, 
differentiation, and turnover of trophoblast cells are required for normal placental 
development, while aberrations in the normal program of gene expression may 
trigger these disorders of early pregnancy. 
The trophectoderm is the first lineage to differentiate in the developing 
embryo, and is the source of the established placenta.257 During human 
implantation, cytotrophoblast cells begin to differentiate into invasive extravillous 
cytotrophoblasts, which invade the maternal decidua, and villous 
cytotrophoblasts, which fuse to form the multinucleated syncytium.258,259 
Ruminant and porcine conceptuses undergo a period of rapid elongation just 
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prior to attachment to the endometrium.260,261 This process of elongation results 
from a combination of both proliferation and cellular remodeling.262 A balance of 
cell turnover and renewal allows for appropriate and controlled growth of the 
placenta. Trophoblast apoptosis is increased in pregnancies complicated by 
IUGR and preeclampsia, suggesting a disruption in the normal balance of cell 
death and proliferation in these placentas.263 In all mammalian species, a 
coordinated expression of transcription factors, cell cycle regulators, growth 
factors, and other genes is essential to proper placental development.  
Proline rich 15 (PRR15) is a small, well-conserved nuclear protein 
originally identified in murine intestinal epithelium.247 In situ hybridization analysis 
on sections of small and large intestine and testis showed that PRR15 (G90) 
transcripts were present primarily in post-mitotic cells.247 Further studies of its 
expression during mouse embryonic development were consistent with this 
interpretation, showing a correlation between PRR15 expression and the 
absence of proliferation.248 Stimulating proliferation of rat pancreatic islet β and 
acinar cells led to significant down-regulation of PRR15, further suggesting that it 
plays a role in differentiation or cell cycle arrest.249 However, Meunier et al. 
observed PRR15 expression in mouse gastrointestinal tumors caused by 
mutations in the Apc gene, as well as in several human colorectal cancers and 
suggested that PRR15 is linked to the Wnt signaling pathway.250 
Glover and Seidel251 independently identified PRR15 in elongating bovine 
embryos by mRNA differential display analysis. In silico analysis of this cDNA 
predicted an open reading frame encoding a 126 amino acid protein with four 
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putative protein kinase C (PKC) phosphorylation sites, two casein kinase II 
phosphorylation sites and a nuclear targeting sequence.251 The expression 
profile in the sheep conceptus during pregnancy revealed a peak in expression at 
day 16 of gestation.75  This coincides with a halt in elongation of the conceptus, 
and the period of apposition to the uterine epithelium.264 Immunohistochemistry 
localized PRR15 to the trophectoderm and extraembryonic endoderm of day 15 
sheep conceptuses.75 In humans, PRR15 is immunolocalized to the nuclei of 
both first and second trimester placental sections, predominantly in 
cytotrophoblast cells.254 Lentiviral-mediated knockdown of PRR15 in ovine 
trophectoderm at the blastocyst stage led to demise of the embryo by gestational 
day 15.75 This provides compelling evidence that PRR15 is a critical factor during 
this window of development where proliferation gives way to differentiation of the 
trophoblast cells. 
Our objective was to determine the impact of diminished PRR15 
expression on trophoblast gene expression as well as trophoblast proliferation 
and apoptosis.  
Materials and Methods 
Cell Culture and Lentiviral Infection 
ACH-3P cells, a human first trimester trophoblast cell line generated from 
fusion of AC1-1 cells with primary first trimester trophoblasts, were used to 
generate cell lines for the following experiments.100 ACH-3P cells were grown in 
Ham’s F-12 medium supplemented with 10% fetal bovine serum in a 37°C 
incubator at 5% CO2. The lentiviral vector pLL3.7
265 was used to create stable 
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cell lines by transfection as well as to generate lentivirus for infection, described 
below. This vector contains a multiple cloning site for introducing shRNA 
cassettes downstream of the mouse RNA polymerase III U6 promoter, as well as 
enhanced green fluorescent protein (EGFP) driven by the cytomegalovirus 
promoter. For both infection and transfection, the control cell lines contained the 
LL3.7 vector with no shRNA cassette. To target the PRR15 mRNA for 
degradation, an shRNA homologous to human PRR15 was inserted into the 
pLL3.7 vector (TGGAAATCGCTCACCAACATTTCAAGAGACTGTTGGTGAGCGATTTCCTTTTTT). 
This vector was used previously75 as a negative control during the in vivo 
infections of sheep conceptuses, as it contains 3-bp mismatches to the ovine 
PRR15 mRNA and specifically targeted human PRR15 rather than ovine. The 
transfected and infected cells are referred to as ―control‖ or ―PRR15-shRNA‖ from 
this point forward. 
Lentiviral particles were generated as described previously.75 Briefly, 
293FT cells were grown to confluence in a 15-cm tissue culture plate in high 
glucose DMEM medium supplemented with 10% fetal bovine serum. For each 
15-cm plate, Polyfect (180 µl, Qiagen, Valencia, CA) was added to the following 
lentiviral and packaging vectors in serum-free DMEM to a total volume of 675 µl: 
pLL3.7 lentiviral construct (8.82 µg, control LL3.7 or PRR15-shRNA), pRΔ8.74 
(6.66 µg; gag/pol elements), and pMD2.G (2.70 µg; env elements). The Polyfect-
DNA mixture was added to 293FT cells along with 15 ml complete medium. After 
4-6 hours of incubation in the transfection reagent, the medium was aspirated, 
cells were washed in PBS, and fresh complete medium was added. Two days 
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after transfection, cell culture supernatants were collected and ultracentrifuged 
over a 20% sucrose cushion at 47,000xg for 2 hours at 4°C. After 
ultracentrifugation, lentiviral pellets were resuspended in Ham’s F-12 
supplemented with 10% fetal bovine serum, and stored in aliquots at -80°C. 
Aliquots of lentiviral particles were titered as described previously.75  
ACH-3P cells were infected in three replicate experiments with either 
control LL3.7 or PRR15-shRNA lentivirus at a multiplicity of infection of 100 viral 
particles per cell in 30-mm tissue culture dishes. To create stable lines, ACH-3P 
cells were co-transfected with either the control LL3.7 or PRR15-shRNA vector 
and pcDNA3.1 (Invitrogen, Carlsbad, CA) in a 20:1 ratio using Superfect 
(Qiagen), following the manufacturer’s protocol. The pcDNA3.1 vector contains a 
neomycin-resistance gene, allowing for selection of transfected cells. Transfected 
cells were selected by treatment with 400 µg/ml neomycin (G418) for three 
weeks. The concentration of PRR15 mRNA in transfected and infected cells was 
assessed by quantitative real-time reverse transcriptase PCR, as described 
below. 
RNA Isolation and Microarray Analysis 
Total cellular RNA was isolated from cells using the RNeasy Mini Kit 
(Qiagen) according to the manufacturer’s protocol. RNA quality, measured by the 
260/280 nm absorbance ratio, and concentration were assessed using a 
NanoDrop 1000 Spectrophotometer (Thermo Scientific, Wilmington, DE). 
Samples were stored at -80˚C until use. RNA from three replicate infections with 
control and PRR15-shRNA lentivirus was submitted to the Colorado State 
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University Genomics and Proteomics Core for processing and hybridization to 
the GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix). The raw data 
intensity files were read into ArrayTrack for analysis 
(http://www.fda.gov/ScienceResearch/BioinformaticsTools/Arraytrack/default.htm). 
Data were normalized by scaling to the geometric mean of the intensities of each 
chip. Genes that were flagged in more than three samples due to intensities too 
low to be reliable were excluded from the analysis. Control and PRR15-shRNA 
groups were compared by Welch’s t-test on log base 2 expression values 
(Appendix – Supplemental Table 1 presents differentially expressed genes with 
p<0.05 in Welch’s t-test). Pathway analysis on differentially expressed genes 
(p<0.05, 1.3-fold) was conducted using the Kyoto Encyclopedia of Genes and 
Genomes (http://www.genome.jp/kegg/) pathway maps.266 Fisher’s exact test 
was used to determine pathways that were significantly altered (p<0.05) by 
depletion of PRR15. 
Quantitative Real-Time PCR 
cDNA was generated from 1 µg of total cellular RNA by reverse 
transcription at 55˚C for 50 min using oligo(dT) primers (Superscript III; 
Invitrogen), following the manufacturer’s protocol. Each cDNA sample was 
treated with 5 units of RNase H (Fermentas, Burlington, ON) for 20 min at 37˚C. 
Quantitative real-time RT-PCR (qPCR) was performed as described previously75 
except the samples were analyzed on a Lightcycler 480 (Roche Applied Science, 
Indianapolis, USA) in a 10 µl reaction volume. All primer sets were designed 
using Oligo software (Molecular Biology Insights, Cascade, CO) to amplify an 
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intron-spanning product; forward and reverse primers for each gene are shown in 
Supplemental Table 2 (Appendix), along with conditions for qPCR. A PCR 
product for each gene was generated using cDNA from ACH-3P cells as a 
template and cloned into the PCR-Script Amp SK(+) vector (Agilent 
Technologies, Santa Clara, CA). Each PCR product was sequenced to verify 
amplification of the correct mRNA (Colorado State University Proteomics and 
Metabolomics Facility). A standard curve was generated from 1x102 to 1x10-6 pg 
using a PCR product amplified from the sequenced plasmid for each gene, and 
used to measure amplification efficiency. The starting quantity (picograms) of 
each mRNA was normalized to the starting quantity of ribosomal protein S15, 
after verifying that the rpS15 mRNA concentration did not change with treatment 
(p>0.50). Control and PRR15-shRNA treatments were compared by Students t-
test, with p<0.05 selected as significant. For analysis of GDF15 mRNA in ovine 
conceptuses, total cellular RNA from ovine conceptuses (collected and isolated 
as described previously75) was reverse transcribed as described above and 
analyzed by qPCR. GDF15 mRNA concentrations were normalized to ovine 
GAPDH mRNA concentrations. Normalized data were subjected to analysis of 
variance and comparisons between days of gestation were made using Tukey’s 
honestly significant difference test in SAS software (SAS Institute, Cary, NC).  
Proliferation Assay 
Stably transfected ACH-3P cells were plated in a 96-well plate with 5000 
cells per well and three replicates per treatment. Proliferation was measured 
using the Cell Counting Kit 8 (Enzo Life Sciences, Farmingdale, NY). Ten µl of 
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WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium, monosodium salt] was added to each well and incubated for 3 hours, 
then absorbance at 450 nm was measured using a BioRad Model 680 Microplate 
Reader (Hercules, CA). Measurements were made 3, 24, 48, and 72 hours after 
plating cells. Concurrently, BrdU uptake was measured by ELISA, following the 
manufacturer’s protocol (Calbiochem, Darmstadt, Germany). Briefly, 5000 cells 
were plated in a 96-well plate the day prior to labeling, with three replicates per 
group. BrdU label (diluted 1:10,000) was added to media for 20 hours prior to 
ELISA. Cell media was removed and cells were fixed in provided 
fixative/denaturing solution for 30 minutes at room temperature. Cells were 
incubated in anti-BrdU antibody diluted 1:100 in antibody dilution buffer for one 
hour, washed three times in wash buffer, followed by incubation with peroxidase 
goat anti-mouse IgG HRP conjugate diluted 1:1000 in conjugate diluent for 30 
minutes. The plate was washed three times, then 100 µl substrate solution (tetra-
methylbenzidine solution) was added for 15 minutes in the dark, followed by stop 
solution (2.5N H2SO4). Absorbance was measured on a spectrophotometric 
microplate reader (BioRad) at dual wavelengths of 450-595 nm. Absorbances in 
control and PRR15-shRNA cells were compared by Student’s t-test, with p<0.05 
considered statistically significant.  
Caspase Assays 
Caspase 3/7 and 8 activity was measured using the Caspase-Glo 
Reagent (Promega, Madison, WI) in stably transfected ACH-3P cells following 
the manufacturer’s protocol. Briefly, cells (30,000 per well for Caspase 3/7 and 
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60,000 per well for caspase 8) were plated in triplicate in a white-walled clear-
bottom 96-well plate (Costar). Caspase-Glo Reagent was added and incubated 
at room temperature for 30 minutes. Luminescence was measured on a BioTek 
Microplate Reader (Winooski, VT) with integration for 10 seconds. The amount of 
protein in each well was quantified by a Bradford assay, and used to normalize 
luminescence values. Groups were compared by Student’s t-test, with p<0.05 
considered statistically significant. 
Flow Cytometry for Annexin V   
The FlowCellect Annexin Red Kit (Millipore) was used to quantify 
apoptosis in stably transfected ACH-3P cells. Cells were collected by detaching 
with EDTA (15mM in PBS, pH 7.4) and resuspending in 1X Assay Buffer HSC. 
Annexin V CF647 Working Solution was added to each sample and incubated for 
15 minutes in a 37°C CO2 incubator. Cells were washed in 1X Assay Buffer, then 
incubated with 7AAD reagent in the dark for 5 minutes. Samples were analyzed 
by flow cytometry on a MoFlo flow cytometer (Dako Colorado Inc, Carpinteria, 
CA) at the Colorado State University Proteomics and Metabolomics Facility. The 
7AAD signal was measured on a detector with a 630/30 Band pass filter and the 
CF647 Annexin V signal was measured on a detector with a 670/20 Band pass 
filter, with compensation used between the two dyes. Data were analyzed using 
Summit Software (Dako Colorado Inc). Cell counts for control versus PRR15-
shRNA were compared by a Student’s t-test, with p<0.05 considered statistically 
significant. 
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Results and Discussion 
Microarray and qPCR Analyses 
Transfection and infection of ACH-3P cells with an shRNA to target 
PRR15 resulted in a comparable decrease in PRR15 mRNA concentrations for 
both methods. Lentiviral infection led to a 68% decrease in PRR15 mRNA 
(p<0.01, Figure III-1A), while stably transfected cells exhibited a 69% reduction 
(p<0.01, Figure III-1B). In the microarray comparison of control to PRR15-shRNA 
cells, 1375 genes were differentially expressed with a p<0.05 and greater than 
1.3-fold change (Figure III-2A). Pathway analysis was conducted on these 
differentially expressed genes using KEGG pathway maps. From the 1375 input 
genes, 285 genes were found in 155 total pathway maps. Fisher’s exact test 
revealed significant changes in pathways related to proliferation, cancer, and 
focal adhesion (Figure III-2B). Specifically, colorectal cancer, p53 signaling, and 




A B  
Figure III-1. qPCR for PRR15 in ACH-3P cells transfected and infected with 
shRNA. 
PRR15 mRNA concentration decreased significantly in the presence of an 
shRNA to target the mRNA for degradation. qPCR for PRR15 normalized to 
ribosomal protein S15 in (A) cells infected with lentiviral particles or (B) cells 
transfected with vectors with or without shRNA. LL3.7 indicates cells infected or 
transfected with control lentilox vector; shRNA indicates cells infected or 
transfected with virus/vector containing PRR15-targeting shRNA. ** indicates 

















































A  B  
Figure III-2. Volcano plot and pathway analysis from PRR15 microarray. 
(A) Volcano plot showing changes in all probe sets measured in microarray 
analysis of control compared to PRR15-shRNA ACH-3P cells. (B) KEGG 
pathway analysis of 1375 differentially expressed genes with p<0.05 and greater 
than 1.3-fold change in microarray analysis comparing control to PRR15-shRNA. 
The p-value represents the results of Fisher’s exact test. 
From the microarray analysis, we selected genes for validation with qPCR 
that had the most dramatic changes in the PRR15-depleted cells or had known 
cellular functions potentially related to trophoblast development. Twenty-one 
genes were selected for validation, 18 (86%) of which gave results consistent 
with the microarray study. The remaining genes expressed the same trend of up- 
or down-regulation as in the microarray analysis, but were not statistically 
significant (p≥0.05) in the qPCR results (Table III-1). The genes that were 
validated by qPCR can be divided into several functional groups, with some 




























CCNG2, CDK6, CDNK1A), cell differentiation (JAG1, OVOL2, TWIST1), cell 
survival/apoptosis (CRYAB, GDF15, MXD1, MYC, TNFSF10), cell migration 
and/or invasion (CCDC88A, PTEN, PXN, TFPI2, TWIST1), insulin-like growth 
factor (IGF) signaling (IGF1R, IGFBP3, PTEN, SOCS2), and placental function 




















Table III-1. Differentially expressed genes from PRR15 microarray. 
Genes identified as significantly up- or down-regulated in PRR15-deficient cells 
by microarray analysis with validation by qPCR. For each gene, all probesets 
from the microarray analysis are shown. 
Symbol Name 
Microarray qRT-PCR 
Fold p Fold p 
Cell Cycle Regulation 




CCNG2 cyclin G2 
+2.4 0.012 
+2.1 0.002 +3.3 0.003 
+2.8 0.036 






CDKN1A cyclin-dependent kinase inhibitor 1A (p21) +1.9 0.014 +1.7 0.030 
Cell Differentiation 




OVOL2 ovo-like 2 -2.4 0.030 -2.8 0.034 
TWIST1 twist homolog 1 -1.8 0.025 -1.5 0.206 
Cell Survival or Apoptosis 
CRYAB crystallin α B +4.6 0.009 +3.8 0.002 
GDF15 growth/differentiation factor 15 +3.6 0.007 +49.0 0.0001 





v-myc myelocytomatosis viral oncogene 
homolog -1.6 0.016 -2.4 0.003 
TNFSF10 
tumor necrosis factor superfamily member 
10 (TRAIL) 
+2.8 0.069 
+8.1 0.011 +2.8 0.007 
+3.0 0.001 
Cell Migration or Invasion 
CCDC88A coiled-coil domain containing 88A (girdin) -3.3 0.043 -3.1 0.047 






PXN paxillin -2.1 0.097 -1.4 0.017 





IGF1R insulin-like growth factor 1 receptor 
-1.4 0.300 
-1.6 0.185 -1.4 0.018 
-2.2 0.005 
IGFBP3 insulin-like growth factor binding factor 3 -2.1 0.008 -2.0 0.019 
SOCS2 suppressor of cytokine signaling 2 -2.9 0.008 -2.8 0.009 
Placental Function 







Differential expression of genes related to proliferation and cell cycle 
regulation revealed a reduction in pro-proliferative genes (CCND1, CDK6, JAG1, 
MYC, TWIST1) and an increase in anti-proliferative genes (CCNG2, CDKN1A, 
MXD1) in the PRR15-shRNA cells. Cyclin D1 (CCND1), cyclin G2 (CCNG2), 
cyclin-dependent kinase 6 (CDK6), and cyclin-dependent kinase inhibitor 1A 
(CDKN1A, also known as p21 Cip1) function as direct regulators of cell cycle 
progression. CCND1 and CDK6 promote progression through the G1 phase of 
the cell cycle,267 while CCNG2 induces G1/S phase arrest268 and CDKN1A can 
induce cell cycle arrest at the G1- or G2-phase checkpoints.269 Decreased 
expression of CCND1 and CDK6 and an increase in CCNG2 and CDKN1A in the 
PRR15-shRNA suggest proliferation may be diminished in PRR15-deficient cells.  
The insulin-like growth factor (IGF) signaling axis also plays a role in cell 
proliferation: binding of IGF1 and 2 to the IGF1 receptor (IGF1R) promotes cell 
growth and proliferation.270 Circulating IGFs are often bound to IGFBP3 which 
protects them from proteolysis and enhances IGF activity. Treatment with IGF-I 
and IGF-II promotes proliferation and protects cytotrophoblasts from apoptosis in 
first-trimester villous explants, and this effect is mediated in part through 
IGF1R.271 Both IGF1R and IGFBP3 were down-regulated in the PRR15-shRNA 
cells (1.6-fold, p=0.185, 2.0-fold, p=0.019, respectively), suggesting a decrease 
in IGF-axis activity and a decrease in proliferation in the PRR15-depleted cells. 
Conversely, suppressor of cytokine signaling 2 (SOCS2), a negative regulator of 
the IGF1 signaling pathway,272 was also reduced in the PRR15-shRNA (1.4-fold, 
p=0.009), which conflicts with the directional changes observed in IGF1R and 
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IGFBP3. Furthermore, phosphatase and tensin homolog (PTEN), a well-
described tumor suppressor, was significantly down-regulated in the PRR15-
deficient cells. PTEN has been connected to numerous cellular functions 
including controlling cell migration through its dephosphorylation of 
phosphatidylinositol-3,4,5-trisphosphate (PIP3).273 The reduction of PTEN in the 
PRR15-shRNA may affect cell migration in these cells rather than decreasing 
proliferation. Despite a few discordant results, the majority of validated genes 
suggested that trophoblast cell proliferation would be reduced in the PRR15-
shRNA cells as compared to the control. 
Proliferation decreases and apoptosis increases PRR15-deficient cells 
 Because the microarray revealed differentially expressed genes in 
pathways related to proliferation and cell survival, we opted to measure 
proliferation and apoptosis in PRR15-depleted trophoblast cells. ACH-3P cells 
transfected with the shRNA-expressing vector to target PRR15 mRNA for 
degradation had significantly decreased proliferation based on the CCK-8 assay 
(Figure III-3A). When measured by the uptake of BrdU, the decrease in the 
PRR15-shRNA was not statistically significant (p=0.092), although the same 
trend toward decreased proliferation in the PRR15-shRNA cells was observed 
(Figure III-3B). The CCK-8 assay measures cell metabolic activity through the 
reduction of a tetrazolium salt by cellular dehydrogenases to a yellow-colored 
dye. The decreased absorbance observed in the PRR15-deficient cells may be 
due to a reduction in cellular proliferation, increased apoptosis, decreased 
metabolic activity, or a combination of these phenotypes. The BrdU assay 
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measures DNA synthesis and though it showed a decrease in the PRR15-shRNA 
cells, the difference was not as dramatic, suggesting that the PRR15-deficient 
cells may be more susceptible to apoptosis. 
A   B  
Figure III-3. Proliferation decreases in PRR15-deficient ACH-3P cells.  
(A) CCK-8 assay presenting change in absorbance over time in culture of stably 
transfected ACH-3P cells. (B) ELISA for BrdU uptake in stably transfected ACH-
3P cells. Control indicates cells transfected with control LL3.7 vector; PRR15-
shRNA indicates cells transfected with vector containing PRR15-targeting 
shRNA. ** indicates p<0.01.  
Apoptosis was measured by the activation of caspases involved in the 
apoptotic cascade. Caspase 3/7 activity was significantly increased in the 
PRR15-shRNA cells, while caspase 8 activity was unchanged (Figure III-4A). 
Caspases, or cysteine-dependent aspartate-specific proteases, are enzymes that 
aid in the execution of programmed cell death or apoptosis. Caspase 8 is known 
as an ―initiator‖ caspase in the extrinsic pathway of apoptosis, while caspases 3/7 
are ―executioner‖ caspases activated by both the intrinsic and extrinsic apoptotic 
pathways.274 The changes observed suggest that the PRR15-deficient cells are 

















































We confirmed the changes in apoptosis by measuring annexin V staining 
followed by quantification with flow cytometry. Annexin V specifically binds to 
phosphatidylserine on the outer surface of cells in the early stages of apoptosis; 
phosphatidylserine remains primarily on the inner leaflet of the plasma 
membrane in viable cells.275 In order to distinguish apoptotic from dead cells, 7-
AAD is used which binds to nucleic acids in late apoptotic or necrotic cells. The 
percentage of cells that did not absorb either the Annexin Red or 7-AAD stains 
decreased significantly in the PRR15-shRNA cells, while early apoptotic and late 
apoptotic/necrotic cells increased (Figure III-4B). These results demonstrate an 
increased tendency to undergo apoptosis when PRR15 mRNA concentration is 
decreased in ACH-3P cells.  
A   B  
Figure III-4. Apoptosis increases in PRR15-deficient ACH-3P cells.  
(A) Caspase 3/7 and 8 activity was measured using Caspase-Glo Reagent. 
Luminescence values were normalized to protein concentration in each well. 
Different letters above bars indicate p<0.05 in Student’s t-test. (B) Annexin V 
staining was quantified by flow cytometry. 7AAD(-), AnnV(-) indicates cells that 
were not positive for either stain; 7AAD(+) indicates necrotic cells; AnnV(+) 
indicates early apoptotic cells; 7AAD(+), AnnV(+) indicates late apoptotic and 




























































In the microarray analysis, we observed differential expression of several 
genes related to apoptosis. TNFSF10, also known as TRAIL, is a death receptor 
ligand known to induce apoptosis in transformed and tumor cells;276 TFNSF10 
was up-regulated in PRR15-deficient cells (8.1-fold, p=0.011). This ligand could 
signal to the trophoblast cells themselves, or to endometrial cells in vivo. 
TNFRSF10b (TRAIL-R2, DR5), a receptor for TRAIL, increased 1.5-fold 
(p=0.007) in PRR15-deficient trophoblast cells. TNFSF10 mRNA concentration 
was elevated in placentas from women experiencing recurrent miscarriage, and 
its soluble form was elevated in maternal serum.277 Furthermore, inhibition of 
IGF1R kinase activity increases melanoma cell susceptibility to TRAIL-induced 
apoptosis, and IGF1R was also down-regulated in the PRR15-shRNA.278 These 
studies indicate that TRAIL could directly affect trophoblast apoptosis in vitro and 
may play a role in embryonic loss when PRR15 was targeted for degradation in 
vivo.75 In normal placental development, PRR15 likely protects cells from 
apoptosis and enhances cell survival, aiding in proper remodeling and formation 
of the placenta. In contrast to TNFSF10, CRYAB, a small heat shock protein that 
may protect cells from apoptosis,279,280 was increased 3.8-fold (p=0.002) in the 
PRR15-shRNA. However, recent studies show that CRYAB interacts directly with 
p53 and is required for p53-dependent apoptosis281 and its anti-apoptotic function 
is affected by its phosphorylation status.282 Furthermore, the role of increased 
CRYAB in PRR15-depleted cells may be related to cellular functions other than 
apoptosis, such as acting as a chaperone for vascular endothelial growth factor A 
(VEGFA) during angiogenesis, a process critical for early placentation.283 
65 
Apoptosis, or programmed cell death, is a necessary process in normal 
placental development as trophoblast cells undergo constant turnover and 
renewal. However, apoptosis increases in placentas suffering from complications 
such as preeclampsia, intrauterine growth restriction, and hydatidifiorm moles.284 
In relation to the cell cycle and proliferation, evidence shows that CCND1 is 
decreased in placentas from IUGR and IUGR with preeclampsia285, while 
CDKN1A is increased in IUGR placentas.286 During normal trophoblast 
development, PRR15 may protect cells from apoptosis and promote trophoblast 
cell proliferation and survival. 
MYC is a transcription factor and oncogene that is frequently 
overexpressed in cancer cells; while it drives cell proliferation, it also sensitizes 
cells to death receptor-mediated apoptosis.287 In first-trimester human placentas, 
the extravillous trophoblast, endovascular trophoblast cells, and 
syncytiotrophoblast express MYC protein.288 MXD1 is another transcriptional 
regulator that antagonizes MYC actions, and has anti-apoptotic effects partially 
through its repression of PTEN transcription.289 MYC was down-regulated 2.4-
fold (p=0.003) and MXD1 was up-regulated 1.7-fold (p=0.025) in PRR15-
depleted trophoblast cells, which is consistent with decreased proliferation in 
these cells but not with increased apoptosis. Jagged-1 (JAG1) is a ligand for 
Notch receptors which is highly expressed in first-trimester cytotrophoblasts and 
promotes cell proliferation.290 It may be involved in endovascular remodeling and 
is decreased in cytotrophoblasts from preeclamptic placentas.291 JAG1 was up-
regulated (2.0-fold, p=0.001) in the PRR15-shRNA cells, which is not consistent 
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with decreased proliferation in these cells. The control of cell cycle progression 
and cell survival is maintained through a delicate balance of a plethora of factors; 
these data suggest that PRR15-deficiency shifts the balance toward decreased 
proliferation and increased susceptibility to apoptosis. 
A significant down-regulation of genes which function in cell migration 
and/or invasion was observed in the PRR15-shRNA cells (CCDC88A, PTEN, 
PXN, TFPI2, TWIST1).292 Paxillin (PXN) is a component of focal adhesions and 
is highly expressed from 5 to 8 weeks of gestation in villous and extravillous 
trophoblast cells; expression decreases dramatically at 10-12 weeks of gestation, 
when placental oxygen tension increases.293 IGF1R signaling leads to 
phosphorylation of paxillin (PXN) during the assembly of focal adhesions and 
stimulates extravillous trophoblast migration.294,295 Girdin (CCDC88A) is a non-
receptor guanine nucleotide exchange factor for Gαi which localizes to 
lamellipodia296 and is required for migration and invasion of breast cancer 
cells.297 PXN was down-regulated 1.4-fold (p=0.017) while CCDC88A was down-
regulated 3.1-fold (p=0.047). Conversely, tissue factor pathway inhibitor 2 
(TFPI2), a potent inhibitor of matrix metalloproteinases 2 and 9 and possible 
inhibitor of invasion298 was also significantly down-regulated, which would 
support an increase in the invasive capacity of PRR15-deficient trophoblast cells. 
This protease inhibitor is normally expressed only in the syncytiotrophoblast of 
the human placenta, and is absent from the proliferative cytotrophoblasts and 
invasive extravillous trophoblasts.299 
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TWIST1 is a transcription factor involved in the epithelial-mesenchymal 
transition during cancer metastasis and invasion.300 It has been suggested that 
during implantation, the process of trophoblast invasion into maternal tissue 
requires a partial epithelial-mesenchymal transition of trophoblast cells.301 
TWIST1 is up-regulated upon conceptus attachment to the luminal epithelium in 
bovine pregnancies. 302 It is highly expressed in human first-trimester extravillous 
trophoblast and is required for trophoblast invasion.303 TWIST1 was down-
regulated in the microarray and qPCR analyses but the decrease was not 
statistically significant in the qPCR validation (1.5-fold, p=0.206). Impaired 
trophoblast invasion is a well-described phenotype of severe preeclamptic and 
IUGR placentas, pointing towards a possible function of PRR15 in these 
pregnancy disorders.  
Differentially expressed genes from the microarray analysis with known 
functions in implantation or placentation included LIFR and OVOL2. Endometrial 
expression of leukemia inhibitory factor (LIF) is required for implantation in 
mice,304 and is decreased in women with unexplained infertility and recurrent 
pregnancy loss.305,306  Its receptor, LIFR, increases significantly during the period 
of conceptus elongation in pigs.307 LIFR mRNA was detected by in situ 
hybridization in human villous and extravillous trophoblast, while LIF mRNA was 
primarily detected in the decidua.308 LIF promotes proliferation of trophoblast 
cells in culture and invasiveness of JEG3 cells.309,310 Down-regulation of LIFR 
(1.3-fold, p=0.033) in the PRR15-shRNA cells could contribute to the decreased 
proliferation observed. OVOL2 is a zinc-finger transcription factor that directly 
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represses transcription of MYC and NOTCH1.311 OVOL2 knockout mice exhibit 
impaired placental labyrinth development and embryonic mortality by day 12.5 of 
gestation.312 Down-regulation of both LIFR and OVOL2 (2.8-fold, p=0.034) in the 
PRR15-shRNA may have contributed to the embryonic loss observed in sheep 
when PRR15 was depleted in vivo.75 
Growth/differentiation factor 15 is up-regulated in PRR15-deficient cells 
Growth/differentiation factor 15 (GDF15, MIC1) was up-regulated in the 
microarray analysis by 3.6-fold (p=0.007). When evaluated with qPCR, we 
observed a 49-fold increase (p<0.01) in the PRR15-depleted cells. This 
suggested PRR15 may have a substantial impact on the concentration of GDF15 
mRNA. The time course of PRR15 expression in the sheep conceptus reveals a 
peak in expression at day 16 of gestation, which diminishes dramatically by day 
30 (Figure III-5A), as reported previously.75 Analysis of GDF15 mRNA 
concentrations in the same samples revealed low levels of GDF15 during peak 
PRR15 expression, and a striking increase in GDF15 at day 30 of gestation 
(Figure III-5B). This demonstrated an inverse relationship between PRR15 and 





A   B  
Figure III-5. PRR15 and GDF15 mRNA concentrations during early ovine 
gestation. 
Profile of PRR15 (A – reproduced from Purcell et al. 2009) and GDF15 (B) 
mRNA concentrations in ovine conceptuses from days 11 to 30 of gestation, as 
measured by qPCR and normalized to GAPDH. Bars with different letters above 
them are statistically different (p<0.05). 
GDF15 is a non-canonical member of the transforming growth factor β 
superfamily of cytokines that is significantly up-regulated during pregnancy.230 
GDF15 peaks in circulation at 12-14 weeks gestation, and again at 33-35 weeks 
at approximately double the initial concentrations.230 It is expressed primarily in 
villous and extravillous cytotrophoblast as well as decidual stroma, but not in the 
syncytiotrophoblast.313,233 Treatment of immature dendritic cells with exogenous 
GDF15 favored the development of an immature more tolerant phenotype, which 
may contribute to maternal immune tolerance to the semiallogenic conceptus.233 
During the first trimester, Tong et al. demonstrated decreased concentrations of 
GDF15 in maternal serum in pregnancies that ended in miscarriage.314 
Furthermore, GDF15 placental mRNA concentrations were elevated in 
preeclampsia when compared to control samples from term placentas; this 
elevation was also observed in maternal and fetal circulation.315,236 However, 
Marjono et al. detected no significant differences in serum concentrations of 
GDF15 associated with either labor or preeclampsia.230 The discrepancy may be 
a result of how the authors defined preeclampsia in these studies or the very 


















day of gestation 
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limited sample size in the study by Marjono et al. Treatment of HTR8-SVneo cells 
with GDF15 resulted in reduced proliferation and increased apoptosis as GDF15 
concentrations increased.316 This parallels the phenotypic changes observed 
when we diminish PRR15 in ACH-3P cells, where GDF15 expression increased 
nearly 50-fold. The function of GDF15 in early implantation and placentation is 
not known, though the significant up-regulation observed in the PRR15-shRNA 
cells may infer a contribution to pregnancy failure when PRR15 was targeted for 
degradation in ovine trophectoderm.75 Moreover, it may act as a secreted signal 
of placental dysfunction during early implantation 
This study provides evidence that PRR15 affects gene expression of 
trophoblast cells and is required for trophoblast proliferation and survival. 
Diminished expression of PRR15 in ACH-3P cells produced changes in the 
expression of genes related to cell cycle control as well as apoptosis, migration, 
and invasion. PRR15 may function through a variety of mechanisms in order to 
directly affect gene expression. Immunohistochemistry and the conserved 
nuclear localization signal suggest that PRR15 is primarily nuclear, although it 
lacks a putative DNA- or RNA-binding motif.75 It may bind to other transcription 
factors to suppress or activate transcription of GDF15 and other genes, or its 
effects could be post-transcriptional. Post-transcriptional gene regulation can 
occur through alternative splicing, modified capping and polyadenylation, 
restriction of nuclear export, and translational inhibition.317 Preliminary evidence 
from our laboratory shows that PRR15 interacts with proteins involved in mRNA 
processing and transport, such as heterogeneous nuclear ribonucleoprotein 
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(hnRNP) A2/B1, hnRNP D0, lin28 homolog B, and nucleophosmin (Cantlon JD, 
Anthony RV, unpublished results). These interactions suggest that PRR15 could 
directly affect mRNA concentrations by modulating processing or splicing of initial 
transcripts, or by sequestering mRNAs in nuclear bodies. Many of the effects of 
PRR15 on gene expression are likely indirect via changes to upstream regulators 
of multiple other genes.  
The microarray analysis was conducted in ACH-3P cells, a fusion of 
primary first-trimester trophoblast cells with a choriocarcinoma cell line.318 The 
fact that these cells are transformed for continuous culture and express some 
degree of tumorigenic potential could affect the transcriptome.319 Confirmation of 
the differentially expressed genes in a primary cell line would reinforce the 
validity of these results. However, primary first-trimester human trophoblast cells 
are difficult to obtain, and problematic to culture due to their rapid 
differentiation.320,321 Limited time is allowed for altering gene expression prior to 
replicative senescence. Post-transcriptional regulation plays an important role in 
regulating a number of genes which could be involved in early placental 
development. This study is limited to identifying those genes regulated at the 
mRNA level due to the nature of a microarray analysis. Nevertheless, it sheds 
light on potential pathways involved in early placental development which may be 
critical to early embryonic survival. The demonstration of early embryonic loss 
when PRR15 was targeted for degradation in vivo75 supports a critical role for 
this protein and the pathways in which it functions for appropriate formation of the 
placenta during early pregnancy. Though PRR15 itself may not be a useful 
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biomarker due to its nuclear localization, secreted downstream proteins such as 
TRAIL and GDF15 could act as signals of impending embryonic loss and/or 
dysfunctional placentation. Furthermore, understanding the regulatory pathways 
involved in embryonic survival and normal placental development will aid in 
identifying therapeutic targets for pathologic changes. The microarray results and 
phenotype of PRR15-deficient cells suggest that PRR15 promotes trophoblast 
proliferation and enhances cell survival – roles that are critical to proper placental 
development during early pregnancy.  
Summary 
Maintenance of pregnancy in mammals requires a sophisticated and 
tightly regulated program of gene expression in order to develop a fully functional 
placenta. This transient organ mediates nutrient and gas exchange between the 
mother and fetus while protecting the fetus from the maternal immune system. 
Deviations from the normal regulation of gene expression during early pregnancy 
can lead to early embryonic loss as well as dysfunctional placentation, which can 
cause significant maternal and fetal morbidity and mortality. Proline rich 15 
(PRR15) is a low molecular weight nuclear protein expressed by the trophoblast 
during early gestation in several mammalian species, including humans, mice, 
cattle, sheep, and horses. Immunohistochemistry localized PRR15 to the 
trophectoderm and extraembryonic endoderm of day 15 sheep conceptuses. In 
humans, PRR15 is localized in the nuclei of both first and second trimester 
trophoblast cells. PRR15 mRNA expression increases when trophoblast cells, 
both sheep (oTR) and human (ACH-3P), are cultured on Matrigel, a basement 
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membrane matrix. The expression profile in the sheep conceptus during 
pregnancy revealed a rise during the period of conceptus elongation with a peak 
in expression at day 16 of gestation, followed by a decline to day 30 of gestation. 
This peak coincides with a halt in elongation of the conceptus, and the initial 
period of apposition to the uterine luminal epithelium. Lentiviral-mediated 
knockdown of PRR15 in ovine trophectoderm at the blastocyst stage led to 
demise of the embryo by gestational day 15. This provides compelling evidence 
that PRR15 is a critical factor during this precarious window of development 
when initial attachment and implantation begin. The aims of these experiments 
were to determine the effect of PRR15 knockdown on trophoblast gene 
expression, as well as trophoblast proliferation and survival. The human first 
trimester trophoblast cell line, ACH-3P, was infected with control lentivirus 
(LL3.7) and lentivirus expressing a short hairpin (sh)RNA to target PRR15 mRNA 
for degradation, resulting in a 68% decrease in PRR15 mRNA (p<0.01). 
Microarray analysis of these cell lines revealed differential expression of genes 
related to cancer, focal adhesion, and p53 signaling. We selected 21 genes for 
validation of mRNA levels by quantitative real-time RT-PCR, 18 (86%) of which 
gave results consistent with the microarray analysis. These changes included 
significant up-regulation of GDF15, a cytokine increased in pregnancies with 
preeclampsia. We evaluated GDF15 mRNA concentrations during early ovine 
gestation and found that GDF15 was low during peak PRR15 expression, then 
increased significantly at day 30 when PRR15 was nearly undetectable. 
Proliferation decreased in the absence of PRR15, which was consistent with a 
74 
decrease observed in cell cycle-related genes CCND1 and CDK6, and an 
increase CCNG2 and CDKN1A in the PRR15-deficient cells. TNFSF10, a tumor 
necrosis factor superfamily member known to induce apoptosis, and its receptor, 
TNFRSF10b, increased significantly in the PRR15-deficient cells, suggesting 
trophoblast cells may be more susceptible to apoptosis when depleted of PRR15. 
Assays for caspase activity and annexin V staining revealed an increased 
population of apoptotic cells when treated with shRNA to target PRR15. These 
results suggest that PRR15 is required for driving trophoblast proliferation and 
survival during early development of the placenta, functions that are critical to 
early embryonic survival and successful placentation. 
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CHAPTER IV – Transcriptional Regulation of PRR15 
Introduction 
Reproduction in mammals requires the development of the placenta: a 
transient yet essential organ that mediates maternal to fetal exchange while 
protecting the fetus from the maternal immune system. After successful 
fertilization, the embryo must navigate through a precarious time in development: 
implantation and early placentation. In humans, it is estimated that nearly half of 
all conceptions are lost, with the majority of these losses occurring during early 
pregnancy.322,323 Additionally, pregnancy complications such as early-onset 
preeclampsia and intrauterine growth restriction, originate with defective 
placentation during the first trimester.324 Ruminants experience similar early 
embryonic losses to humans, with up to 30% loss during the period of 
trophectoderm outgrowth and elongation.325 Expressing the appropriate 
repertoire of proteins in specific spatial and temporal patterns is critical to 
reproductive success, while aberrations in expression can lead to pregnancy loss 
and placental dysfunction.  
Proline rich 15 (PRR15) is a small, well-conserved nuclear protein 
expressed by the trophectoderm during early pregnancy in ruminants.75 The 
PRR15 gene encodes a 126 amino acid protein with four putative protein kinase 
C (PKC) phosphorylation sites, two casein kinase II phosphorylation sites, and a 
nuclear targeting sequence.251 The expression profile in the sheep conceptus 
during pregnancy revealed a peak in expression at day 16 of gestation, followed 
by a decline to day 30.75 The peak of PRR15 expression coincides with a halt in 
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elongation of the conceptus, and the period of apposition to the uterine 
epithelium.326 Immunohistochemistry demonstrated localization of PRR15 to the 
trophectoderm and extraembryonic endoderm of day 15 sheep conceptuses.75 In 
humans, PRR15 is immunolocalized to the nuclei of both first and second 
trimester placental sections, predominantly in cytotrophoblast cells.253 Lentiviral-
mediated knockdown of PRR15 in ovine trophectoderm at the blastocyst stage 
led to demise of the embryo by gestational day 15,75 indicating that PRR15 is a 
critical factor during implantation and early trophoblast development.  
PRR15 transcripts were concurrently identified by in situ hybridization of 
small and large intestine, and were present primarily in cells that lie in the 
transitional zone of intestinal villi.248 This zone represents a population of cells 
which have migrated out of the proliferative crypts, and continue to differentiate 
as they migrate toward the villous tips.327 Meunier et al. observed PRR15 
expression in mouse gastrointestinal tumors caused by mutations in the Apc 
gene, as well as in several human colorectal cancers and suggested that PRR15 
is linked to the Wnt signaling pathway.251  
Wnt signaling is a conserved pathway involved in development and is 
frequently altered in cancer. In the absence of Wnt binding to its extracellular 
receptor, β-catenin is phosphorylated by glycogen synthase kinase 3β (GSK3β) 
in a destruction complex with adenomatous polyposis coli (Apc), axin, and casein 
kinase I, and is targeted for proteasomal degradation. When Wnt ligands are 
present, the destruction complex is inactive; β-catenin accumulates within the 
cytoplasm and translocates to the nucleus where it interacts with T cell 
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factor/lymphoid enhancer factor (TCF-LEF) transcription factors to activate 
transcription of Wnt target genes.328 This pathway is known as the ―canonical‖ 
Wnt signaling cascade, while the ―non-canonical‖ pathway regulates cell polarity 
and cell division independent of β-catenin.329 Mutations in Apc are commonly 
found in cancers, leading to accumulation of β-catenin and transcription of Wnt 
target genes. Given the increased expression of PRR15 observed in Apc 
mutants, it is feasible that PRR15 is a Wnt target gene.  
Transcriptional regulation is the first step in determining the amount of 
protein a cell will produce in different conditions or developmental stages. Spatial 
and temporal regulation of gene transcription is primarily determined by the 5’-
flanking region or promoter, which contains cis-acting regulatory elements that 
interact with transcription factors. Binding of specific transcription factors can 
either enhance or reduce recruitment of RNA polymerase II and transcription of 
the gene of interest. The pattern of PRR15 expression during early gestation75 
suggests it is under complex positive and negative transcriptional regulation, in 
order to be strictly expressed in specific developmental periods and cell types. 
Given the lethal effect of its absence,75 we aimed to examine regions of the 
PRR15 promoter necessary for regulating its expression in trophoblast cells and 
to localize putative transcription factor binding sites. We also examined the role 
of the Wnt signaling pathway on the transcription of PRR15.  
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Materials and Methods 
Cell Culture 
ACH-3P cells, a fusion of human first-trimester trophoblasts with a 
choriocarcinoma cell line,100 were cultured as described previously (Chapter III). 
oTR-19 cells were generated by collecting day 15 ovine conceptuses to generate 
trophoblast cell lines as described.330 Estrus was detected in mature ewes in the 
presence of a vasectomized ram. At estrus, day 0, ewes were mated to intact 
rams. On day 15 after mating, the uterus was flushed with sterile PBS to collect 
the conceptuses. These were minced and plated on plastic culture dishes in 
DMEM/F12 medium supplemented with 10% fetal bovine serum, 2 mM 
glutamine, 700 nM insulin, 1 mM pyruvate, and 0.1 mM non-essential amino 
acids. Cells were maintained for no more than 20 passages. HT29 cells, derived 
from a human colorectal carcinoma, and BHK21 cells, hamster kidney 
fibroblasts, cells were obtained from American Type Culture Collection 
(Manassas, VA) and grown in McCoy’s 5A Medium Modified or Eagle’s Minimum 
Essential Medium, respectively, supplemented with 10% FBS.  
Promoter Deletion Constructs and Transfections 
Genomic DNA from human blood was isolated using the Wizard® 
Genomic DNA Purification Kit (Promega, Madison, WI). The 5’-flanking sequence 
from -824 to +7 bp relative to the annotated transcription start site of the human 
PRR15 gene (Accession  NM_175887, National Center for Biotechnology 
Information) was amplified by PCR using human genomic DNA as a template 
and cloned into PCR-Script Amp SK(+) (Agilent Technologies). Deletion 
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constructs from -640, -424, -326, and -284 bp to the transcription start site were 
generated by PCR using the full-length construct as a template, and cloned into 
PCR-Script Amp SK(+). All vectors were sequenced to determine authenticity 
and the direction of insertion, then sub-cloned and ligated into pGL3-Basic 
(Promega). Reporter vectors were sequenced to verify the correct direction of 
insertion of the promoter cassette.  
Transient transfections were performed as described by Jeckel et al. with 
some modifications.331 ACH-3P, oTR-19, HT29, and BHK21 cells were co-
transfected with the reporter vectors and a RSV-β-galactosidase vector as a 
transfection control in a 20:1 ratio using Superfect (Qiagen), following the 
manufacturer’s protocol. The day prior to transfection, 2x105 cells per well were 
seeded on 6-well plates. In a total volume of 300 µl, 5.7 µg reporter vector and 
0.3 µg RSV-β-galactosidase vector were added to serum-free medium for 
transfection of three replicate wells. The DNA mixture was incubated with 30 µl 
Superfect reagent at room temperature for 10 minutes, then split among three 
wells in 600 µl complete medium per well. Transfection complexes were removed 
after three hours and replaced with fresh complete medium.  
Two days after transfection, cells were washed three times in PBS and 
lysed in 200 µl lysis buffer (25 mM glycyl-glycine, pH 7.8; 1.0% Triton X-100, 10 
mM MgSO4, and 1.0 mM dithiothreitol). For luciferase activity, 20 µl of cell lysate 
was added to 100 µl luciferin; luminescence was measured after a two second 
delay with 10 second integration. Luminescence was measured on a TD 20/20 
Luminometer (Turner Designs, Sunnyvale, CA). For β-galactosidase activity, the 
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Galacto-Light Plus system (Applied Biosystems, Carlsbad, CA) was used. Cell 
extract (10 µl) was added to reaction buffer (200 µl) and incubated for one hour 
at room temperature. Accelerator II (300 µl) was added and luminescence 
integrated over 4 seconds. Experiments were repeated on three separate 
preparations of reporter plasmids. Activity of each reporter vector was compared 
to the empty vector control (pGL3 Basic) in a Dunnett’s t-test after normalizing to 
β-galactosidase activity. 
GSK3β Inhibitor, β-catenin Plasmids, and Quantitative Real-time PCR 
The GSK3β inhibitor SB216763 (Sigma-Aldrich, St. Louis, MO) was used 
to generate active β-catenin/TCF-LEF signaling in treated cells. ACH-3P cells 
were serum-starved (0.5% FBS) for two hours, then treated with either 10 µM 
SB216763 dissolved in DMSO or DMSO alone as a vehicle control for 24 hours 
prior to assay. For reporter activity in the presence of SB216763, transfections 
were performed as described above. For analysis of PRR15 mRNA 
concentrations, total cellular RNA was collected using the RNeasy Mini Kit 
(Qiagen). Reverse transcription and quantitative real-time PCR (qPCR) was 
performed as described previously (Chapter III). Concentrations of PRR15 
mRNA were normalized to the mRNA concentration of ribosomal protein S15. 
Proliferation of ACH-3P cells in the presence or absence of SB216763 was 
measured using the Cell-Counting Kit 8 (Enzo Life Sciences) as previously 
described (Chapter III). All samples were run in triplicate and experiments were 
repeated three independent times. DMSO- and SB216763-treated groups were 
compared by a Student’s t-test, with p<0.05 considered statistically different. 
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In order to determine the role of β-catenin in PRR15 promoter activity, 
ACH-3P cells were transfected with constitutively active β-catenin or shRNA 
targeting β-catenin mRNA for degradation. The pMXs-beta-catenin-S33Y plasmid 
(Addgene, Cambridge, MA) harbors a point mutation (S33Y) resulting in 
expression of a constitutively active form of β-catenin.332 pLKO.1-puro-shRNA-
beta-catenin (Addgene) is a plasmid that expresses a shRNA directed against β-
catenin mRNA.333 Transfections were performed as described above with some 
modifications. The -824 reporter plasmid was co-transfected in a 1:1 ratio with 
pBlueScript as a negative control and treated with DMSO or SB216763 as 
previously described. Additional samples were co-transfected in a 1:1 ratio with 
the -824 reporter plasmid and the plasmid expressing a shRNA to target β-
catenin mRNA for degradation or the plasmid expressing constitutively active β-
catenin (S33Y). Transactivation of the luciferase reporter was measured as 
described above. Luciferase activity of each sample was compared to the DMSO 
control in a Student’s t-test, with p<0.05 considered statistically significant. 
Nuclear Extraction 
ACH-3P and HT29 cells were dislodged from subconfluent culture dishes 
using trypsin (0.25% with 0.5 mM EDTA), washed in PBS, and pelleted. Nuclear 
protein was extracted using a modified Dignam method.334 Cells were 
resuspended in three volumes of hypotonic buffer (10 mM HEPES, 1.5 mM 
MgCl2, 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF) and allowed to swell on ice for 
10 minutes. The cells were homogenized in a Dounce homogenizer and nuclei 
were pelleted by centrifugation at 3300xg for 30 minutes. The nuclear pellet was 
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resuspended in ½ volume low salt buffer (0.15 M NaCl, 0.1 mM EDTA, 20 mM 
TrisHCl, 0.5 mM DTT, 0.2 mM PMSF), followed by slowly adding ½ volume of 
high salt buffer (same as low salt with 1 M NaCl). Nuclei were extracted by gentle 
shaking on ice for 30 minutes, then pelleted by centrifugation at 25,000xg for 30 
minutes. The nuclear extract was dialyzed overnight in 10,000 molecular weight 
cutoff (MWCO) Slide-A-Lyzer dialysis cassettes (Thermo Scientific) against 
dialysis buffer (20 mM HEPES, 0.2 mM EDTA, 0.5 mM DTT, and 0.2 mM PMSF). 
Following dialysis, the extract was concentrated by centrifugation over a 3,000 
MWCO Amicon centrifugal filter (Millipore) and protein concentration was 
determined by Bradford assay. Glycerol (20%) was added as a cryoprotectant 
prior to aliquoting and storing at -80°C until use. ACH-3P cells for EMSA were 
treated with DMSO or GSK3β inhibitor (SB216763) for 24 hours prior to collection 
of nuclear extract. 
DNase I Footprinting 
Non-radiochemical DNase I footprinting was performed as described in 
Zianni et al. with some modifications.335 DNA fragments for footprinting were 
prepared by PCR of three overlapping constructs from the PRR15 proximal 
promoter (-855 to -510, -562 to -268, -286 to +7) using the plasmid containing the 
full proximal promoter as a template. Each forward primer was labeled on the 5’-
end with 6-FAM (Integrated DNA Technologies, Coralville, IA). The PCR was 
performed in 50 µl reactions as follows: 95°C for 5 minutes, followed by 40 cycles 
of 95°C for 1 minute, 55°C for 1 minute, and 72°C for 1 minute, followed by 72°C 
for 10 minutes. Reactions were electrophoresed through a 1% agarose gel to 
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verify size, then purified using QiaQuick PCR Purification columns (Qiagen). 
Concentration was assessed with a NanoDrop 1000 spectrophotometer (Thermo 
Scientific).  
Nuclear extracts or bovine serum albumin (100 µg) were incubated in 
binding buffer (12 mM Tris-HCl (pH 7.9), 1 mM MgCl2, 1 mM CaCl2, 5 mM NaCl, 
0.1 mM DTT, 5% glycerol, 1 µg herring sperm DNA) in 50 µl total volume on ice 
for 10 minutes. FAM-labeled probe (250 ng) was added, and incubated at 30°C 
for 30 minutes. RNase-free DNase I (Thermo Scientific) was added and reactions 
were incubated at 30°C for varying times, which were optimized for each 
promoter fragment. To terminate digestion, EDTA (50mM, pH 7.4) was added to 
a final concentration of 5 mM and reactions were incubated at 75°C for 10 
minutes. The FAM-labeled fragments were purified with QiaQuick PCR 
Purification columns (Qiagen) and eluted in nuclease-free water. Analysis was 
performed on an ABI 3130xL Genetic Analyzer (Applied Biosystems) by adding 3 
µl sample to 10 µl HiDi formamide (Applied Biosystems) and 0.3 µl GeneScanTM-
600 LIZ size standards (Applied Biosystems). Fragmentation patterns were 
analyzed using PeakScanner software (Applied Biosystems). 
Electrophoretic Mobility Shift Assay 
Oligonucleotides were generated with a biotin label on the 5’ end 
(Integrated DNA Technologies). Oligonucleotides were derived from the 
optimized TCF-LEF binding site336,337 (sense 5’- CCCTTTGATCTTACC-3’, 
antisense 5’-GGTAAGATCAAAGGG-3’) and from the protected -98 to -68 region 
of the PRR15 proximal promoter (sense 5’-
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GCACTGCACAGCTTTTCTCCAATCAGACAC-3’, antisense 5’-
GTGTCTGATTGGAGAAAAGCTGTGCAGTGC-3’). Complementary oligos were 
annealed by mixing in a 1:1 ratio to a final concentration of 1 pmol/µl in annealing 
buffer (10 mM Tris, 1 mM EDTA, 50 mM NaCl, pH 8.0) and heating to 95°C for 5 
minutes, followed by gradually cooling to room temperature. Gel shifts were 
performed using the LightShift Chemiluminescent EMSA Kit (Thermo Scientific). 
In a total of 20 µl, 10 µg nuclear extract and 0.5 pmol biotinylated oligos were 
combined in 1X Binding Buffer, 50 ng/µl Poly(dI:dC), 5% glycerol, 100 mM KCl, 1 
mM EDTA, and incubated at 37°C for 30 minutes. Unlabeled competing 
oligonucleotides were added in 200-fold molar excess to verify specificity of 
binding. Loading buffer (5 µl) was added to each binding reaction and samples 
were electrophoresed through a 5% polyacrylamide TBE gel (BioRad) at 100V 
for 45 to 90 minutes. DNA-protein complexes were transferred to a positively 
charged Biodyne B Nylon Membrane (Thermo Scientific) at 100V for one hour at 
4°C. Complexes were cross-linked for one minute at 120 mJ/cm2 using a CL-
1000 Ultraviolet Crosslinker (UVP, Upland, CA). Biotinylated DNA was detected 
by chemiluminescence following the manufacturer’s instructions. Membrane was 
exposed to X-ray film (Kodak, Rochester, NY) or analyzed on the ChemiDoc 
XRS (BioRad).  
Results and Discussion 
Proximal Promoter Transactivation 
The homology of the 5’-flanking region of the PRR15 gene is well-
conserved between the human and the cow in the first 800 bp (75% identity), and 
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begins to deviate widely beyond this point. The longest construct designed 
encompassed this evolutionarily conserved region to -824 bases of the human 
PRR15 5’-flanking region. Progressive deletions of the proximal promoter were 
generated at -640, -424, -326, and -284 bp from the annotated transcriptional 
start site. First trimester human trophoblast cells (ACH-3P) were co-transfected 
with promoter deletion constructs and a RSV-β-galactosidase transfection 
control. Transactivation of the luciferase reporter was measured by luminescence 
and normalized to β-galactosidase activity (Figure IV-1A). Transfections were 
repeated in primary ovine trophoblast cells (oTR-19), human colorectal 
carcinoma (HT29), and hamster kidney fibroblast (BHK21, Figure IV-1B, C, D, 
respectively). ACH-3P, oTR-19, and HT29 cells normally express PRR15 mRNA, 










A   B  
C   D  
Figure IV-1. Transactivation of luciferase reporter from PRR15 promoter deletion 
constructs.  
(A) ACH-3P = human first trimester trophoblast, (B) oTR-19 = primary ovine 
trophoblast, (C) HT29 = human colorectal carcinoma, (D) BHK21 = hamster 
kidney fibroblast. * indicates p<0.05 in Dunnett’s t-test when compared to empty 
vector control (pGL3-Basic).  
Maximal transactivation of the luciferase reporter was observed in the -
326 (15.4 ± 4.8-fold) and -824 (14.8 ± 5.8-fold) constructs in ACH-3P cells. 
Significant promoter activity was absent in the -284, -424, and -640 constructs in 
all cell lines. These results suggest that cis-acting elements within the proximal 
promoter of the PRR15 gene are essential for transcription in trophoblast cells, 
requiring the regions from -284 to -326 and -640 to -824. We examined these 
regions for putative transcription factor binding sites using the Transcription 
Element Search System (TESS, www.cbil.upenn.edu/tess/ ) and identified 



























































































electrophoretic mobility shift assays, discussed below, were used to verify 
protein-DNA interactions at these sites.  
ACH-3P cells exhibited the largest fold changes over the empty vector 
control, while none of the constructs demonstrated significant transactivation in 
the BHK21 cells. Though HT29 cells express relatively high levels of PRR15 
mRNA, transactivation of the luciferase reporter was not as robust as expected. 
This is could be due to the low transfection efficiencies we observed in these 
cells, or transcriptional activation of the PRR15 gene in these cells could be 
imparted primarily by more distant regulatory elements. HT29 cells express a 
truncated form of the Apc protein338 which results in the accumulation of β-
catenin and activation of Wnt target genes. Meunier et al. observed increased 
PRR15 in colorectal cancers with mutations in Apc and suggested a link between 
PRR15 and the Wnt signaling pathway.251 We opted to explore the connection 
between Wnt signaling and PRR15 transcription using an inhibitor of glycogen 
synthase kinase 3β (GSK3β). GSK3β is the kinase responsible for 
phosphorylation of β-catenin, which leads to degradation of β-catenin by the 
proteasome and a lack of Wnt target gene activation. Inhibition of this kinase is 
comparable to treating cells with exogenous Wnts in order to activate Wnt target 
genes through the accumulation and translocation of β-catenin to the nucleus. 
Inhibition of GSK3β Activity and the Role of β-catenin 
ACH-3P cells treated with the GSK3β inhibitor, SB216763, had 
significantly reduced concentrations of PRR15 mRNA, as measured by qPCR 
(Figure IV-2A). In keeping with this observation, transactivation of the luciferase 
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reporter from the proximal -824 bases of the PRR15 promoter was significantly 
decreased after cells were treated with GSK3β inhibitor, SB216763 (Figure IV-
2B). When transactivation of the promoter deletion constructs was tested in the 
presence of GSK3β inhibitor, all constructs demonstrated a comparable 
reduction in luciferase activity (Figure IV-2C). This suggests that the effect of 
GSK3β on PRR15 promoter activity is mediated through the most proximal 284 












A    B  
C  
Figure IV-2. GSK3β inhibition decreases PRR15 transcriptional activity.  
(A) qPCR for PRR15 normalized to rpS15 in ACH-3P cells treated with GSK3β 
inhibitor (SB216763) or vehicle control (DMSO); (B) Fold change of normalized 
luciferase activity in ACH-3P cells transfected with a reporter vector containing 
the proximal 824 bp of the PRR15 5’-flanking region. Cells were treated with 
SB216763 or vehicle control; (C) Luciferase reporter activity of all PRR15 
promoter constructs normalized to β-galactosidase in ACH-3P cells after 
treatment with SB216763. Numbers indicate percent change when treated with 
SB216763. * indicates p<0.05, ** indicates p<0.01 when compared to vehicle 
control in Student’s t-test. 
In order to verify that β-catenin was involved in the transcriptional 
repression of PRR15, ACH-3P cells were co-transfected with the -824 reporter 
construct as well as vectors expressing either shRNA to target β-catenin (β-cat 
































































































shRNA did not affect transactivation of the luciferase reporter from the proximal -
824 bp of the promoter (Figure IV-3). Over-expression of constitutively active β-
catenin resulted in a reduction in luciferase activity comparable to that observed 
after treatment with the GSK3β inhibitor (SB216763). These results infer that the 
effect of GSK3β inhibition on PRR15 transcriptional activity is in fact mediated 
through β-catenin activity.  
 
Figure IV-3. Constitutive activity of β-catenin reduces PRR15 promoter activity. 
ACH-3P cells were co-transfected with the -824 reporter plasmid and plasmids 
expressing either shRNA to target β-catenin (β-cat shRNA) or constitutively 
active β-catenin (S33Y). All samples were compared to the DMSO control by a 
Student’s t-test, with * indicating p<0.05. 
The fact that PRR15 transcriptional activity decreases upon inhibition of 
GSK3β is counter to what we predicted based on the results of Meunier et al.251 
Their data suggested increased PRR15 mRNA concentrations in colorectal 
tumors with mutations in the Apc protein, but these data were limited to in situ 
hybridization analysis. The characteristic action of Wnt signaling is transcriptional 
activation of target genes through the interaction of β-catenin with TCF-LEF 
transcription factors. Here, we demonstrate decreased transcriptional activity of 




























signaling. Furthermore, expression of constitutively active β-catenin causes a 
comparable decrease in promoter activity. In the absence of β-catenin, TCF-LEF 
transcription factors typically bind to target regions and can repress transcription; 
during active Wnt signaling, nuclear β-catenin complexes with TCF-LEFs to 
activate transcription.339 Transcriptional repression by β-catenin-TCF-LEF 
complexes is uncharacteristic but not unprecedented; Jamora et al. observed 
reduced transcription of E-cadherin as a result of β-catenin activation of Lef1 
transcription complexes.340 Our data infer that active Wnt signaling through β-
catenin represses transcription of PRR15 in trophoblast cells.  
Because we observed a decrease in proliferation in PRR15-deficient cells 
(Chapter III), we measured proliferation of ACH-3P cells after treatment with the 
GSK3β inhibitor. Proliferation decreased (p<0.01) when ACH-3P cells were 
treated with SB216763 after 96 hours (Figure IV-4), which is consistent with the 
reduced proliferation of the PRR15-depleted cells. Constitutive activation of Wnt 
signaling is a characteristic event in several types of cancer,341 resulting in 
activation of pro-proliferative genes such as c-MYC and cyclin D1.342,343 In 
contrast to the stimulation of proliferation observed in cancers, activation of 
canonical Wnt signaling was shown to induce invasive differentiation in primary 
first-trimester human trophoblast cells;344,345 this differentiated state is associated 
with a lack of proliferation. It appears that in trophoblast cells, canonical Wnt 
signaling may regulate more genes promoting differentiation and invasion rather 
than proliferation.  
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Figure IV-4. Proliferation decreases in ACH3P cells when treated with GSK3β 
inhibitor.  
ACH-3P cells were treated with GSK3β inhibitor (SB216763) or vehicle control 
(DMSO) for 24 hours. Cell metabolic activity was measure by CCK-8 assay 48 
and 96 hours after treatment. ** indicates p<0.01 in Students t-test. 
DNase I Footprinting of PRR15 5’-flanking region 
We used DNase I footprinting to identify protected regions of the PRR15 
proximal promoter that may bind to transcriptional activators or repressors. The -
824 promoter was divided into three over-lapping constructs which were 
amplified by PCR with a 6-FAM-labeled forward primer. These products were 
incubated with nuclear extract, digested with DNase I, and analyzed by capillary 
electrophoresis in an automated DNA sequencer following the protocol of Zianni 
et al.335 Traces from reactions incubated with nuclear extract or BSA as a 
negative control were overlaid to identify regions in which the peak heights were 
lower for the samples incubated with nuclear extract, indicating regions that were 





























Figure IV-5. DNase I Footprinting of PRR15 proximal promoter. 
Representative trace from fragment analysis from DNase I footprinting of FAM-
labeled probe incubated with ACH-3P nuclear extract. Brackets delineate 
protected regions. Graph shows the region from -135 to -35 of the PRR15 5’-
flanking region. 
Protected regions, or footprints, were identified throughout the PRR15 
proximal promoter. These regions were searched for putative transcription factor 
binding sites using TESS (Table IV-1). The most distal probe from -510 to -855 
bp did not reveal any discernible protected regions. This is not expected, 
because the reporter activity demonstrated significant transactivation when the 
region from -640 to -824 was added to the construct, suggesting transcriptional 
activators are binding in this region. The base composition of this probe may 
affect DNase I digestion, making certain regions of the probe less accessible to 
digestion in the samples incubated with BSA. This could mask any difference 






-124 to -116 -110 to -104 -92 to -74 -57 to -49 
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Table IV-1. Protected regions of the PRR15 proximal promoter. 
Region Putative Transcription Factor Binding Sites 
-453 to -435 POU3F2 
-414 to -396 GT-IIBα, LEF/TCF, HSTF, YY1 
-237 to -217 Yi, GAL4, Hb, YY1, POU3F2, POU1F1a 
-196 to -176 T-Ag, LEF/TCF 
-144 to -131  
-110 to -104  
-92 to -74 Sp1, LEF/TCF, GT-IIBα, HSTF, NF-1, AP-1, CBF 
-57 to -49  
-32 to -19 GATA-1, CACCC-binding factor, PuF 
DNase I footprinting identified protected regions of the PRR15 proximal 
promoter that included binding sites for TCF-LEF, YY1, Sp1, and AP-1. TCF-LEF 
transcription factors are mediators of Wnt signaling, and may be involved in 
transcriptional repression of the PRR15 gene. Yin Yang 1 (YY1) is widely 
expressed and can activate or repress transcription; it is expressed in the early 
murine trophectoderm and when disrupted, causes embryonic lethality shortly 
after implantation.346 Specificity protein 1 (Sp1) can also act as an activator or 
repressor of transcription, and is involved in regulation of murine trophoblast cell 
differentiation.347 It is involved in activating or enhancing expression of several 
genes crucial to trophoblast development, such as syncytin-1,348 placental 
lactogen,349 and matrix metalloproteinase 2 (MMP-2).350 In bovine trophoblast, its 
expression is low during conceptus elongation (gestational days 15-18) but 
increases significantly after implantation at gestational day 25.351 Activator 
protein 1 (AP-1) is a family of transcription factors that bind as a dimer consisting 
of Jun, Fos, and Fra proteins to a consensus DNA element.352 AP-1 transcription 
factors have been implicated in trophoblast invasion353,354 and are expressed 
primarily in human extravillous trophoblast as well as elongating bovine 
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trophectoderm.355,356 C-fos, a component of the AP-1 transcription factor, mRNA 
and protein were detected in high amounts in ovine conceptuses prior to 
attachment and decreased after attachment to the uterine epithelium.357 Lack of 
JunB in mice causes embryonic lethality due to impaired placental labyrinth 
development.358 These studies demonstrate a central function for AP-1 
transcription factors during early placentation. The specific factors binding to the 
PRR15 proximal promoter remain to be determined. 
Electrophoretic Mobility Shift Assay 
Electrophoretic mobility shift assays were performed using 
oligonucleotides designed with the consensus TCF-LEF binding site, as well as 
oligonucleotides specific to the PRR15 5’-flanking region from -98 to -68. The 
TCF-LEF oligonucleotides demonstrated a shift only when incubated with nuclear 
extract from ACH-3P cells treated with the GSK3β inhibitor (SB216763, Figure 
IV-6A). Addition of 200-fold molar excess of unlabeled oligonucleotides was able 
to effectively inhibit binding, suggesting a specific protein-DNA interaction. This 
infers that nuclear β-catenin is required in order to observe a specific protein-
DNA interaction for the TCF-LEF consensus sequence. When analyzing the -98 
to -68 oligonucleotides, we observed a shift for both the DMSO- and SB216763-
treated nuclear extract that were both inhibited by the addition of 200-fold molar 
excess unlabeled oligonucleotides (Figure IV-6B). Intriguingly, the migration of 
this shift changed in the two different extracts, migrating more rapidly in the 
SB216763-treated extract. These results suggest that the composition of the 
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protein or protein complex binding to the -98 to -68 oligonucleotides changes 
after treatment of ACH-3P cells with the GSK3β inhibitor.  
ACH3P nuc ext   -   +   +   +   +     -   +   +   +   +      
SB216763        -   -   -   +   +     -   -   -   +   + 
200X unlabeled  -   -   +   -   +     -   -   +   -   + 
    A   B  
Figure IV-6. Electrophoretic mobility shift assay. 
(A) Biotinylated oligonucleotides containing the consensus TCF-LEF binding site 
were incubated in the presence of ACH-3P nuclear extract treated with vehicle or 
GSK3β inhibitor (SB216763) and electrophoresed through a 5% polyacrylamide 
gel. A 200-fold molar excess of unlabeled oligonucleotides was added in lanes 3 
and 5. (B) Biotinylated oligonucleotides from -98 to -68 of the PRR15 proximal 
promoter were incubated in the presence of ACH-3P nuclear extract treated with 
vehicle or GSK3β inhibitor (SB216763) and electrophoresed through a 5% 
polyacrylamide gel. A 200-fold molar excess of unlabeled oligonucleotides was 
added in lanes 3 and 5. 
The -98 to -68 oligonucleotides contain additional putative transcription 
factor binding sites other than TCF-LEF, including activator protein 1 (AP-1), 
Sp1, and CCAAT-binding factor (CBF). These factors may compete with TCF-
LEF transcription factors for binding to this region of the PRR15 promoter. 
Special AT-rich binding protein 1 (SATB1), a DNA-binding protein, was shown to 
compete with TCFs for binding to β-catenin and thus affect TCF-mediated 
transcription.359 These two factors do not bind to the same target sequence on 
Shift  
Free Probe  
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DNA, but both interact with β-catenin to influence the transcription of target 
genes. In our experiments, the protein-DNA interaction observed in the -98 to -68 
oligonucleotides could be due to a number of transcriptional regulators; 
antibodies specific to these factors will help to identify the protein binding this 
region. The protein(s) binding in the DMSO-treated reactions are likely activating 
PRR15 transcription, while the protein(s) derived from the SB216763-treated 
extract may be repressing transcription of PRR15 through the interaction with this 
region.  
Transcriptional activity of PRR15 in response to canonical Wnt signaling in 
trophoblast cells appears to be contrary to the typical activation by β-catenin-
TCF-LEF complexes; PRR15 mRNA concentrations and promoter activity 
decrease in conditions with augmented β-catenin activity. Furthermore, inhibition 
of GSK3β causes a reduction in trophoblast cell proliferation in culture. We 
observed a similar reduction in proliferation after depleting cells of PRR15 using 
RNAi (Chapter III); these data support the hypothesis that PRR15 may promote 
trophoblast cell proliferation. During conceptus elongation, PRR15 mRNA 
concentrations rise and peak at the point of initial conceptus attachment, followed 
by a decline to day 30 of gestation.75 These data infer that canonical Wnt 
signaling may play a role in repressing transcription of PRR15 prior to and 
following this period of dramatic trophectoderm outgrowth. During outgrowth, it 
appears PRR15 is required for normal trophoblast proliferation and survival 
(Chapter III). The transcriptional activators and repressors responsible for its up- 
and down-regulation during placental development remain to be specifically 
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identified. Understanding the pathways which regulate PRR15 transcription will 
reveal pathways that may be affected during early embryonic loss and 
dysfunctional placentation.   
Summary 
Proline-rich 15 (PRR15) is a low molecular weight nuclear protein 
expressed by the trophoblast during early gestation in several mammalian 
species, including humans, mice, cattle, sheep, and horses. 
Immunohistochemistry localized PRR15 to the trophectoderm and 
extraembryonic endoderm of day 15 sheep conceptuses. In humans, PRR15 was 
immunolocalized to the nuclei of both first and second trimester trophoblast cells. 
PRR15 mRNA expression increases when trophoblast cells, both sheep (oTR) 
and human (ACH-3P), are cultured on Matrigel, a basement membrane matrix. 
The expression profile in the sheep conceptus during pregnancy revealed a peak 
in expression at day 16 of gestation. This coincides with a halt in elongation of 
the conceptus, and the period of apposition to the uterine epithelium. Additional 
research has shown increased PRR15 transcription in colorectal cancers with 
mutations in the Apc protein, suggesting a link to the Wnt signaling pathway. 
Lentiviral-mediated knockdown of PRR15 in ovine trophectoderm at the 
blastocyst stage led to demise of the embryo by gestational day 15. This 
provides compelling evidence that PRR15 is a critical factor during this window of 
development where proliferation gives way to differentiation of the trophoblast 
cells. The aims of these experiments were to examine regions of the PRR15 
promoter necessary for regulating its expression in trophoblast cells and to 
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identify the role of Wnt signaling in PRR15 transcription. The 5’-flanking 
sequences from -824, -640, -424, -326, and -284 bp to +7 bp relative to the 
transcription start site were amplified by PCR and ligated into pGL3-Basic. These 
vectors were co-transfected into the first trimester human trophoblast cell line, 
ACH-3P, HT29 (human colorectal carcinoma), oTR, and BHK-21 (hamster kidney 
fibroblast) with a RSV-β-galactosidase vector control. In ACH-3P cells, 
transactivation of the luciferase reporter was maximal with the -326 construct 
(15.4 ± 4.8-fold). Significant promoter activity was absent in the -284, -424, and -
640 constructs, but regained with the -824 construct (14.8 ± 5.8-fold). These 
results suggest that cis-acting elements within the proximal promoter of the 
PRR15 gene are essential for expression in trophoblast cells, requiring the 
regions from -284 to -326 and -640 to -824. DNase I footprinting and 
electrophoretic mobility shift assays were used to identify transcription factor 
binding sites within these regions. Due to the potential link to the Wnt signaling 
pathway, cells were treated with an inhibitor to GSK3β, the kinase responsible for 
phosphorylation and proteasomal degradation of β-catenin. Inhibition of GSK3β 
decreased PRR15 mRNA concentrations and decreased transactivation of the 
luciferase reporter in all proximal promoter reporter constructs; this effect was 
mediated through β-catenin activity. Furthermore, trophoblast cell proliferation 
decreased after treatment with the GSK3β inhibitor. Electrophoretic mobility shift 
assays on the region from -98 to -68 revealed differential binding of nuclear 
proteins derived from ACH-3P cells grown in the presence or absence of the 
GSK3β inhibitor. These results reveal that canonical Wnt signaling inhibits the 
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transcription of PRR15, mediated in part through the -98 to -68 region of the 5’-
flanking region, and decreases proliferation in trophoblast cells. This indicates 
that suppression of Wnt signaling may be crucial during early trophectoderm 
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Supplemental Table 1. Differentially expressed from PRR15 microarray.  
Genes with p<0.05 and greater than 1.3-fold change in PRR15-shRNA compared 
to control from microarray analysis.  






L27624 TFPI2 NM_006528 0.0024 0.026 -38.911 
BE883300 PGBD1 NM_032507 0.0035 0.207 -4.822 
NM_002064 GLRX NM_002064 0.0004 0.225 -4.452 
AF333388 MT1P2 NM_001039954 0.0104 0.251 -3.990 
NM_002450 MT1X NM_005952 0.0041 0.252 -3.973 
BF664545 
  
0.0035 0.252 -3.962 
T75480 KCTD6 NM_153331 0.0041 0.258 -3.871 
AL162069 KRT80 NM_001081492 0.0050 0.269 -3.723 
BE967019 SPRED1 NM_152594 0.0211 0.271 -3.690 
AF039698 TSHZ1 NM_005786 0.0421 0.271 -3.690 
BE466195 RBM25 NM_021239 0.0386 0.278 -3.593 
AW051379 LOC790955 NM_001085372 0.0018 0.280 -3.575 
NM_013238 DNAJC15 NM_013238 0.0417 0.282 -3.547 
NM_004078 CSRP1 NM_004078 0.0048 0.287 -3.479 
NM_005952 MT1X NM_005952 0.0259 0.291 -3.438 
NM_017571 CCDC88A NM_018084 0.0429 0.300 -3.331 
NM_021963 NAP1L2 NM_021963 0.0008 0.302 -3.308 
N95414 ITGA2 NM_002203 0.0042 0.304 -3.285 
BE222344 
  
0.0008 0.318 -3.147 
AW885748 
  
0.0442 0.319 -3.140 
C06331 LOC399818 NM_212554 0.0243 0.320 -3.121 
NM_014125 POLQ NM_199420 0.0173 0.320 -3.121 
NM_001394 DUSP4 NM_001394 0.0001 0.324 -3.085 
AI827906 LOC169834 NM_001101338 0.0165 0.334 -2.998 
AI768894 CGN NM_020770 0.0023 0.335 -2.982 
AW069729 ACPL2 NM_001037172 0.0004 0.337 -2.966 
AW963217 NUDT19 NM_001105570 0.0368 0.339 -2.952 
NM_003877 SOCS2 NM_003877 0.0077 0.341 -2.937 
BF593263 NKAIN4 NM_152864 0.0188 0.352 -2.838 
NM_002426 MMP12 NM_002426 0.0050 0.354 -2.822 
AA205660 TRIM52 NM_032765 0.0055 0.354 -2.822 
NM_004328 BCS1L NM_001079866 0.0145 0.356 -2.811 
AW170571 CPNE2 NM_152727 0.0246 0.357 -2.800 
AI888594 TTL NM_153712 0.0248 0.359 -2.789 
AI742551 XAGE3 NM_130776 0.0302 0.362 -2.762 
AI920953 
  
0.0014 0.363 -2.756 
NM_001964 EGR1 NM_001964 0.0287 0.366 -2.731 
AK001836 KLHL5 NM_001007075 0.0348 0.367 -2.724 
BF593263 NKAIN4 NM_152864 0.0349 0.368 -2.719 
AL832995 
  
0.0171 0.369 -2.711 
AW274756 CDK6 NM_001259 0.0118 0.375 -2.668 
U79277 
  
0.0002 0.376 -2.660 
NM_013337 TIMM22 NM_013337 0.0106 0.379 -2.636 
AL117589 KIF26A NM_015656 0.0021 0.381 -2.623 
BE542563 LOC728342 XM_001129097 0.0068 0.384 -2.608 
AI983896 
  
0.0356 0.384 -2.604 
AA776892 LOC399818 NM_212554 0.0128 0.385 -2.599 
N74530 
  
0.0193 0.385 -2.599 
AI821399 
  
0.0270 0.385 -2.597 
AI669235 ELAC1 NM_018696 0.0373 0.385 -2.596 
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NM_000499 CYP1A1 NM_000499 0.0179 0.386 -2.593 
AK024255 
  
0.0004 0.386 -2.591 
AU155515 RPL37A NM_000998 0.0314 0.388 -2.577 
AW972359 
  
0.0314 0.391 -2.560 
AF276659 MAP1LC3C NM_001004343 0.0404 0.391 -2.556 
NM_021083 XK NM_021083 0.0030 0.392 -2.554 
AK023354 UBQLN4 NM_020131 0.0369 0.392 -2.552 
AA835417 
  
0.0024 0.392 -2.552 
NM_018584 CAMK2N1 NM_018584 0.0081 0.393 -2.545 
AI655015 
  
0.0007 0.394 -2.538 
BE964048 TTL NM_153712 0.0044 0.394 -2.535 
NM_003246 THBS1 NM_003246 0.0024 0.397 -2.521 
BI791845 
  
0.0441 0.398 -2.512 
AI021902 
  
0.0008 0.400 -2.499 
AJ278150 AGK NM_018238 0.0024 0.401 -2.496 
NM_017542 POGK NM_017542 0.0224 0.401 -2.491 
AW193600 LOC439949 XM_001128367 0.0007 0.404 -2.478 
NM_030781 COLEC12 NM_030781 0.0150 0.405 -2.470 
NM_024669 ANKRD55 NM_001039935 0.0016 0.405 -2.470 
W60810 TSHZ1 NM_005786 0.0015 0.406 -2.466 
AI654093 LOC645431 XR_015289 0.0175 0.406 -2.462 
BC042908 RRP12 NM_015179 0.0423 0.407 -2.455 
AW614120 TMEM136 NM_174926 0.0050 0.408 -2.451 
AF010314 ENC1 NM_003633 0.0062 0.409 -2.448 
AA191336 ZNF496 NM_032752 0.0190 0.410 -2.437 
NM_003979 GPRC5A NM_003979 0.0341 0.411 -2.435 
NM_013245 VPS4A NM_013245 0.0294 0.411 -2.434 
AI928241 FERMT2 NM_006832 0.0387 0.412 -2.430 
AW514267 LOC202134 /// LOC653316 /// NY-REN-7 NM_001079527 0.0414 0.413 -2.424 
AW975638 HK2 NM_000189 0.0213 0.413 -2.422 
BG493862 TCHP NM_032300 0.0282 0.413 -2.421 
NM_005103 FEZ1 NM_005103 0.0383 0.415 -2.409 
NM_000296 PKD1 NM_000296 0.0075 0.416 -2.403 
NM_007240 DUSP12 NM_007240 0.0150 0.417 -2.398 
AA045184 S100A16 NM_080388 0.0101 0.419 -2.388 
NM_001393 ECM2 NM_001393 0.0082 0.419 -2.386 
AV693653 TNRC6B NM_001024843 0.0381 0.420 -2.383 
NM_004395 DBN1 NM_004395 0.0445 0.420 -2.381 
BC006148 OVOL2 NM_021220 0.0298 0.420 -2.379 
NM_005953 MT2A NM_005953 0.0123 0.421 -2.375 
AI870369 ZNF553 NM_152652 0.0339 0.422 -2.368 
BE795648 SSRP1 NM_003146 0.0180 0.423 -2.365 
T68150 PHLDB2 NM_145753 0.0026 0.423 -2.364 
AA468591 CLK4 NM_020666 0.0005 0.425 -2.355 
NM_014724 ZSCAN12 NM_001039643 0.0304 0.425 -2.353 
AI479440 
  
0.0258 0.426 -2.349 
AL110225 DBN1 NM_004395 0.0485 0.426 -2.348 
AI884858 TUSC3 NM_006765 0.0221 0.427 -2.341 
NM_002766 PRPSAP1 NM_002766 0.0019 0.430 -2.328 
AW971198 GRAMD3 NM_023927 0.0500 0.430 -2.326 
AW294686 TTBK2 NM_173500 0.0499 0.431 -2.318 
AI613273 CHD4 NM_001273 0.0001 0.435 -2.300 
NM_003146 SSRP1 NM_003146 0.0122 0.436 -2.293 
NM_005416 SPRR3 NM_001097589 0.0113 0.437 -2.290 
D60621 LPHN3 NM_015236 0.0237 0.438 -2.285 
AI948503 ABCC4 NM_001105515 0.0035 0.438 -2.285 
NM_003157 NEK4 NM_003157 0.0057 0.438 -2.283 
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NM_014962 BTBD3 NM_014962 0.0062 0.439 -2.277 
AW206286 
  
0.0282 0.440 -2.275 
NM_014583 LMCD1 NM_014583 0.0095 0.440 -2.275 
AA701657 LIFR NM_002310 0.0251 0.441 -2.266 
NM_016034 MRPS2 NM_016034 0.0472 0.443 -2.257 
M34421 PSG9 NM_002784 0.0189 0.445 -2.249 
AI692432 ARID2 NM_152641 0.0325 0.445 -2.247 
AI741586 ZNF720 NM_001004300 0.0116 0.446 -2.244 
NM_014344 FJX1 NM_014344 0.0109 0.449 -2.230 
BC014479 PXK NM_017771 0.0212 0.449 -2.227 
AI261467 IKZF4 NM_022465 0.0309 0.450 -2.222 
Z24725 FERMT2 NM_006832 0.0006 0.451 -2.219 
AK022566 B4GALT7 NM_007255 0.0355 0.451 -2.218 
NM_006596 POLQ NM_199420 0.0126 0.451 -2.217 
AK001697 RIOK2 NM_018343 0.0009 0.451 -2.217 
BG291550 FYTTD1 NM_001011537 0.0011 0.452 -2.214 
NM_014950 ZBTB1 NM_014950 0.0364 0.452 -2.214 
AW592684 LIFR NM_002310 0.0078 0.453 -2.208 
AJ003062 TUBGCP3 NM_006322 0.0136 0.453 -2.206 
AL530462 ZNF364 NM_014455 0.0237 0.454 -2.203 
NM_007361 NID2 NM_007361 0.0250 0.454 -2.201 
AY114106 GEMIN7 NM_001007269 0.0474 0.455 -2.196 
H05812 IGF1R NM_000875 0.0052 0.456 -2.194 
NM_004124 GMFB NM_004124 0.0047 0.457 -2.186 
W22690 C1orf175 /// TTC4 NM_001039464 0.0008 0.458 -2.182 
NM_022443 MLF1 NM_022443 0.0057 0.460 -2.176 
BC002791 FLJ35348 NR_002800 0.0029 0.460 -2.174 
AW971205 
  
0.0004 0.460 -2.172 
NM_024597 MAP7D3 NM_024597 0.0493 0.460 -2.172 
H17038 FLJ25076 XM_059689 0.0011 0.461 -2.172 
AI701430 MLL NM_005933 0.0056 0.462 -2.166 
NM_007038 ADAMTS5 NM_007038 0.0203 0.462 -2.165 
BF060767 ADAMTS5 NM_007038 0.0099 0.462 -2.164 
NM_014391 ANKRD1 NM_014391 0.0139 0.462 -2.163 
AA527587 ZNF498 NM_145115 0.0094 0.463 -2.158 
NM_014830 ZBTB39 NM_014830 0.0046 0.464 -2.157 
NM_006322 TUBGCP3 NM_006322 0.0013 0.464 -2.155 
NM_018478 DBNDD2 /// SYS1-DBNDD2 NM_001048221 0.0001 0.465 -2.151 
AL050297 R3HCC1 XM_114618 0.0172 0.465 -2.151 
AU145127 FBXL7 NM_012304 0.0329 0.467 -2.143 
BQ944989 STRAP NM_007178 0.0123 0.467 -2.143 
AV726956 BEX5 NM_001012978 0.0335 0.467 -2.139 
N62996 ZNF70 NM_021916 0.0377 0.468 -2.137 
AF087573 DFFA NM_004401 0.0080 0.469 -2.132 
AA789332 VANGL1 NM_138959 0.0015 0.469 -2.130 
AI983428 COL5A1 NM_000093 0.0372 0.470 -2.130 
NM_001036 RYR3 NM_001036 0.0116 0.470 -2.129 
AI937060 NAV1 NM_020443 0.0440 0.470 -2.129 
BE856822 C3orf39 NM_032806 0.0265 0.470 -2.127 
NM_000216 KAL1 NM_000216 0.0197 0.471 -2.124 
AF247167 TMEM133 NM_032021 0.0058 0.471 -2.122 
BG251218 RBM25 NM_021239 0.0445 0.472 -2.120 
AL136932 KIAA0922 NM_015196 0.0016 0.473 -2.116 
AL080170 TRIM58 NM_015431 0.0307 0.473 -2.115 
AW291487 NHS NM_198270 0.0175 0.473 -2.115 
NM_024534 LOC728193 XM_001128013 0.0032 0.475 -2.104 
M31159 IGFBP3 NM_000598 0.0080 0.476 -2.101 
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W72455 ZNF362 NM_152493 0.0068 0.476 -2.101 
AA715041 MLL NM_005933 0.0430 0.476 -2.099 
BF684446 AXIN2 NM_004655 0.0237 0.477 -2.099 
AA100793 LMO7 NM_005358 0.0274 0.477 -2.098 
BC006118 ZKSCAN3 NM_024493 0.0479 0.477 -2.097 
AF317887 CEP290 NM_025114 0.0098 0.477 -2.096 
AI695695 
  
0.0062 0.478 -2.094 
NM_018238 AGK NM_018238 0.0260 0.479 -2.087 
AK021539 DSEL NM_032160 0.0027 0.480 -2.086 
NM_004494 HDGF NM_004494 0.0001 0.480 -2.083 
NM_004623 TTC4 NM_004623 0.0358 0.481 -2.081 
AI684747 PXK NM_017771 0.0493 0.482 -2.075 
AF033861 ADCY3 NM_004036 0.0106 0.484 -2.066 
AW044606 TTC5 NM_138376 0.0028 0.485 -2.062 
BC030710 TMEM74 NM_153015 0.0076 0.485 -2.061 
X79780 RAB11B NM_004218 0.0243 0.485 -2.060 
BC015881 STRA6 NM_022369 0.0239 0.486 -2.058 
AK024318 USP46 NM_022832 0.0079 0.486 -2.058 
AK022622 NAV1 NM_020443 0.0005 0.487 -2.055 
AA020010 KLF12 NM_007249 0.0290 0.487 -2.054 
NM_005756 GPR64 NM_001079858 0.0225 0.487 -2.052 
AI307763 VTI1B NM_006370 0.0170 0.489 -2.047 
M29277 MCAM NM_006500 0.0079 0.491 -2.036 
NM_012342 BAMBI NM_012342 0.0045 0.491 -2.036 
AY078987 GTPBP3 NM_032620 0.0195 0.492 -2.034 
BF002121 
  
0.0252 0.492 -2.031 
AI692880 GJA5 NM_005266 0.0146 0.492 -2.031 
AA361361 MAP3K1 NM_005921 0.0329 0.492 -2.031 
AI521273 
  
0.0382 0.493 -2.030 
AI824012 NRIP1 NM_003489 0.0041 0.493 -2.030 
AK021888 
  
0.0455 0.493 -2.028 
BF513233 LOC284952 XM_001126137 0.0324 0.493 -2.027 
AA214704 TNRC6B NM_001024843 0.0094 0.494 -2.026 
AI911518 GPATCH4 NM_015590 0.0241 0.494 -2.025 
AW117765 PEX13 NM_002618 0.0217 0.495 -2.022 
BC002671 DUSP4 NM_001394 0.0081 0.495 -2.021 
BC013912 TTC26 NM_024926 0.0288 0.495 -2.021 
NM_018079 SRBD1 NM_018079 0.0109 0.495 -2.021 
AI200443 MAGEA5 NM_021049 0.0263 0.495 -2.020 
BC002827 TPM4 NM_003290 0.0277 0.495 -2.020 
NM_012460 TIMM9 NM_012460 0.0049 0.496 -2.015 
BC038589 
  
0.0123 0.497 -2.014 
AK001007 
  
0.0353 0.497 -2.011 
AW002876 
  
0.0077 0.497 -2.010 
N31717 RIPK5 NM_015375 0.0208 0.498 -2.008 
AW469573 FERMT2 NM_006832 0.0142 0.498 -2.008 
AI183453 AARS2 NM_020745 0.0138 0.499 -2.005 
W31002 ZNF498 NM_145115 0.0198 0.499 -2.004 
BC038557 
  
0.0354 0.500 -1.998 
NM_014817 KIAA0644 NM_014817 0.0398 0.501 -1.998 
AI130969 COL5A1 NM_000093 0.0128 0.501 -1.994 
NM_018343 RIOK2 NM_018343 0.0070 0.502 -1.993 
NM_022483 C5orf28 NM_022483 0.0277 0.503 -1.989 
AA524029 C9orf61 NM_004816 0.0280 0.503 -1.987 
BF513384 
  
0.0096 0.504 -1.985 
NM_006466 POLR3F NM_006466 0.0144 0.504 -1.984 
AA788946 COL12A1 NM_004370 0.0115 0.506 -1.976 
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NM_007018 CEP110 NM_007018 0.0026 0.506 -1.976 
NM_021964 ZNF148 NM_021964 0.0022 0.508 -1.970 
AV724192 KIAA0644 NM_014817 0.0066 0.508 -1.969 
AI679268 PIK3R1 NM_181504 0.0280 0.508 -1.967 
AA976778 WDR32 NM_024345 0.0045 0.509 -1.966 
AI739389 SF3B1 NM_001005526 0.0312 0.510 -1.960 
AL831862 TNRC6B NM_001024843 0.0035 0.512 -1.955 
AV703555 
  
0.0101 0.513 -1.951 
AI917328 WDR75 NM_032168 0.0005 0.513 -1.950 
N57538 NAV1 NM_020443 0.0155 0.513 -1.949 
NM_004759 MAPKAPK2 NM_004759 0.0437 0.514 -1.947 
AF124145 AMFR NM_001144 0.0054 0.514 -1.947 
AI277642 CDCA7 NM_031942 0.0473 0.514 -1.945 
AI471723 RBM45 NM_152945 0.0070 0.514 -1.945 
NM_001784 CD97 NM_001025160 0.0158 0.514 -1.944 
BF109381 
  
0.0493 0.514 -1.944 
BF446943 
  
0.0102 0.515 -1.941 
BC029425 FILIP1 NM_015687 0.0361 0.516 -1.939 
AB033007 ERGIC1 NM_001031711 0.0188 0.516 -1.938 
AW103422 PCBP2 NM_001098620 0.0415 0.516 -1.937 
BC034621 LPGAT1 NM_014873 0.0240 0.517 -1.936 
NM_014159 SETD2 NM_014159 0.0220 0.517 -1.935 
AI174988 
  
0.0189 0.518 -1.930 
AF059317 RSF1 NM_016578 0.0487 0.519 -1.926 
NM_018495 CALD1 NM_004342 0.0301 0.519 -1.926 
NM_007066 PKIG NM_007066 0.0192 0.519 -1.925 
AU153412 OPRK1 NM_000912 0.0083 0.519 -1.925 
NM_020354 ENTPD7 NM_020354 0.0294 0.520 -1.925 
AI299467 
  
0.0204 0.520 -1.924 
AA580691 RBM25 NM_021239 0.0130 0.520 -1.923 
AU118165 ZNF37A /// ZNF37B NM_001007094 0.0126 0.520 -1.923 
NM_000248 MITF NM_000248 0.0101 0.520 -1.922 
AI094626 OSBPL6 NM_032523 0.0385 0.521 -1.920 
AB033105 KIAA1279 NM_015634 0.0030 0.523 -1.914 
BE379761 STON2 NM_033104 0.0077 0.523 -1.913 
NM_002402 MEST NM_002402 0.0468 0.523 -1.913 
AA765470 
  
0.0114 0.524 -1.909 
NM_016010 C8orf70 NM_016010 0.0067 0.524 -1.909 
BF059479 FLJ14712 XM_001131663 0.0292 0.524 -1.909 
AL512725 MIDN NM_177401 0.0439 0.524 -1.907 
AB037776 IGSF9 NM_020789 0.0016 0.524 -1.907 
AI623155 TRAF3IP1 NM_015650 0.0144 0.524 -1.907 
AI377688 GTF2H1 NM_005316 0.0332 0.525 -1.907 
NM_022344 C17orf75 NM_022344 0.0462 0.525 -1.904 
NM_001150 ANPEP NM_001150 0.0286 0.526 -1.900 
AV699825 LOC145786 
 
0.0024 0.528 -1.895 
AI525402 LPHN1 NM_001008701 0.0405 0.528 -1.894 
NM_002431 MNAT1 NM_002431 0.0134 0.528 -1.894 
AA504356 PCBP2 NM_001098620 0.0013 0.528 -1.894 
BC005359 GMFB NM_004124 0.0008 0.529 -1.892 
AK023585 NSFL1C NM_016143 0.0193 0.529 -1.890 
NM_023008 KRI1 NM_023008 0.0420 0.529 -1.890 
AB002364 ADAMTS3 NM_014243 0.0017 0.529 -1.889 
NM_006227 PLTP NM_006227 0.0422 0.530 -1.887 
BE544096 UBE2Z NM_023079 0.0096 0.530 -1.885 
NM_030952 C11orf17 /// NUAK2 NM_020642 0.0145 0.532 -1.881 
NM_015909 NAG NM_015909 0.0019 0.532 -1.881 
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NM_016205 PDGFC NM_016205 0.0034 0.532 -1.881 
AK001574 GORASP1 NM_031899 0.0016 0.532 -1.879 
NM_005414 SKIL NM_005414 0.0116 0.532 -1.879 
AW305097 OLFML1 NM_198474 0.0007 0.533 -1.878 
NM_006738 AKAP13 NM_006738 0.0365 0.533 -1.877 
BC000254 ACVR1B NM_004302 0.0123 0.534 -1.874 
BE676248 DEF8 NM_017702 0.0478 0.534 -1.872 
BE907791 GTPBP8 NM_001008235 0.0156 0.534 -1.872 
AW194766 CDK6 NM_001259 0.0154 0.535 -1.871 
AW409794 FAM80B NM_020734 0.0003 0.535 -1.869 
NM_021813 BACH2 NM_021813 0.0316 0.535 -1.869 
W73820 KCTD15 NM_024076 0.0163 0.537 -1.863 
NM_144990 SLFNL1 NM_144990 0.0356 0.537 -1.862 
AA740754 BCLAF1 NM_001077440 0.0077 0.538 -1.858 
AW025928 
  
0.0206 0.538 -1.858 
BE271180 
  
0.0187 0.539 -1.855 
U79297 ANKRD46 NM_198401 0.0013 0.539 -1.855 
AL578102 IL20RB NM_144717 0.0147 0.540 -1.851 
AW051349 CDK6 NM_001259 0.0160 0.540 -1.850 
AK024273 COPS7B NM_022730 0.0212 0.541 -1.850 
BF197274 
  
0.0029 0.541 -1.850 
AF070571 EXT1 
 
0.0428 0.542 -1.844 
AK095622 C1orf61 NM_006365 0.0280 0.544 -1.838 
AA259174 TMED5 NM_016040 0.0029 0.544 -1.837 
AK094821 ATAD2B NM_017552 0.0368 0.545 -1.836 
AU144734 NASP NM_002482 0.0247 0.545 -1.834 
AA872583 SERINC2 NM_178865 0.0454 0.545 -1.834 
AB028957 SATB2 NM_015265 0.0310 0.546 -1.833 
AL138455 SHROOM1 NM_133456 0.0033 0.547 -1.830 
AI040029 B4GALT7 NM_007255 0.0041 0.547 -1.829 
NM_017745 BCOR NM_017745 0.0260 0.547 -1.828 
NM_024724 ZBTB38 NM_001080412 0.0007 0.547 -1.827 
AI766311 LOC162073 NM_001034841 0.0455 0.548 -1.823 
AK026220 MRPL35 NM_016622 0.0031 0.549 -1.822 
AW297204 NHLRC2 NM_198514 0.0202 0.549 -1.821 
BC001247 LIMA1 NM_016357 0.0040 0.550 -1.819 
AW265065 
  
0.0010 0.550 -1.818 
NM_024513 FYCO1 NM_024513 0.0117 0.551 -1.815 
NM_003633 ENC1 NM_003633 0.0034 0.552 -1.811 
NM_024010 MTRR NM_002454 0.0031 0.552 -1.810 
U20165 BMPR2 NM_001204 0.0181 0.553 -1.810 
AI219740 LSG1 NM_018385 0.0465 0.553 -1.809 
N32508 GNG12 NM_018841 0.0163 0.554 -1.807 
NM_005211 CSF1R NM_005211 0.0129 0.554 -1.807 
NM_017651 AHI1 NM_017651 0.0171 0.556 -1.799 
AI814644 WDR22 NM_003861 0.0446 0.556 -1.798 
AI917716 LOXL3 NM_032603 0.0021 0.556 -1.798 
NM_018650 MARK1 NM_018650 0.0100 0.557 -1.796 
NM_007173 PRSS23 NM_007173 0.0329 0.557 -1.794 
AW104509 ARID2 NM_152641 0.0124 0.557 -1.794 
AF117234 FLOT1 NM_005803 0.0082 0.559 -1.791 
AI953362 EIF2AK4 NM_001013703 0.0304 0.560 -1.786 
BF749719 
  
0.0224 0.560 -1.786 
AA905942 TEAD2 NM_003598 0.0299 0.560 -1.785 
N30339 COL5A1 NM_000093 0.0107 0.561 -1.784 
AB032983 PPM1H NM_020700 0.0353 0.561 -1.783 
AA207013 CLUAP1 NM_015041 0.0212 0.561 -1.782 
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NM_018178 GOLPH3L NM_018178 0.0043 0.562 -1.780 
BF696912 EXOC5 NM_006544 0.0140 0.562 -1.778 
NM_014840 NUAK1 NM_014840 0.0068 0.564 -1.773 
NM_015322 FEM1B NM_015322 0.0308 0.565 -1.771 
AI743612 FAM80B NM_020734 0.0161 0.565 -1.771 
BE083088 SSFA2 NM_006751 0.0455 0.565 -1.771 
NM_004672 MAP3K6 NM_004672 0.0191 0.565 -1.770 
AI796536 
  
0.0492 0.565 -1.770 
AL578583 APITD1 NM_198544 0.0305 0.565 -1.769 
AF057354 MTMR1 NM_003828 0.0009 0.566 -1.767 
BE963370 BCLAF1 NM_001077440 0.0176 0.566 -1.767 
NM_017687 NHLRC2 NM_198514 0.0291 0.567 -1.765 
AI167164 MTMR1 NM_003828 0.0053 0.567 -1.763 
BM987612 
  
0.0448 0.568 -1.761 
U32645 ELF4 NM_001421 0.0013 0.569 -1.759 
AW467480 
  
0.0204 0.570 -1.756 
BF526978 
  
0.0291 0.570 -1.755 
C18965 
  
0.0404 0.570 -1.755 
AW003030 SF3B1 NM_001005526 0.0137 0.570 -1.754 
AF245505 MXRA5 NM_015419 0.0189 0.570 -1.754 
X99268 TWIST1 NM_000474 0.0252 0.570 -1.754 
AA704766 MLL NM_005933 0.0456 0.571 -1.751 
BG170743 EXOC5 NM_006544 0.0000 0.571 -1.751 
AI936517 NEK1 NM_012224 0.0240 0.571 -1.750 
AW117498 FOXO1 NM_002015 0.0087 0.571 -1.750 
AW165979 ZNF609 NM_015042 0.0047 0.571 -1.750 
BF878343 COX15 NM_004376 0.0307 0.572 -1.749 
AW304871 
  
0.0289 0.572 -1.749 
NM_014478 RCP9 NM_001040647 0.0364 0.572 -1.748 
NM_000633 BCL2 NM_000633 0.0474 0.573 -1.746 
AW139179 FEM1B NM_015322 0.0038 0.573 -1.744 
NM_024926 TTC26 NM_024926 0.0161 0.574 -1.743 
BE620457 NRP1 NM_001024628 0.0295 0.574 -1.742 
BC019922 ZNF252 
 
0.0043 0.574 -1.742 
BC032757 LOC219731 
 
0.0223 0.574 -1.742 
L04282 ZNF148 NM_021964 0.0037 0.574 -1.741 
AA536004 RNF169 NM_001098638 0.0076 0.575 -1.740 
BF215996 MYO1B NM_012223 0.0007 0.575 -1.739 
NM_015062 PPRC1 NM_015062 0.0203 0.575 -1.739 
AI807026 CBL NM_005188 0.0438 0.575 -1.739 
NM_017650 PPP1R9A NM_017650 0.0038 0.577 -1.734 
NM_024773 JMJD5 NM_024773 0.0108 0.577 -1.734 
BF940043 NID1 NM_002508 0.0196 0.577 -1.733 
AA977481 
  
0.0241 0.577 -1.732 
AB020719 CEP152 NM_014985 0.0348 0.578 -1.732 
AF231056 ARID1A NM_006015 0.0228 0.578 -1.731 
AA551075 KCTD12 NM_138444 0.0040 0.578 -1.731 
AK002174 KLHL5 NM_001007075 0.0018 0.578 -1.730 
AA912476 LOC145786 
 
0.0005 0.578 -1.730 
NM_005558 LAD1 NM_005558 0.0436 0.578 -1.729 
AF465843 ZAK NM_016653 0.0062 0.578 -1.729 
AI041854 SFRS15 NM_020706 0.0004 0.580 -1.725 
NM_003607 CDC42BPA NM_003607 0.0488 0.580 -1.724 
AI282485 BAT1 NM_004640 0.0331 0.580 -1.723 
AA777641 KIAA0157 NM_032182 0.0200 0.581 -1.722 
NM_004401 DFFA NM_004401 0.0263 0.581 -1.721 
N40199 LOC729810 XM_001131395 0.0140 0.581 -1.720 
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N92507 HMGB1 NM_002128 0.0272 0.581 -1.720 
AL033538 TTC28 XM_929318 0.0107 0.582 -1.719 
AF263462 CGN NM_020770 0.0058 0.582 -1.719 
AA922068 CDK6 NM_001259 0.0035 0.582 -1.718 
AW242125 USP54 NM_152586 0.0123 0.582 -1.717 
AK022838 
  
0.0317 0.583 -1.716 
NM_016129 COPS4 NM_016129 0.0292 0.583 -1.716 
NM_006942 SOX15 NM_006942 0.0151 0.583 -1.715 
NM_007203 AKAP2 /// PALM2-AKAP2 NM_001004065 0.0303 0.583 -1.715 
AB033831 PDGFC NM_016205 0.0168 0.583 -1.715 
AU146891 SMAD1 NM_001003688 0.0243 0.583 -1.714 
BG054922 CCDC113 NM_014157 0.0407 0.584 -1.714 
BC000822 C16orf58 NM_022744 0.0074 0.584 -1.714 
AF155117 KIF21A NM_017641 0.0164 0.584 -1.713 
D42044 KIAA0090 NM_015047 0.0131 0.584 -1.713 
NM_016561 BFAR NM_016561 0.0186 0.584 -1.711 
D79987 ESPL1 NM_012291 0.0243 0.584 -1.711 
AI040432 TM9SF3 NM_020123 0.0067 0.585 -1.711 
AV700132 SIAH1 NM_001006610 0.0364 0.585 -1.710 
NM_015694 ZNF777 NM_015694 0.0280 0.585 -1.709 
NM_003370 VASP NM_001008736 0.0272 0.586 -1.708 
AW055205 ARL6IP2 NM_022374 0.0483 0.586 -1.707 
NM_002015 FOXO1 NM_002015 0.0073 0.586 -1.707 
AI700188 ZNF30 NM_001099437 0.0214 0.586 -1.706 
NM_000305 PON2 NM_000305 0.0015 0.586 -1.705 
U87460 GPR37 NM_005302 0.0328 0.586 -1.705 
BE878463 
  
0.0252 0.587 -1.705 
AW264082 FAM110B NM_147189 0.0250 0.587 -1.704 
BG288755 
  
0.0184 0.587 -1.704 
NM_014783 ARHGAP11A NM_014783 0.0178 0.587 -1.704 
AW264273 ZNF445 NM_181489 0.0398 0.587 -1.703 
BC000761 SNAPIN NM_012437 0.0391 0.587 -1.703 
AK026898 FOXP1 NM_001012505 0.0380 0.587 -1.702 
AW612461 
  
0.0163 0.588 -1.702 
U20489 PTPRO NM_002848 0.0061 0.588 -1.702 
AC004770 C11orf9 NM_013279 0.0327 0.588 -1.701 
BC029890 LOC653110 /// LOC728449 XM_001128973 0.0008 0.588 -1.701 
BC007934 ARMC8 NM_014154 0.0461 0.588 -1.701 
BF062828 BRWD2 NM_018117 0.0477 0.588 -1.701 
H43976 MORF4L2 NM_012286 0.0109 0.589 -1.699 
AK026659 
  
0.0072 0.589 -1.697 
AI580162 BTBD7 NM_001002860 0.0161 0.590 -1.696 
T16257 GPR37 NM_005302 0.0274 0.590 -1.696 
M10943 MT1F NM_005949 0.0343 0.590 -1.696 
BF432550 MYO1B NM_012223 0.0389 0.591 -1.693 
N51597 SFRS12 NM_001077199 0.0119 0.591 -1.693 
BC002836 EFCAB2 NM_032328 0.0007 0.592 -1.690 
BC012090 HNRPA3 NM_194247 0.0322 0.592 -1.689 
NM_018321 BXDC2 NM_018321 0.0416 0.592 -1.689 
T16443 SNHG5 /// SNORD50A /// SNORD50B NR_002743 0.0444 0.593 -1.686 
BE502826 
  
0.0095 0.593 -1.686 
NM_006599 NFAT5 NM_001113178 0.0350 0.593 -1.685 
AW135003 
  
0.0188 0.594 -1.685 
BG285417 SH3D19 NM_001009555 0.0156 0.594 -1.684 
NM_005983 SKP2 NM_005983 0.0178 0.594 -1.684 
AA037483 HIST1H2BC NM_003526 0.0297 0.594 -1.683 
AB023179 DNAJC16 NM_015291 0.0337 0.594 -1.683 
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AK002200 SMC4 NM_001002799 0.0112 0.595 -1.681 
BF057682 C14orf131 NM_018335 0.0010 0.595 -1.680 
L24521 HDGF NM_004494 0.0122 0.596 -1.679 
H97931 SPRED2 NM_181784 0.0233 0.596 -1.678 
NM_024520 C2orf47 NM_024520 0.0420 0.596 -1.678 
BF594371 TNRC6B NM_001024843 0.0464 0.596 -1.678 
NM_001273 CHD4 NM_001273 0.0272 0.596 -1.677 
AW242920 
  
0.0058 0.596 -1.677 
NM_022838 ARMCX5 NM_022838 0.0152 0.597 -1.676 
AF234161 CIZ1 NM_012127 0.0026 0.597 -1.674 
NM_004523 KIF11 NM_004523 0.0124 0.598 -1.673 
AI380704 BOLA3 NM_001035505 0.0350 0.598 -1.673 
AK024480 LOC126917 XM_928886 0.0252 0.598 -1.673 
AA535128 C11orf74 NM_138787 0.0378 0.599 -1.671 
NM_002228 JUN NM_002228 0.0150 0.599 -1.671 
NM_012302 LPHN2 NM_012302 0.0236 0.599 -1.671 
AW009638 LOC728377 XM_001127355 0.0202 0.599 -1.671 
AI073984 IRF8 NM_002163 0.0441 0.599 -1.669 
N33174 
  
0.0351 0.600 -1.668 
NM_032773 LRCH3 NM_032773 0.0200 0.600 -1.668 
NM_000173 GP1BA NM_000173 0.0261 0.600 -1.667 
AV709406 TMEM125 NM_144626 0.0207 0.600 -1.667 
AU149503 G3BP2 NM_012297 0.0113 0.600 -1.667 
NM_025243 SLC19A3 NM_025243 0.0354 0.600 -1.667 
AI628573 FGFBP3 NM_152429 0.0008 0.600 -1.666 
BC017275 
  
0.0324 0.600 -1.666 
NM_018082 POLR3B NM_018082 0.0003 0.601 -1.665 
BE538424 WDR68 NM_005828 0.0226 0.601 -1.664 
AF249273 BCLAF1 NM_001077440 0.0193 0.601 -1.663 
AI375486 APC NM_000038 0.0199 0.602 -1.662 
AY034482 SYNCRIP NM_006372 0.0290 0.602 -1.662 
N66622 
  
0.0197 0.602 -1.660 
AL031602 MT1M NM_176870 0.0303 0.603 -1.659 
NM_001065 TNFRSF1A NM_001065 0.0314 0.604 -1.657 
AA422049 WIZ NM_021241 0.0140 0.604 -1.656 
AI375916 TCF7L2 NM_030756 0.0302 0.604 -1.656 
BF576458 NCOA1 NM_003743 0.0012 0.605 -1.652 
AI721172 AARS2 NM_020745 0.0328 0.605 -1.652 
AW471145 PRSS23 NM_007173 0.0231 0.606 -1.651 
M23254 CAPN2 NM_001748 0.0002 0.606 -1.651 
AA527515 FAM86B1 NM_001083537 0.0451 0.606 -1.651 
NM_025099 C17orf68 NM_025099 0.0402 0.606 -1.651 
NM_005649 ZNF354A NM_005649 0.0207 0.606 -1.651 
NM_030912 TRIM8 NM_030912 0.0259 0.606 -1.650 
BF436101 
  
0.0385 0.606 -1.650 
AI743109 TRIM41 NM_033549 0.0310 0.606 -1.650 
AW236976 ZNF770 NM_014106 0.0113 0.606 -1.650 
AI829721 LOC647859 XM_001127102 0.0131 0.606 -1.650 
AI022089 CSNK2A2 NM_001896 0.0254 0.607 -1.649 
BC029474 
  
0.0337 0.607 -1.648 
BI832220 C1orf53 NM_001024594 0.0382 0.607 -1.648 
NM_016357 LIMA1 NM_016357 0.0065 0.607 -1.647 
AI028241 DGCR8 NM_022720 0.0248 0.607 -1.647 
NM_021731 C19orf28 NM_001042680 0.0089 0.608 -1.645 
AF161419 ING3 NM_019071 0.0252 0.608 -1.644 
U66065 GRB10 NM_001001549 0.0182 0.609 -1.643 
AI498126 BTBD14B NM_052876 0.0143 0.609 -1.643 
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AA121502 HEG1 NM_020733 0.0207 0.609 -1.642 
AF085357 FLOT1 NM_005803 0.0230 0.610 -1.640 
BC004988 FEM1A NM_018708 0.0193 0.610 -1.639 
BF242537 ALKBH8 NM_138775 0.0029 0.610 -1.638 
BG250721 KLF6 NM_001008490 0.0199 0.611 -1.638 
AW263497 SYTL5 
 
0.0171 0.611 -1.638 
AK025925 WDR68 NM_005828 0.0124 0.611 -1.637 
W74620 HNRPD NM_001003810 0.0393 0.612 -1.635 
AL354612 TMEM48 NM_018087 0.0096 0.612 -1.635 
NM_022841 RFXDC2 NM_022841 0.0156 0.612 -1.633 
AI458417 LOC162073 NM_001034841 0.0341 0.613 -1.632 
T79216 OTUD4 NM_001102653 0.0368 0.613 -1.632 
AK000752 ERGIC1 NM_001031711 0.0322 0.613 -1.631 
AI458128 CBX6 NM_014292 0.0325 0.613 -1.631 
AI272805 SNX24 NM_014035 0.0420 0.613 -1.630 
AA541479 MAP3K1 NM_005921 0.0075 0.614 -1.629 
AW629515 VCPIP1 NM_025054 0.0018 0.614 -1.629 
BG260337 
  
0.0164 0.614 -1.628 
BC010363 LINS1 NM_001040614 0.0358 0.614 -1.628 
NM_004841 RASAL2 NM_004841 0.0338 0.615 -1.627 
NM_003567 BCAR3 NM_003567 0.0026 0.615 -1.627 
BG168471 MGLL NM_001003794 0.0014 0.615 -1.626 
AA728758 C14orf65 
 
0.0010 0.615 -1.626 
AK091107 C15orf37 NM_175898 0.0050 0.615 -1.625 
NM_024658 IPO4 NM_024658 0.0066 0.616 -1.625 
BF131947 WDR51B NM_172240 0.0030 0.616 -1.624 
NM_014289 CAPN6 NM_014289 0.0352 0.616 -1.624 
BF439533 FLJ32810 XM_001127587 0.0189 0.616 -1.623 
NM_025128 MUS81 NM_025128 0.0126 0.616 -1.623 
BF196642 UBE2D2 NM_003339 0.0073 0.617 -1.622 
NM_006506 RASA2 NM_006506 0.0105 0.617 -1.620 
AF132818 KLF5 NM_001730 0.0001 0.618 -1.618 
BG230586 SLC7A6 NM_001076785 0.0090 0.619 -1.615 
R50822 LPHN3 NM_015236 0.0442 0.619 -1.615 
NM_014016 SACM1L NM_014016 0.0032 0.619 -1.614 
AL567808 ZNF19 /// ZNF23 NM_006961 0.0251 0.620 -1.613 
NM_004635 MAPKAPK3 NM_004635 0.0404 0.620 -1.613 
NM_001982 ERBB3 NM_001005915 0.0053 0.621 -1.612 
NM_012297 G3BP2 NM_012297 0.0120 0.621 -1.611 
NM_002428 MMP15 NM_002428 0.0038 0.621 -1.611 
NM_002310 LIFR NM_002310 0.0417 0.621 -1.610 
AF049103 SETD2 NM_014159 0.0044 0.622 -1.609 
NM_018090 NECAP2 NM_018090 0.0275 0.622 -1.608 
BC041094 TAF5L NM_001025247 0.0199 0.622 -1.608 
R61374 HEY1 NM_001040708 0.0108 0.622 -1.608 
NM_018324 OLAH NM_001039702 0.0486 0.622 -1.607 
AF116707 KIAA1147 NM_001080392 0.0485 0.622 -1.607 
AW967916 
  
0.0017 0.622 -1.607 
AK024051 LRRC41 NM_006369 0.0474 0.623 -1.606 
BF184089 ZDHHC21 NM_178566 0.0256 0.623 -1.605 
AI625235 C20orf199 NR_003604 0.0245 0.623 -1.604 
AW576195 
  
0.0105 0.624 -1.604 
BF447954 DOCK5 NM_024940 0.0053 0.624 -1.603 
AW235608 TTC9 NM_015351 0.0007 0.624 -1.602 
AA706895 ADAT2 NM_182503 0.0109 0.624 -1.602 
NM_018695 ERBB2IP NM_001006600 0.0030 0.624 -1.602 




0.0212 0.625 -1.601 
BF576005 FYTTD1 NM_001011537 0.0032 0.625 -1.600 
AF037448 SYNCRIP NM_006372 0.0341 0.625 -1.599 
BG223334 C9orf114 NM_016390 0.0256 0.625 -1.599 
AV722693 ETV6 NM_001987 0.0331 0.626 -1.598 
AL038092 ZNF134 NM_003435 0.0306 0.626 -1.598 
BC006236 MAG1 NM_032717 0.0034 0.626 -1.598 
NM_024584 CCDC121 NM_024584 0.0462 0.627 -1.596 
NM_017742 ZCCHC2 NM_017742 0.0397 0.627 -1.595 
BC004995 MARVELD1 NM_031484 0.0086 0.627 -1.594 
NM_004380 CREBBP NM_001079846 0.0253 0.628 -1.594 
NM_004184 WARS NM_004184 0.0257 0.628 -1.593 
AA001052 RAB12 NM_001025300 0.0095 0.628 -1.592 
BE676543 ZCCHC2 NM_017742 0.0215 0.628 -1.592 
NM_030672 ARHGAP28 NM_001010000 0.0426 0.628 -1.592 
BF435769 LOC646214 XR_016124 0.0084 0.628 -1.591 
BF064224 
  
0.0286 0.629 -1.591 
AW052119 HOMER1 NM_004272 0.0043 0.629 -1.590 
BF512491 
  
0.0331 0.629 -1.590 
AF007217 TRIP11 NM_004239 0.0298 0.629 -1.589 
AW294869 
  
0.0043 0.629 -1.589 
AL110209 LYPLA3 NM_012320 0.0005 0.629 -1.589 
AL110131 ANKRD50 NM_020337 0.0187 0.629 -1.589 
NM_016955 SEPSECS NM_016955 0.0487 0.630 -1.588 
BC031487 MGAT4A NM_012214 0.0244 0.630 -1.588 
R71157 TRIM62 NM_018207 0.0163 0.630 -1.588 
BE564430 
  
0.0009 0.630 -1.587 
BF508843 KIAA0907 NM_014949 0.0322 0.630 -1.586 
AI949549 FGD4 NM_139241 0.0220 0.630 -1.586 
AL109658 NSFL1C NM_016143 0.0043 0.631 -1.586 
AB028980 USP24 NM_015306 0.0188 0.631 -1.586 
AB011113 WDR7 NM_015285 0.0288 0.631 -1.586 
AV733308 ITGA6 NM_000210 0.0228 0.631 -1.585 
AB047005 MAST2 NM_015112 0.0484 0.631 -1.584 
AA988769 
  
0.0335 0.632 -1.584 
U35004 MAPK8 NM_002750 0.0004 0.632 -1.583 
AK026691 GUSBL2 NM_206908 0.0482 0.632 -1.583 
NM_017702 DEF8 NM_017702 0.0492 0.632 -1.583 
BG260069 
  
0.0044 0.632 -1.583 
BG427809 BMS1P5 NR_003611 0.0218 0.633 -1.581 
AL117653 MITF NM_000248 0.0220 0.633 -1.580 
AI467947 C3orf21 NM_152531 0.0469 0.633 -1.580 
NM_006717 SPIN1 NM_006717 0.0410 0.633 -1.580 
AI521618 TPM1 NM_000366 0.0447 0.633 -1.579 
AK027217 PDLIM5 NM_001011513 0.0493 0.633 -1.579 
NM_005886 KATNB1 NM_005886 0.0067 0.633 -1.579 
AA504249 
  
0.0473 0.634 -1.579 
AI016784 ZNF148 NM_021964 0.0007 0.634 -1.578 
AL574660 ABCD4 NM_005050 0.0369 0.634 -1.577 
NM_018087 TMEM48 NM_018087 0.0013 0.634 -1.577 
AK074354 BTBD7 NM_001002860 0.0133 0.635 -1.576 
NM_024772 ZMYM1 NM_024772 0.0062 0.635 -1.576 
NM_002467 MYC NM_002467 0.0159 0.635 -1.576 
D87811 GATA6 NM_005257 0.0117 0.635 -1.575 
BC005369 EGLN1 NM_022051 0.0344 0.636 -1.573 
AI703074 TCF7L2 NM_030756 0.0309 0.636 -1.572 
BE856374 USP46 NM_022832 0.0065 0.636 -1.572 
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U41815 NUP98 NM_005387 0.0369 0.637 -1.571 
AB007830 SCARA3 NM_016240 0.0104 0.637 -1.570 
AF081567 PRKRIR NM_004705 0.0159 0.637 -1.570 
NM_024790 CSPP1 NM_001077204 0.0030 0.637 -1.570 
NM_003387 WIPF1 NM_001077269 0.0385 0.637 -1.569 
NM_005716 GIPC1 NM_005716 0.0331 0.638 -1.569 
AA417970 ZNF621 NM_001098414 0.0048 0.638 -1.568 
AA609488 CHDH NM_018397 0.0040 0.638 -1.567 
BE881219 ATPAF1 NM_001042546 0.0078 0.638 -1.567 
N35244 ZNF782 NM_001001662 0.0242 0.638 -1.567 
BC031345 
  
0.0398 0.638 -1.567 
NM_016358 IRX4 NM_016358 0.0167 0.638 -1.566 
N79601 
  
0.0248 0.639 -1.566 
AA706480 LOC286260 XM_926851 0.0288 0.639 -1.566 
N21008 ZYG11B NM_024646 0.0227 0.639 -1.565 
BF574430 RAB12 NM_001025300 0.0358 0.639 -1.564 
AK002110 NDUFS8 NM_002496 0.0061 0.640 -1.564 
NM_032876 JUB NM_032876 0.0368 0.640 -1.563 
BE207758 ARRB1 NM_004041 0.0139 0.640 -1.563 
NM_031283 TCF7L1 NM_031283 0.0431 0.640 -1.562 
AK024516 
  
0.0473 0.640 -1.562 
BE000929 MSI2 NM_138962 0.0335 0.641 -1.561 
AW079553 
  
0.0098 0.641 -1.560 
BQ899060 
  
0.0453 0.641 -1.559 
NM_004834 MAP4K4 NM_004834 0.0128 0.642 -1.559 
NM_004353 SERPINH1 NM_001235 0.0467 0.642 -1.558 
AK025567 JUB NM_032876 0.0008 0.642 -1.557 
AW102941 FARP1 NM_001001715 0.0310 0.643 -1.556 
BQ433060 ZNF642 NM_198494 0.0023 0.643 -1.555 
AI888256 RNF217 NM_152553 0.0026 0.643 -1.555 
NM_014160 MKRN2 NM_014160 0.0223 0.644 -1.554 
AI872645 DNAH5 NM_001369 0.0261 0.644 -1.554 
BG036203 LOC203547 NM_001017980 0.0328 0.644 -1.554 
NM_017515 SLC35F2 NM_017515 0.0018 0.644 -1.553 
BC015343 LOC162073 NM_001034841 0.0380 0.645 -1.550 
NM_001566 INPP4A NM_001566 0.0320 0.645 -1.550 
AA678492 C9orf100 NM_032818 0.0115 0.646 -1.549 
BF696931 CCDC50 NM_174908 0.0166 0.646 -1.548 
AW204088 DCP1B NM_152640 0.0341 0.646 -1.548 
AI916242 EEA1 NM_003566 0.0331 0.646 -1.547 
NM_007357 COG2 NM_007357 0.0204 0.647 -1.546 
BC000050 NOB1 NM_014062 0.0215 0.647 -1.545 
U47635 MTMR6 NM_004685 0.0185 0.647 -1.545 
AK025444 PHLDB2 NM_145753 0.0139 0.648 -1.544 
BF339566 NAV1 NM_020443 0.0152 0.648 -1.543 
NM_003489 NRIP1 NM_003489 0.0138 0.648 -1.542 
AI660619 SLC7A6 NM_001076785 0.0346 0.649 -1.542 
AA631242 RAB15 NM_198686 0.0276 0.649 -1.542 
BE671084 ARHGAP26 NM_015071 0.0049 0.649 -1.541 
AI743903 FLJ39051 
 
0.0086 0.649 -1.540 
AI912523 KIAA1430 NM_020827 0.0022 0.650 -1.539 
BE550452 HOMER1 NM_004272 0.0055 0.650 -1.539 
AA129776 SUOX NM_000456 0.0254 0.650 -1.538 
AA278233 LOC286052 
 
0.0246 0.650 -1.538 
BC000915 PDLIM1 NM_020992 0.0045 0.650 -1.538 
NM_006584 CCT6B NM_006584 0.0275 0.650 -1.538 
NM_003878 GGH NM_003878 0.0067 0.651 -1.537 
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AW138594 KLHL9 NM_018847 0.0350 0.651 -1.536 
NM_024834 C10orf119 NM_024834 0.0156 0.651 -1.536 
BF213575 EPS15 NM_001981 0.0264 0.651 -1.536 
BC000251 GSK3B NM_002093 0.0200 0.651 -1.536 
AW500220 KCTD20 NM_173562 0.0106 0.651 -1.536 
NM_012201 GLG1 NM_012201 0.0383 0.651 -1.535 
AW029619 CKAP4 NM_006825 0.0184 0.652 -1.534 
BE927772 SFRS3 NM_003017 0.0304 0.652 -1.533 
AI652633 
  
0.0414 0.652 -1.533 
BE379393 C6orf132 XM_371820 0.0479 0.652 -1.533 
D21851 LARS2 NM_015340 0.0188 0.652 -1.533 
AL832682 PARVA NM_018222 0.0020 0.653 -1.532 
BF438203 ZXDC NM_001040653 0.0499 0.653 -1.532 
NM_000188 HK1 NM_000188 0.0348 0.653 -1.531 
AA531337 CRIPAK NM_175918 0.0324 0.654 -1.530 
BC001327 IFRD2 NM_006764 0.0163 0.654 -1.530 
AI743880 
  
0.0235 0.654 -1.529 
R85437 VANGL1 NM_138959 0.0044 0.654 -1.528 
BC013077 
  
0.0015 0.655 -1.528 
BC040723 AFAP1L1 NM_152406 0.0216 0.655 -1.528 
BC004490 FOS NM_005252 0.0239 0.655 -1.527 
AL562733 ERAL1 NM_005702 0.0341 0.655 -1.527 
N58163 WDR32 NM_024345 0.0078 0.655 -1.526 
BE879367 AKAP2 /// PALM2-AKAP2 NM_001004065 0.0256 0.655 -1.526 
AI652645 IQSEC1 NM_014869 0.0135 0.656 -1.525 
AI184512 THEM4 NM_053055 0.0167 0.656 -1.525 
BU683415 KLF6 NM_001008490 0.0154 0.656 -1.524 
NM_024121 TMEM185B NR_000034 0.0092 0.657 -1.523 
AI742039 OGT NM_181672 0.0455 0.657 -1.522 
AA582932 RAB15 NM_198686 0.0309 0.657 -1.522 
AU157304 C3orf59 NM_178496 0.0044 0.658 -1.520 
BF001312 EEF2K NM_013302 0.0173 0.658 -1.520 
BE501789 NSL1 NM_001042549 0.0253 0.658 -1.520 
BE858180 PEG10 NM_001040152 0.0024 0.659 -1.519 
AW952547 MDH1 NM_005917 0.0422 0.659 -1.519 
AW593330 
  
0.0038 0.659 -1.518 
AA960804 LOC728613 NR_003713 0.0150 0.659 -1.518 
AA481141 VAV2 NM_003371 0.0365 0.659 -1.517 
NM_018117 BRWD2 NM_018117 0.0114 0.659 -1.517 
AI769569 MAML2 NM_032427 0.0130 0.660 -1.516 
BE552097 PWWP2A NM_052927 0.0491 0.660 -1.516 
AA148301 COMMD7 NM_001099339 0.0273 0.660 -1.516 
AL046979 TNS1 NM_022648 0.0096 0.660 -1.515 
AA829836 C9orf126 NM_173690 0.0123 0.660 -1.515 
BC005821 PTEN NM_000314 0.0076 0.660 -1.514 
NM_012179 FBXO7 NM_001033024 0.0329 0.661 -1.514 
NM_004125 GNG10 /// LOC552891 NM_001017998 0.0261 0.661 -1.513 
AV704797 KIAA1549 NM_020910 0.0460 0.661 -1.513 
T58129 HUNK NM_014586 0.0330 0.662 -1.511 
NM_015623 TANC2 NM_025185 0.0279 0.662 -1.511 
NM_004034 ANXA7 NM_001156 0.0260 0.662 -1.511 
NM_004865 TBPL1 NM_004865 0.0124 0.663 -1.509 
BG286920 RSF1 NM_016578 0.0270 0.663 -1.509 
AF119841 PECR NM_018441 0.0219 0.663 -1.508 
BE049621 LUC7L NM_018032 0.0456 0.663 -1.507 
AL117352 EGLN1 NM_022051 0.0300 0.664 -1.507 
AA234096 MGC16121 XM_001128419 0.0406 0.664 -1.507 
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AK023513 SNAPC4 NM_003086 0.0417 0.664 -1.507 
BG540494 AKAP2 /// PALM2-AKAP2 NM_001004065 0.0063 0.664 -1.506 
AI623211 LOC645166 XM_001129441 0.0498 0.664 -1.506 
AW593801 
  
0.0466 0.664 -1.506 
AI949095 FAM83H NM_198488 0.0320 0.665 -1.505 
AF272663 GPHN NM_001024218 0.0325 0.665 -1.504 
NM_014612 FAM120A NM_014612 0.0469 0.665 -1.504 
AF084513 RAD1 NM_002853 0.0319 0.665 -1.503 
NM_005842 SPRY2 NM_005842 0.0349 0.666 -1.502 
BE048857 VPS13B NM_015243 0.0084 0.666 -1.501 
NM_017615 NSMCE4A NM_017615 0.0108 0.666 -1.501 
AF083105 SOX13 NM_005686 0.0098 0.666 -1.501 
AA741090 CALML4 NM_001031733 0.0234 0.667 -1.500 
BC013132 GDAP2 NM_017686 0.0209 0.667 -1.500 
AL078459 DDAH1 NM_012137 0.0028 0.667 -1.499 
BG289967 RAD21 NM_006265 0.0164 0.667 -1.499 
NM_024098 CCDC86 NM_024098 0.0063 0.667 -1.499 
NM_001270 CHD1 NM_001270 0.0214 0.668 -1.498 
AI459274 ZFR NM_016107 0.0436 0.668 -1.497 
AW469181 TMC5 NM_001105248 0.0275 0.668 -1.497 
NM_001323 CST6 NM_001323 0.0449 0.669 -1.496 
AA526844 MYLK NM_005965 0.0404 0.669 -1.494 
AF161528 NIP7 NM_016101 0.0346 0.670 -1.493 
NM_000698 ALOX5 NM_000698 0.0347 0.670 -1.493 
AI672489 
  
0.0365 0.670 -1.492 
NM_001386 DPYSL2 NM_001386 0.0123 0.671 -1.491 
AI241810 
  
0.0266 0.671 -1.491 
AI807206 ZDHHC21 NM_178566 0.0164 0.671 -1.490 
AI130715 CEP152 NM_014985 0.0478 0.672 -1.489 
AL832823 HS3ST3B1 NM_006041 0.0270 0.672 -1.489 
AI356895 RHBDD1 NM_032276 0.0174 0.672 -1.489 
AA909035 COL4A2 NM_001846 0.0145 0.672 -1.488 
BE549973 UBA5 NM_024818 0.0307 0.672 -1.488 
AU147713 SRRM1 NM_005839 0.0119 0.672 -1.488 
NM_005808 CTDSPL NM_001008392 0.0065 0.673 -1.486 
M58596 FUT4 NM_002033 0.0205 0.673 -1.486 
H37943 
  
0.0369 0.673 -1.485 
AL136782 KBTBD7 NM_032138 0.0376 0.674 -1.485 
U90902 TIAM1 NM_003253 0.0233 0.674 -1.483 
AF305057 ENOSF1 NM_017512 0.0151 0.674 -1.483 
AF020543 PPT2 NM_005155 0.0482 0.674 -1.483 
AI590926 SLC35B4 NM_032826 0.0111 0.674 -1.483 
AB011100 KIAA0528 NM_014802 0.0107 0.675 -1.481 
AI762884 
  
0.0306 0.675 -1.481 
NM_001821 CHML NM_001821 0.0118 0.676 -1.480 
AW151538 C21orf45 NM_018944 0.0428 0.676 -1.480 
NM_004504 HRB NM_004504 0.0029 0.676 -1.480 
AW195407 C10orf30 NM_001100912 0.0378 0.676 -1.479 
AL045882 PCGF5 NM_032373 0.0300 0.676 -1.479 
AK027737 PRMT5 NM_001039619 0.0072 0.677 -1.477 
NM_001649 SHROOM2 NM_001649 0.0074 0.677 -1.477 
BC003697 KCTD20 NM_173562 0.0134 0.677 -1.477 
BE328496 MBNL2 NM_144778 0.0099 0.677 -1.477 
BF214358 FAM76B NM_144664 0.0393 0.677 -1.477 
NM_005544 IRS1 NM_005544 0.0195 0.678 -1.475 
AI680541 LIFR NM_002310 0.0480 0.678 -1.475 
AL359939 VPS54 NM_001005739 0.0055 0.678 -1.475 
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AF362887 TPM4 NM_003290 0.0419 0.678 -1.474 
Y11162 SNORA68 NR_000012 0.0489 0.678 -1.474 
AA007367 FAM109A NM_144671 0.0047 0.678 -1.474 
AA195024 LONP2 NM_031490 0.0477 0.679 -1.474 
BF439282 RAPGEF2 NM_014247 0.0371 0.679 -1.472 
AV721430 TCF7L2 NM_030756 0.0119 0.680 -1.471 
AU152194 LOC388720 /// RPS27A NM_002954 0.0321 0.681 -1.468 
BF217861 MT1E NM_175617 0.0321 0.681 -1.468 
AF085969 
  
0.0255 0.682 -1.467 
BF197122 KIAA0090 NM_015047 0.0128 0.682 -1.466 
AI708524 LOC440552 
 
0.0213 0.682 -1.466 
BG532405 C13orf1 NM_020456 0.0163 0.682 -1.466 
AI400463 CTGLF3 
 
0.0068 0.682 -1.465 
BC001161 ZNF174 NM_001032292 0.0343 0.683 -1.465 
N64780 ASXL1 NM_015338 0.0242 0.683 -1.465 
BE221212 COL1A1 NM_000088 0.0090 0.683 -1.465 
AI554467 LOC388344 /// RPL13 /// SNORD68 NM_000977 0.0302 0.683 -1.465 
AK026630 C10orf84 NM_022063 0.0212 0.683 -1.464 
NM_006090 CEPT1 NM_001007794 0.0277 0.683 -1.464 
NM_152484 ZNF569 NM_152484 0.0221 0.684 -1.463 
NM_014942 ANKRD6 NM_014942 0.0440 0.684 -1.463 
U94363 GYG2 NM_001079855 0.0482 0.684 -1.463 
AK001380 ASPM NM_018136 0.0324 0.684 -1.462 
AI382123 MYH10 NM_005964 0.0071 0.684 -1.462 
NM_006296 VRK2 NM_006296 0.0043 0.684 -1.462 
BC004234 LONP2 NM_031490 0.0168 0.685 -1.460 
AL136776 MED23 NM_004830 0.0201 0.685 -1.460 
NM_000951 PRRG2 NM_000951 0.0127 0.685 -1.460 
AB014560 G3BP2 NM_012297 0.0475 0.685 -1.460 
NM_001943 DSG2 NM_001943 0.0323 0.685 -1.460 
NM_020674 CYP20A1 NM_020674 0.0266 0.685 -1.459 
BF590317 CTDSPL NM_001008392 0.0356 0.686 -1.459 
BE503981 
  
0.0473 0.686 -1.458 
NM_018127 ELAC2 NM_018127 0.0067 0.687 -1.456 
AF033861 ADCY3 NM_004036 0.0405 0.687 -1.456 
BF058944 SCAMP1 NM_004866 0.0276 0.687 -1.455 
BF001666 FBXL14 NM_152441 0.0061 0.687 -1.455 
AA121673 ZNF281 NM_012482 0.0091 0.688 -1.454 
AU137607 NAV2 NM_001111018 0.0474 0.688 -1.454 
BF432532 TIAL1 NM_001033925 0.0280 0.688 -1.453 
NM_014873 LPGAT1 NM_014873 0.0256 0.689 -1.452 
BC032942 GSTCD NM_001031720 0.0144 0.689 -1.452 
NM_003144 SSR1 NM_003144 0.0203 0.689 -1.451 
NM_002184 IL6ST NM_002184 0.0155 0.689 -1.451 
AU155298 CHD1 NM_001270 0.0064 0.690 -1.449 
AL117518 ASXL1 NM_015338 0.0293 0.690 -1.449 
NM_173709 
  
0.0047 0.690 -1.449 
AI636233 TMEM8 NM_021259 0.0464 0.691 -1.447 
AI291720 DPH5 NM_001077394 0.0236 0.691 -1.447 
AK024300 MGC45800 XR_017723 0.0038 0.691 -1.447 
BE621259 UBE2D2 NM_003339 0.0219 0.691 -1.447 
NM_006470 TRIM16 /// TRIM16L NM_001037330 0.0320 0.691 -1.447 
NM_020380 CASC5 NM_144508 0.0449 0.692 -1.446 
NM_021930 RINT1 NM_021930 0.0321 0.692 -1.445 
AW271106 IQGAP3 NM_178229 0.0315 0.692 -1.444 
NM_012204 GTF3C4 NM_012204 0.0363 0.693 -1.444 




0.0017 0.693 -1.443 
AB051513 ZC3H12C NM_033390 0.0065 0.693 -1.443 
AK027737 PRMT5 NM_001039619 0.0166 0.694 -1.442 
AI912190 
  
0.0255 0.694 -1.442 
AA807529 MCM5 NM_006739 0.0174 0.694 -1.442 
NM_005246 FER NM_005246 0.0030 0.694 -1.441 
BF732413 SEC22C NM_004206 0.0476 0.694 -1.441 
AL122121 PAPD1 NM_018109 0.0241 0.694 -1.441 
AI650892 NSUN4 NM_199044 0.0330 0.694 -1.441 
BF223021 B4GALT4 NM_003778 0.0160 0.695 -1.440 
AI334297 KLHDC5 NM_020782 0.0324 0.695 -1.439 
NM_004901 ENTPD4 NM_004901 0.0199 0.695 -1.439 
BG026723 QSER1 NM_001076786 0.0283 0.695 -1.439 
AI761110 SETD2 NM_014159 0.0500 0.695 -1.438 
AK022897 RECK NM_021111 0.0343 0.695 -1.438 
BG257762 CDV3 NM_017548 0.0315 0.696 -1.438 
NM_006747 SIPA1 NM_006747 0.0465 0.696 -1.438 
AI769587 ARHGAP27 NM_199282 0.0002 0.696 -1.436 
BE892293 
  
0.0409 0.697 -1.436 
AK000776 
  
0.0463 0.697 -1.436 
AF167343 IL1RAP NM_002182 0.0247 0.697 -1.436 
AV700030 IL6R NM_000565 0.0484 0.697 -1.435 
AB032977 NAV1 NM_020443 0.0002 0.697 -1.435 
AW613203 PAIP1 NM_006451 0.0067 0.697 -1.434 
NM_012230 POMZP3 /// ZP3 NM_001110354 0.0339 0.698 -1.433 
NM_014924 KIAA0831 NM_014924 0.0206 0.698 -1.432 
BC041487 
  
0.0168 0.698 -1.432 
AI359368 LETM1 NM_012318 0.0252 0.698 -1.432 
N93774 C21orf45 NM_018944 0.0183 0.698 -1.432 
AF320070 EHD4 NM_139265 0.0403 0.699 -1.431 
NM_024622 FASTKD1 NM_024622 0.0160 0.699 -1.431 
BC000376 ZFR NM_016107 0.0384 0.699 -1.430 
AI082078 ACTN1 NM_001102 0.0152 0.699 -1.430 
AI379751 
  
0.0364 0.700 -1.429 
BG289456 USP31 NM_020718 0.0423 0.700 -1.429 
NM_000268 NF2 NM_000268 0.0398 0.700 -1.429 
AA664258 HNRNPC NM_001077442 0.0104 0.701 -1.427 
AK001821 GNPTAB NM_024312 0.0128 0.702 -1.425 
NM_018256 WDR12 NM_018256 0.0261 0.702 -1.424 
AU157049 LOC153346 
 
0.0488 0.702 -1.424 
NM_012343 NNT NM_012343 0.0049 0.702 -1.424 
AK094809 RASGRF2 NM_006909 0.0064 0.703 -1.423 
BF435773 SHANK2 NM_012309 0.0223 0.703 -1.423 
AW515443 NUCKS1 NM_022731 0.0219 0.703 -1.423 
AK074161 SLC46A1 NM_080669 0.0072 0.703 -1.423 
AA740875 GSTCD NM_001031720 0.0498 0.703 -1.423 
BF966015 ZNF18 NM_144680 0.0150 0.703 -1.423 
NM_144692 C19orf55 NM_001039887 0.0222 0.703 -1.423 
AW014593 GBP1 NM_002053 0.0212 0.703 -1.422 
NM_016653 ZAK NM_016653 0.0490 0.704 -1.421 
U13261 METAP2 NM_006838 0.0202 0.704 -1.420 
AI391443 SRFBP1 NM_152546 0.0108 0.705 -1.418 
BF444916 FNDC3B NM_022763 0.0157 0.706 -1.417 
AI830698 IGF1R NM_000875 0.0184 0.707 -1.415 
AL044018 LPP NM_005578 0.0203 0.707 -1.415 
AF212224 CLK4 NM_020666 0.0051 0.707 -1.414 
NM_005195 CEBPD NM_005195 0.0061 0.707 -1.414 
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AJ278245 LANCL2 NM_018697 0.0104 0.707 -1.414 
AL049285 
  
0.0241 0.707 -1.414 
BC002666 GBP1 NM_002053 0.0476 0.708 -1.413 
AI821787 
  
0.0381 0.708 -1.412 
AA209239 ABHD6 NM_020676 0.0214 0.708 -1.412 
AL031313 EIF3J /// LOC730021 NM_003758 0.0321 0.709 -1.411 
AL080111 NEK7 NM_133494 0.0272 0.709 -1.411 
AI049962 ZCCHC11 NM_001009881 0.0143 0.709 -1.411 
AI832363 
  
0.0305 0.710 -1.409 
AI888150 PPP1R9A NM_017650 0.0148 0.710 -1.408 
BC000212 GTF3C2 NM_001035521 0.0402 0.710 -1.408 
BC000853 C2orf3 NM_003203 0.0214 0.711 -1.407 
NM_017555 EGLN2 NM_017555 0.0271 0.711 -1.407 
AA648913 BIRC5 NM_001012270 0.0259 0.711 -1.407 
D26069 CENTB2 NM_012287 0.0185 0.712 -1.405 
AW001101 KIAA0368 NM_001080398 0.0137 0.712 -1.405 
AL575922 SPARC NM_003118 0.0344 0.712 -1.404 
AU157155 AMOTL1 NM_130847 0.0010 0.712 -1.404 
AB044661 XAB1 NM_007266 0.0235 0.712 -1.404 
AA524536 LGR6 NM_001017403 0.0133 0.713 -1.403 
BC004517 MRPL9 NM_031420 0.0108 0.713 -1.403 
AL359571 NIN NM_016350 0.0288 0.713 -1.403 
BG105365 SKP2 NM_005983 0.0098 0.713 -1.403 
AU149225 MGA NM_001080541 0.0150 0.714 -1.401 
AW009330 C13orf1 NM_020456 0.0315 0.714 -1.401 
AL045513 POFUT1 NM_015352 0.0048 0.714 -1.400 
NM_024657 MORC4 NM_001085354 0.0098 0.714 -1.400 
AV699857 RPE NM_006916 0.0024 0.714 -1.400 
AI431597 WDR22 NM_003861 0.0096 0.715 -1.400 
AK024986 PTEN NM_000314 0.0232 0.715 -1.399 
NM_018443 ZNF302 NM_001012320 0.0089 0.715 -1.399 
NM_022766 CERK NM_022766 0.0009 0.715 -1.399 
NM_006800 MSL3L1 NM_006800 0.0478 0.715 -1.399 
NM_003079 SMARCE1 NM_003079 0.0359 0.715 -1.399 
H95263 STX2 NM_001980 0.0431 0.715 -1.398 
AI674915 
  
0.0429 0.715 -1.398 
AL575509 ETS2 NM_005239 0.0121 0.715 -1.398 
NM_017688 BSPRY NM_017688 0.0185 0.715 -1.398 
NM_015198 COBL NM_015198 0.0336 0.715 -1.398 
NM_014832 TBC1D4 NM_014832 0.0346 0.716 -1.397 
BF515963 WARS2 NM_015836 0.0081 0.716 -1.397 
AL552001 PRKAB2 NM_005399 0.0283 0.716 -1.397 
AF044286 H2AFY NM_001040158 0.0092 0.716 -1.396 
AB037732 RBM27 
 
0.0205 0.718 -1.394 
NM_012338 TSPAN12 NM_012338 0.0017 0.718 -1.394 
AI800609 STX17 NM_017919 0.0414 0.718 -1.393 
BC004558 RTKN NM_001015055 0.0020 0.718 -1.392 
AA528140 DDIT4L NM_145244 0.0210 0.718 -1.392 
NM_016056 TMBIM4 NM_016056 0.0191 0.719 -1.392 
AI346432 MINA NM_001042533 0.0203 0.719 -1.390 
AW157070 EGFR NM_005228 0.0409 0.720 -1.389 
NM_005754 G3BP1 NM_005754 0.0285 0.720 -1.389 
AL046696 BMPR2 NM_001204 0.0414 0.720 -1.388 
NM_001450 FHL2 NM_001039492 0.0499 0.720 -1.388 
AL117643 ACVR1B NM_004302 0.0067 0.720 -1.388 
NM_005154 USP8 NM_005154 0.0150 0.721 -1.388 




0.0334 0.722 -1.385 
NM_003630 PEX3 NM_003630 0.0184 0.724 -1.382 
AU151801 C1QBP NM_001212 0.0437 0.724 -1.382 
BG168720 ZDHHC18 NM_032283 0.0030 0.724 -1.381 
AV724783 PRDM2 NM_001007257 0.0376 0.724 -1.381 
AL390164 GATAD2A NM_017660 0.0303 0.725 -1.380 
W93584 POLR1A NM_015425 0.0470 0.725 -1.380 
AA235202 WDR36 NM_139281 0.0419 0.725 -1.380 
AA521508 ZMYM4 NM_005095 0.0172 0.725 -1.380 
AA825925 
  
0.0371 0.725 -1.379 
AI935647 ARHGAP28 NM_001010000 0.0230 0.726 -1.378 
AK002205 VPS54 NM_001005739 0.0212 0.726 -1.377 
BC003525 MAX NM_002382 0.0179 0.726 -1.377 
BC001745 D4S234E NM_001040101 0.0067 0.727 -1.376 
N90719 
  
0.0123 0.727 -1.376 
AI167592 
  
0.0437 0.727 -1.375 
NM_005463 HNRPDL NM_005463 0.0421 0.728 -1.375 
AI160440 USP7 NM_003470 0.0088 0.729 -1.373 
AA126793 HNRNPC NM_001077442 0.0259 0.729 -1.372 
BC004862 UBE2R2 NM_017811 0.0433 0.729 -1.372 
AU150752 ZNF281 NM_012482 0.0117 0.730 -1.370 
NM_003746 DYNLL1 NM_001037494 0.0313 0.730 -1.370 
NM_016265 ZNF12 NM_006956 0.0049 0.730 -1.370 
AU144413 SP3 NM_001017371 0.0326 0.730 -1.370 
AA251906 METT5D1 NM_152636 0.0208 0.731 -1.369 
NM_025103 IFT74 NM_001099222 0.0122 0.731 -1.368 
AI707721 
  
0.0175 0.731 -1.368 
BF678497 LIN54 NM_194282 0.0115 0.731 -1.368 
AI672159 
  
0.0011 0.731 -1.368 
AV700302 ZNF641 NM_152320 0.0496 0.731 -1.368 
AB023215 TTLL5 NM_015072 0.0406 0.731 -1.367 
NM_002398 MEIS1 NM_002398 0.0214 0.731 -1.367 
NM_002533 NVL NM_002533 0.0142 0.732 -1.366 
AB007930 POGZ NM_015100 0.0368 0.732 -1.366 
AL136736 KIAA1549 NM_020910 0.0475 0.732 -1.366 
NM_005077 TLE1 NM_005077 0.0240 0.733 -1.364 
AI088843 C7orf30 NM_138446 0.0322 0.733 -1.364 
T53175 C7orf38 NM_145111 0.0241 0.733 -1.364 
BE856541 CXorf39 NM_207318 0.0081 0.733 -1.364 
AW467472 APPL1 NM_012096 0.0414 0.733 -1.364 
NM_016229 CYB5R2 NM_016229 0.0460 0.733 -1.364 
BC004902 KIAA0947 NM_015325 0.0468 0.734 -1.363 
NM_005012 ROR1 NM_001083592 0.0375 0.734 -1.363 
BC004183 C10orf119 NM_024834 0.0369 0.734 -1.362 
AF179221 FBXL11 NM_012308 0.0222 0.734 -1.362 
BE670307 
  
0.0286 0.735 -1.361 
AJ278112 DEPDC1 NM_017779 0.0138 0.735 -1.360 
BF059159 ROBO1 NM_002941 0.0128 0.736 -1.360 
AU116818 FAM120A NM_014612 0.0134 0.736 -1.359 
AB051499 KIAA1712 NM_001040157 0.0356 0.736 -1.359 
AA495988 C9orf5 NM_001099734 0.0381 0.736 -1.359 
AI350995 
  
0.0244 0.736 -1.359 
BE620258 
  
0.0436 0.736 -1.359 
AB024703 RNF11 NM_014372 0.0389 0.737 -1.358 
NM_018229 C14orf108 NM_018229 0.0209 0.737 -1.357 
AU147399 CAV1 NM_001753 0.0441 0.737 -1.357 
AI936976 KIAA0562 NM_014704 0.0037 0.737 -1.357 
149 
AI765051 DARS2 NM_018122 0.0320 0.737 -1.357 
BF978647 GFM1 NM_024996 0.0364 0.738 -1.356 
U30894 SGSH NM_000199 0.0299 0.739 -1.354 
AI571166 
  
0.0249 0.739 -1.353 
AF059318 USP47 NM_017944 0.0441 0.740 -1.352 
AW204564 CREBZF NM_001039618 0.0259 0.740 -1.352 
AV724508 SDCCAG1 NM_004713 0.0491 0.741 -1.350 
NM_003592 CUL1 NM_003592 0.0196 0.741 -1.349 
N38985 C3orf63 NM_001112736 0.0362 0.741 -1.349 
NM_006965 ZNF24 NM_006965 0.0190 0.741 -1.349 
AY137580 CDC25A NM_001789 0.0170 0.742 -1.348 
BF056507 NSMAF NM_003580 0.0202 0.742 -1.348 
AI763123 ADD3 NM_001121 0.0426 0.743 -1.346 
AF131850 EI24 NM_001007277 0.0191 0.743 -1.346 
BF435513 RASAL2 NM_004841 0.0209 0.743 -1.346 
NM_014669 NUP93 NM_014669 0.0104 0.743 -1.346 
AK002054 COBLL1 NM_014900 0.0265 0.744 -1.344 
BF843343 
  
0.0281 0.745 -1.343 
AK027184 BPTF NM_004459 0.0049 0.745 -1.342 
AA456955 ANKRD38 NM_181712 0.0464 0.745 -1.342 
NM_019005 FLJ20323 NM_019005 0.0241 0.746 -1.341 
BC038440 GALNT1 NM_020474 0.0388 0.746 -1.341 
NM_004713 SDCCAG1 NM_004713 0.0136 0.746 -1.340 
AK023637 AMMECR1 NM_001025580 0.0234 0.747 -1.340 
NM_002901 RCN1 NM_002901 0.0029 0.747 -1.339 
BC001002 TUBB NM_178014 0.0345 0.747 -1.339 
BE999967 
  
0.0023 0.747 -1.339 
BC013009 ZMYM3 NM_005096 0.0354 0.748 -1.338 
BE672408 
  
0.0332 0.748 -1.337 
AI339586 ZNF420 NM_144689 0.0462 0.748 -1.337 
NM_006825 CKAP4 NM_006825 0.0062 0.748 -1.337 
NM_017810 ZNF434 NM_017810 0.0264 0.748 -1.337 
NM_021078 GCN5L2 NM_021078 0.0249 0.748 -1.337 
NM_006307 SRPX NM_006307 0.0207 0.748 -1.337 
AI742925 RAD1 NM_002853 0.0439 0.749 -1.336 
BE737620 PPP1R12A NM_002480 0.0036 0.750 -1.334 
AF262027 RAD23B NM_002874 0.0139 0.751 -1.332 
AL561281 MAP4K4 NM_004834 0.0473 0.751 -1.332 
AV707142 KCTD20 NM_173562 0.0244 0.751 -1.332 
AI277617 FGD4 NM_139241 0.0212 0.751 -1.332 
BE858199 RPL7L1 NM_198486 0.0053 0.751 -1.331 
AI803633 TSR1 NM_018128 0.0159 0.751 -1.331 
AI652872 EPB41L5 NM_020909 0.0068 0.752 -1.330 
NM_017681 NUP62CL NM_017681 0.0239 0.752 -1.329 
D84109 RBPMS NM_001008710 0.0423 0.752 -1.329 
BC041481 FLJ35848 NM_001033659 0.0328 0.752 -1.329 
AU157441 WDR32 NM_024345 0.0303 0.753 -1.328 
BF062139 POLR3G NM_006467 0.0278 0.754 -1.327 
AI651265 CRKRS NM_015083 0.0295 0.754 -1.327 
AL514547 RBM12 NM_006047 0.0198 0.754 -1.327 
BQ022804 LAYN NM_178834 0.0262 0.754 -1.327 
AI150690 
  
0.0172 0.754 -1.327 
AK025482 TMEM168 NM_022484 0.0433 0.754 -1.326 
AK023184 KIF1B NM_015074 0.0464 0.754 -1.326 
AI744451 
  
0.0264 0.755 -1.325 
U49844 ATR NM_001184 0.0131 0.755 -1.325 
AA541758 CPNE3 NM_003909 0.0442 0.755 -1.324 
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H48840 FXR1 NM_001013438 0.0491 0.756 -1.323 
AB020712 SEC31A NM_001077206 0.0277 0.756 -1.322 
BE503800 DDX31 
 
0.0460 0.756 -1.322 
AA973551 
  
0.0071 0.757 -1.321 
AL136872 COMMD4 NM_017828 0.0174 0.757 -1.321 
U62325 APBB2 NM_173075 0.0288 0.757 -1.321 
AA448956 CAMK2D NM_001221 0.0279 0.757 -1.321 
NM_004390 CTSH NM_004390 0.0045 0.757 -1.321 
NM_005134 PPP4R1 NM_001042388 0.0160 0.757 -1.321 
W84421 LOC647121 NR_003955 0.0215 0.758 -1.320 
AA479290 
  
0.0355 0.758 -1.319 
AB049740 FUT8 NM_004480 0.0380 0.759 -1.318 
AI796010 RAD1 NM_002853 0.0095 0.759 -1.318 
NM_003685 KHSRP NM_003685 0.0360 0.759 -1.317 
NM_002874 RAD23B NM_002874 0.0080 0.759 -1.317 
N24868 PIAS1 NM_016166 0.0040 0.760 -1.316 
BG025078 FXR1 NM_001013438 0.0377 0.760 -1.316 
AF272898 PRDM6 XM_927647 0.0128 0.760 -1.316 
AB018284 EIF5B NM_015904 0.0124 0.761 -1.314 
NM_017735 TTC27 NM_017735 0.0001 0.761 -1.314 
AA026388 
  
0.0128 0.761 -1.314 
AI828221 SHPRH NM_001042683 0.0362 0.761 -1.314 
AI340241 DKFZp686E2433 XM_293828 0.0488 0.762 -1.312 
BF966540 PPP1R2 NM_006241 0.0337 0.762 -1.312 
AA594937 COBL NM_015198 0.0040 0.763 -1.310 
NM_018844 BCAP29 NM_001008405 0.0365 0.764 -1.310 
D84109 RBPMS NM_001008710 0.0053 0.764 -1.309 
BG403361 
  
0.0138 0.764 -1.309 
AI300168 ZNF746 NM_152557 0.0386 0.764 -1.309 
BG341906 ARF3 NM_001659 0.0111 0.765 -1.308 
AL548941 KDELC2 NM_153705 0.0123 0.765 -1.307 
NM_024615 PARP8 NM_024615 0.0095 0.765 -1.307 
NM_012482 ZNF281 NM_012482 0.0053 0.765 -1.307 
AF268193 TBL1XR1 NM_024665 0.0255 0.766 -1.306 
AV712577 ANP32B NM_006401 0.0122 0.767 -1.304 
BE250417 ZMYND11 NM_006624 0.0283 0.767 -1.304 
AA551784 CARM1 NM_199141 0.0296 0.767 -1.304 
AW026194 PDCD11 NM_014976 0.0385 0.768 -1.302 
AF054589 MDFIC NM_199072 0.0000 0.769 -1.301 
AL136770 CLDN12 NM_012129 0.0329 0.769 -1.300 
NM_006048 UBE4B NM_001105562 0.0242 1.301 1.301 
AA573502 TAP2 NM_000544 0.0024 1.303 1.303 
AL527334 
  
0.0442 1.303 1.303 
AV727934 
  
0.0255 1.304 1.304 
AL117612 MAL2 NM_052886 0.0396 1.304 1.304 
AL080220 C2CD3 NM_015531 0.0268 1.308 1.308 
NM_001033 RRM1 NM_001033 0.0392 1.310 1.310 
NM_022067 C14orf133 NM_022067 0.0408 1.311 1.311 
AU145019 FRMD4B NM_015123 0.0167 1.311 1.311 
NM_000057 BLM NM_000057 0.0047 1.314 1.314 
D89678 HNRPDL NM_005463 0.0280 1.314 1.314 
AW296028 
  
0.0197 1.314 1.314 
AW270158 
  
0.0072 1.315 1.315 
AJ131244 SEC24A NM_021982 0.0398 1.316 1.316 
NM_018062 FANCL NM_018062 0.0386 1.316 1.316 
AI587307 MANEA NM_024641 0.0002 1.318 1.318 
AL573951 LOC732402 /// PTPLAD1 NM_016395 0.0075 1.318 1.318 
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NM_004969 IDE NM_004969 0.0055 1.319 1.319 
NM_022969 FGFR2 NM_000141 0.0115 1.320 1.320 
NM_003136 SRP54 NM_003136 0.0249 1.320 1.320 
BF033242 CES2 NM_003869 0.0489 1.320 1.320 
NM_005667 RNF103 NM_005667 0.0174 1.321 1.321 
AF052094 EPAS1 NM_001430 0.0101 1.321 1.321 
NM_021140 UTX NM_021140 0.0251 1.322 1.322 
AL047650 ACBD5 NM_001042473 0.0084 1.322 1.322 
NM_022445 TPK1 NM_001042482 0.0336 1.323 1.323 
NM_005038 PPID NM_005038 0.0019 1.323 1.323 
AA206016 
  
0.0406 1.325 1.325 
BE503392 
  
0.0268 1.325 1.325 
BC002447 PHTF1 NM_006608 0.0281 1.326 1.326 
NM_002945 RPA1 NM_002945 0.0285 1.326 1.326 
AF112216 CMPK NM_016308 0.0311 1.326 1.326 
D83485 PDIA3 NM_005313 0.0338 1.326 1.326 
AI624156 
  
0.0439 1.327 1.327 
AA227879 
  
0.0405 1.327 1.327 
BF055171 ACOX3 NM_001101667 0.0454 1.329 1.329 
BG054844 RND3 NM_005168 0.0012 1.331 1.331 
AK055438 
  
0.0363 1.332 1.332 
BG548811 ZRANB3 NM_032143 0.0133 1.333 1.333 
NM_000161 GCH1 NM_000161 0.0206 1.333 1.333 
AI478300 NFATC2IP NM_032815 0.0173 1.334 1.334 
NM_018318 CCDC91 NM_018318 0.0425 1.334 1.334 
AV734793 ZDBF2 NM_020923 0.0192 1.336 1.336 
AI889160 CABLES1 NM_001100619 0.0314 1.337 1.337 
M87771 FGFR2 NM_000141 0.0310 1.338 1.338 
AA886888 
  
0.0376 1.338 1.338 
AF210057 C3orf1 NM_016589 0.0272 1.338 1.338 
BG501219 TMEM167 NM_174909 0.0331 1.338 1.338 
AA779684 BRMS1L NM_032352 0.0122 1.339 1.339 
NM_022735 ACBD3 NM_022735 0.0229 1.340 1.340 
NM_002013 FKBP3 NM_002013 0.0290 1.341 1.341 
AK025872 TNRC8 
 
0.0498 1.341 1.341 
AI990326 MPHOSPH9 NM_022782 0.0230 1.344 1.344 
AA634272 STAT3 NM_003150 0.0228 1.345 1.345 
X14174 ALPL NM_000478 0.0098 1.345 1.345 
W93554 SH3PXD2A NM_014631 0.0347 1.346 1.346 
AA129773 MAPK1 NM_002745 0.0063 1.348 1.348 
NM_003330 TXNRD1 NM_001093771 0.0012 1.348 1.348 
X57348 SFN NM_006142 0.0375 1.348 1.348 
BF223370 
  
0.0357 1.349 1.349 
BF516305 
  
0.0404 1.350 1.350 
BC036200 C1orf71 NM_152609 0.0171 1.350 1.350 
AA843238 SLU7 NM_006425 0.0043 1.350 1.350 
AF072098 TPT1 NM_003295 0.0215 1.351 1.351 
NM_015542 UPF2 NM_015542 0.0411 1.352 1.352 
AL110136 LOC440944 XR_017845 0.0285 1.352 1.352 
NM_014711 CP110 NM_014711 0.0047 1.352 1.352 
AL133267 LOC442175 XM_001130492 0.0242 1.353 1.353 
NM_015986 CRLF3 NM_015986 0.0405 1.353 1.353 
NM_003133 SRP9 NM_003133 0.0063 1.353 1.353 
AI927993 OSBP NM_002556 0.0117 1.355 1.355 
NM_018023 YEATS2 NM_018023 0.0064 1.356 1.356 
BF114745 
  
0.0437 1.356 1.356 
BG109855 SEMA5A NM_003966 0.0322 1.356 1.356 
152 
BC001393 C2orf24 NM_015680 0.0271 1.358 1.358 
H40020 
  
0.0395 1.360 1.360 
AI991996 KIAA1211 NM_020722 0.0403 1.360 1.360 
AU145642 C16orf52 NM_173501 0.0468 1.361 1.361 
AL031295 hCG_2003956 /// LYPLA2 /// LYPLA2P1 NM_007260 0.0395 1.362 1.362 
NM_016399 TRIAP1 NM_016399 0.0480 1.362 1.362 
NM_006353 HMGN4 NM_006353 0.0060 1.364 1.364 
AW006290 RIOK3 NM_003831 0.0014 1.364 1.364 
BE677844 
  
0.0283 1.366 1.366 
AA975427 
  
0.0384 1.367 1.367 
H09470 FLJ31958 
 
0.0368 1.367 1.367 
BC005176 TM7SF3 NM_016551 0.0075 1.368 1.368 
NM_025201 PLEKHO2 NM_025201 0.0089 1.368 1.368 
BG104860 CSNK1G1 NM_022048 0.0252 1.368 1.368 
BG496998 FAM33A NM_001100595 0.0138 1.369 1.369 
AI949179 BCL2L11 NM_006538 0.0113 1.370 1.370 
NM_017998 C9orf40 NM_017998 0.0040 1.370 1.370 
NM_030801 MAGED4 /// MAGED4B NM_001098800 0.0373 1.371 1.371 
NM_006810 PDIA5 NM_006810 0.0453 1.371 1.371 
NM_002318 LOXL2 NM_002318 0.0278 1.372 1.372 
AI378406 EGLN3 NM_022073 0.0097 1.372 1.372 
AW188940 B2M NM_004048 0.0314 1.374 1.374 
BF666293 FVT1 NM_002035 0.0106 1.374 1.374 
BC001362 CNP NM_033133 0.0205 1.375 1.375 
NM_021947 SRR NM_021947 0.0395 1.375 1.375 
NM_005475 SH2B3 NM_005475 0.0243 1.376 1.376 
AL542358 SLC36A4 NM_152313 0.0134 1.377 1.377 
AI674647 SPPL2A NM_032802 0.0300 1.377 1.377 
BE890365 WWC2 NM_024949 0.0284 1.378 1.378 
AI190287 ZNF788 XR_015208 0.0477 1.380 1.380 
AK057473 LOC339260 
 
0.0263 1.382 1.382 
U62317 LMF2 NM_033200 0.0401 1.382 1.382 
NM_014736 KIAA0101 NM_001029989 0.0035 1.383 1.383 
AB007899 NEDD4L NM_015277 0.0310 1.384 1.384 
NM_022471 GMCL1 NM_178439 0.0426 1.384 1.384 
AI807211 
  
0.0043 1.385 1.385 
NM_018639 WSB2 NM_018639 0.0146 1.385 1.385 
BF540749 
  
0.0300 1.386 1.386 
BG391282 
  
0.0257 1.387 1.387 
N51717 
  
0.0329 1.387 1.387 
NM_015710 GLTSCR2 NM_015710 0.0036 1.388 1.388 
NM_013257 SGK3 NM_001033578 0.0482 1.388 1.388 
BE897866 ACADSB NM_001609 0.0033 1.388 1.388 
AI354864 GPC1 NM_002081 0.0299 1.388 1.388 
BG537190 FTL NM_000146 0.0001 1.393 1.393 
BC005997 C1orf97 NM_032705 0.0280 1.393 1.393 
NM_003610 RAE1 NM_001015885 0.0025 1.393 1.393 
AI701170 
  
0.0198 1.395 1.395 
BE645144 FAM73A NM_198549 0.0181 1.395 1.395 
AV758242 CCDC111 NM_152683 0.0400 1.395 1.395 
AI816243 STX12 NM_177424 0.0129 1.396 1.396 
NM_016371 HSD17B7 /// HSD17B7P2 /// LOC730412 NM_016371 0.0379 1.396 1.396 
AI749451 CISD2 NM_001008388 0.0382 1.396 1.396 
AI831738 DDX59 NM_001031725 0.0232 1.396 1.396 
BC000873 GNB4 NM_021629 0.0448 1.396 1.396 
AL519710 CADM1 NM_001098517 0.0100 1.396 1.396 
AB020681 ANKRD12 NM_001083625 0.0212 1.397 1.397 
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AF072506 ERVWE1 NM_014590 0.0172 1.400 1.400 
AI032786 EDG5 NM_004230 0.0075 1.401 1.401 
BU846215 
  
0.0242 1.401 1.401 
NM_012382 TTC33 NM_012382 0.0031 1.402 1.402 
AI754404 PLOD2 NM_000935 0.0097 1.402 1.402 
AI744083 MOSPD2 NM_152581 0.0438 1.402 1.402 
AI760772 RFFL NM_001017368 0.0233 1.403 1.403 
NM_019114 EPB41L4B NM_018424 0.0082 1.405 1.405 
D85181 SC5DL NM_001024956 0.0306 1.407 1.407 
R43205 GUSBL2 NM_206908 0.0250 1.408 1.408 
BC000268 PSMB2 NM_002794 0.0029 1.408 1.408 
AL513583 GM2A NM_000405 0.0359 1.408 1.408 
NM_013229 APAF1 NM_001160 0.0407 1.409 1.409 
AV683529 C2orf49 
 
0.0349 1.411 1.411 
BF185904 GRPEL2 NM_152407 0.0005 1.411 1.411 
AI627666 FCHO2 NM_138782 0.0242 1.411 1.411 
BC011119 SPIRE2 NM_032451 0.0136 1.412 1.412 
AW504458 GNB4 NM_021629 0.0433 1.412 1.412 
N51405 DXS542 
 
0.0217 1.413 1.413 
BC004185 C16orf35 NM_001039476 0.0145 1.413 1.413 
NM_023948 MOSPD3 NM_001040097 0.0116 1.413 1.413 
NM_024310 PLEKHF1 NM_024310 0.0226 1.415 1.415 
BG284827 
  
0.0420 1.415 1.415 
AL136827 WDR37 NM_014023 0.0216 1.417 1.417 
AB037793 USP35 NM_020798 0.0255 1.417 1.417 
AV704232 
  
0.0090 1.418 1.418 
N51263 PHCA NM_018367 0.0385 1.419 1.419 
AB033058 DLG3 NM_020730 0.0326 1.420 1.420 
BC039551 
  
0.0473 1.422 1.422 
AI307586 
  
0.0177 1.423 1.423 
D83243 NPAT NM_002519 0.0123 1.423 1.423 
M31659 SLC25A16 NM_152707 0.0319 1.428 1.428 
AI355709 ZNF789 NM_001013258 0.0070 1.428 1.428 
AV702692 
  
0.0113 1.429 1.429 
AF158185 POLH NM_006502 0.0256 1.429 1.429 
BF038366 TMEM97 NM_014573 0.0137 1.429 1.429 
NM_152327 AK7 NM_152327 0.0362 1.430 1.430 
AK001393 EFCAB2 NM_032328 0.0460 1.431 1.431 
BF219240 ZNF655 NM_001009956 0.0147 1.432 1.432 
NM_001755 CBFB NM_001755 0.0022 1.433 1.433 
BE256900 JMJD2B NM_015015 0.0320 1.435 1.435 
NM_001294 CLPTM1 NM_001294 0.0214 1.435 1.435 
AW150236 SNX16 NM_022133 0.0151 1.437 1.437 
BG035985 HMGCS1 NM_001098272 0.0166 1.438 1.438 
AI341146 E2F7 NM_203394 0.0066 1.439 1.439 
NM_003422 MZF1 NM_003422 0.0319 1.439 1.439 
AW237290 
  
0.0032 1.440 1.440 
BC000143 ELMO2 NM_133171 0.0342 1.440 1.440 
NM_004855 PIGB NM_004855 0.0397 1.441 1.441 
NM_023923 PHACTR4 NM_001048183 0.0026 1.441 1.441 
NM_000617 SLC11A2 NM_000617 0.0422 1.441 1.441 
AA453163 PCMTD1 NM_052937 0.0040 1.442 1.442 
BF979497 SQLE NM_003129 0.0485 1.442 1.442 
NM_006564 CXCR6 NM_006564 0.0344 1.443 1.443 
NM_024899 CEP76 NM_024899 0.0243 1.445 1.445 
AI659800 C13orf31 NM_153218 0.0127 1.445 1.445 




0.0404 1.446 1.446 
BG393032 LOC641845 /// LOC647087 /// SLC13A4 NM_012450 0.0075 1.446 1.446 
AL049452 LOC144874 
 
0.0485 1.447 1.447 
AV690866 SGK3 NM_001033578 0.0203 1.448 1.448 
AW291187 C1orf71 NM_152609 0.0151 1.448 1.448 
AW611729 CEP27 NM_018097 0.0071 1.448 1.448 
NM_006493 CLN5 NM_006493 0.0309 1.449 1.449 
AI148567 USP32 NM_032582 0.0186 1.449 1.449 
AL534095 GPR177 NM_001002292 0.0309 1.451 1.451 
AI796222 
  
0.0476 1.457 1.457 
BF223300 ENAH NM_001008493 0.0115 1.457 1.457 
BC004162 PPARA NM_001001928 0.0384 1.457 1.457 
AL534095 GPR177 NM_001002292 0.0303 1.458 1.458 
AL569476 ANKRD13A NM_033121 0.0369 1.458 1.458 
AK023732 RBM41 NM_018301 0.0311 1.459 1.459 
NM_018986 SH3TC1 NM_018986 0.0459 1.460 1.460 
AI890529 
  
0.0484 1.461 1.461 
NM_024854 PYROXD1 NM_024854 0.0036 1.461 1.461 
Y16521 CDS2 NM_003818 0.0360 1.462 1.462 
AL037450 RIT1 NM_006912 0.0328 1.463 1.463 
AI539710 ABCC1 NM_004996 0.0068 1.463 1.463 
BC005127 ADFP NM_001122 0.0116 1.464 1.464 
AA514384 PHPT1 NM_014172 0.0295 1.465 1.465 
AB050049 MCCC2 NM_022132 0.0198 1.466 1.466 
AF272036 RRAGD NM_021244 0.0220 1.467 1.467 
NM_031296 RAB33B NM_031296 0.0277 1.469 1.469 
AI675308 
  
0.0138 1.469 1.469 
AA574240 LOC90826 NM_138364 0.0065 1.470 1.470 
BG285017 HDGFRP3 NM_016073 0.0049 1.471 1.471 
AB032261 SCD NM_005063 0.0003 1.471 1.471 
N38751 KLHL22 NM_032775 0.0230 1.471 1.471 
AW084510 LSS NM_001001438 0.0303 1.472 1.472 
AF225425 SEMA6A NM_020796 0.0008 1.472 1.472 
AW444944 
  
0.0465 1.473 1.473 
AI761250 MBOAT2 NM_138799 0.0383 1.473 1.473 
AK098125 RETSAT NM_017750 0.0428 1.473 1.473 
AI246590 IRAK2 NM_001570 0.0249 1.474 1.474 
NM_021183 RAP2C NM_021183 0.0213 1.475 1.475 
AI140985 
  
0.0127 1.475 1.475 
NM_021729 VPS11 NM_021729 0.0460 1.476 1.476 
NM_014959 CARD8 NM_014959 0.0032 1.477 1.477 
NM_004688 NMI NM_004688 0.0430 1.477 1.477 
AF021834 TFPI NM_001032281 0.0292 1.477 1.477 
BC005979 UBE2B NM_003337 0.0261 1.477 1.477 
X57348 SFN NM_006142 0.0012 1.480 1.480 
AA743462 
  
0.0114 1.480 1.480 
NM_016325 ZNF274 NM_016324 0.0353 1.481 1.481 
NM_001673 ASNS NM_001673 0.0238 1.482 1.482 
AB028951 CDC2L6 NM_015076 0.0399 1.485 1.485 
NM_017911 FAM118A NM_001104595 0.0013 1.485 1.485 
BE645154 
  
0.0435 1.486 1.486 
AI684281 P15RS NM_018170 0.0148 1.487 1.487 
AI910842 
  
0.0415 1.487 1.487 
AA219354 HPS3 NM_032383 0.0153 1.488 1.488 
BE962615 SNX3 NM_003795 0.0382 1.489 1.489 
BC004419 VPS24 NM_001005753 0.0246 1.489 1.489 
AI339606 C10orf88 NM_024942 0.0011 1.489 1.489 
155 
BC001282 HMGN4 NM_006353 0.0101 1.490 1.490 
NM_080867 SOCS4 NM_080867 0.0093 1.492 1.492 
NM_014905 GLS NM_014905 0.0092 1.492 1.492 
AW575737 CCDC32 NM_001080791 0.0477 1.493 1.493 
AL049942 ZNF337 NM_015655 0.0331 1.494 1.494 
NM_003692 TMEFF1 NM_003692 0.0303 1.494 1.494 
AI635131 C1orf136 
 
0.0087 1.495 1.495 
AW276572 SBF2 NM_030962 0.0038 1.495 1.495 
AF126181 MAGED2 NM_014599 0.0172 1.497 1.497 
AF088033 VCPIP1 
 
0.0090 1.498 1.498 
BF000047 
  
0.0234 1.498 1.498 
BC000282 TMEM116 NM_138341 0.0032 1.498 1.498 
NM_016061 YPEL5 NM_016061 0.0123 1.499 1.499 
NM_024942 C10orf88 NM_024942 0.0311 1.500 1.500 
AA460299 MLF1IP NM_024629 0.0287 1.500 1.500 
NM_007034 DNAJB4 NM_007034 0.0230 1.501 1.501 
AL564683 CEBPB NM_005194 0.0388 1.502 1.502 
NM_002032 FTH1 NM_002032 0.0157 1.505 1.505 
AI339732 CIAO1 NM_004804 0.0364 1.506 1.506 
AI766279 
  
0.0145 1.506 1.506 
BF115203 MPP5 NM_022474 0.0123 1.506 1.506 
NM_000259 MYO5A NM_000259 0.0120 1.507 1.507 
AA777752 ELOVL6 
 
0.0049 1.511 1.511 
AW993257 
  
0.0210 1.512 1.512 
AI742358 SVIP NM_148893 0.0095 1.513 1.513 
AW136032 
  
0.0160 1.513 1.513 
BG028765 LIN52 NM_001024674 0.0197 1.515 1.515 
AB033024 ZNF490 NM_020714 0.0322 1.518 1.518 
J04755 FTHP1 
 
0.0034 1.519 1.519 
AF016266 TNFRSF10B NM_003842 0.0069 1.519 1.519 
AL122088 LYSMD1 NM_212551 0.0462 1.519 1.519 
AK092760 ZNF564 NM_144976 0.0085 1.520 1.520 
NM_024498 ZNF117 NM_015852 0.0305 1.522 1.522 
AF288392 C1orf26 NM_001105518 0.0397 1.522 1.522 
NM_002946 RPA2 NM_002946 0.0438 1.525 1.525 
AI768723 UBE2B NM_003337 0.0091 1.526 1.526 
AI800025 
  
0.0102 1.526 1.526 
AA648506 FAM149B1 
 
0.0055 1.527 1.527 
AW299507 GGPS1 NM_001037277 0.0188 1.528 1.528 
AI458208 
  
0.0228 1.530 1.530 
AW592266 MYBL1 NM_001080416 0.0076 1.532 1.532 
NM_004294 MTRF1 NM_004294 0.0098 1.533 1.533 
NM_014665 LRRC14 NM_014665 0.0448 1.534 1.534 
NM_018456 EAF2 NM_018456 0.0211 1.534 1.534 
BM980001 APOL6 NM_030641 0.0447 1.534 1.534 
AI625741 UBE2W NM_001001481 0.0382 1.535 1.535 
BC043596 FANCB NM_001018113 0.0081 1.536 1.536 
AW131553 C21orf86 NM_153454 0.0340 1.536 1.536 
BE674103 CROT NM_021151 0.0290 1.536 1.536 
AW612407 PHF20L1 NM_016018 0.0014 1.538 1.538 
NM_001935 DPP4 NM_001935 0.0203 1.538 1.538 
AF098865 SQLE NM_003129 0.0173 1.540 1.540 
BE857704 
  
0.0485 1.540 1.540 
AF070448 CTSL2 NM_001333 0.0348 1.541 1.541 
AI090331 PPP1R7 
 
0.0168 1.542 1.542 
BF593252 ADSSL1 NM_152328 0.0369 1.542 1.542 
AW295547 WIPF2 NM_133264 0.0227 1.542 1.542 
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AV734646 FAM26F NM_001010919 0.0409 1.543 1.543 
AF111804 CAMTA1 NM_015215 0.0143 1.544 1.544 
BE856302 
  
0.0429 1.546 1.546 
AA553722 SPIRE2 NM_032451 0.0061 1.547 1.547 
NM_004260 RECQL4 NM_004260 0.0436 1.549 1.549 
NM_003563 SPOP NM_001007226 0.0430 1.550 1.550 
NM_024610 HSPBAP1 NM_024610 0.0160 1.554 1.554 
AW024656 
  
0.0321 1.556 1.556 
BE620598 LOC201725 NM_001008393 0.0057 1.557 1.557 
AB051515 TANC1 NM_033394 0.0278 1.559 1.559 
AA744682 LOC653256 /// RABL3 NM_173825 0.0077 1.561 1.561 
NM_005044 PRKX NM_005044 0.0465 1.562 1.562 
NM_004431 EPHA2 NM_004431 0.0081 1.564 1.564 
AI765445 BTG3 NM_006806 0.0331 1.564 1.564 
AW070229 IQCK NM_153208 0.0043 1.566 1.566 
NM_005213 CSTA NM_005213 0.0453 1.567 1.567 
NM_000235 LIPA NM_000235 0.0431 1.568 1.568 
AL577866 ZNF615 NM_198480 0.0341 1.569 1.569 
NM_003408 ZFP37 NM_003408 0.0209 1.570 1.570 
NM_014872 ZBTB5 NM_014872 0.0180 1.570 1.570 
AL365375 SIRT6 NM_016539 0.0487 1.572 1.572 
AA460299 MLF1IP NM_024629 0.0401 1.572 1.572 
NM_000950 PRRG1 NM_000950 0.0123 1.574 1.574 
NM_018656 SLC35E3 NM_018656 0.0262 1.575 1.575 
AL133609 CCDC21 NM_022778 0.0262 1.575 1.575 
AW162758 
  
0.0261 1.575 1.575 
BC038383 TMEM80 NM_001042463 0.0348 1.579 1.579 
AI760332 
  
0.0361 1.581 1.581 
AK026921 SLC17A5 NM_012434 0.0206 1.583 1.583 
BE217882 JHDM1D NM_030647 0.0241 1.583 1.583 
AK056852 LOC144571 
 
0.0027 1.584 1.584 
NM_000935 PLOD2 NM_000935 0.0035 1.584 1.584 
BF131886 SESN2 NM_031459 0.0070 1.584 1.584 
AW449169 SPOP NM_001007226 0.0437 1.585 1.585 
AF022375 VEGFA NM_001025366 0.0087 1.587 1.587 
AB041261 PNPLA8 NM_015723 0.0215 1.588 1.588 
AA417878 RIT1 NM_006912 0.0175 1.589 1.589 
AW188087 FLJ30428 /// LOC730024 XM_496597 0.0494 1.589 1.589 
NM_014399 TSPAN13 NM_014399 0.0153 1.591 1.591 
AI761561 HK2 NM_000189 0.0189 1.591 1.591 
X16354 CEACAM1 NM_001024912 0.0232 1.592 1.592 
NM_024810 CXorf45 NM_001039210 0.0456 1.592 1.592 
AI433712 MUT NM_000255 0.0240 1.595 1.595 
AF217519 PNPLA8 NM_015723 0.0320 1.597 1.597 
NM_022168 IFIH1 NM_022168 0.0305 1.597 1.597 
NM_016508 CDKL3 NM_016508 0.0182 1.599 1.599 
NM_004779 CNOT8 NM_004779 0.0372 1.600 1.600 
AI633652 
  
0.0475 1.600 1.600 
AI962276 PCMTD1 NM_052937 0.0245 1.600 1.600 
AA488687 SLC7A11 NM_014331 0.0299 1.601 1.601 
NM_001107 ACYP1 NM_001107 0.0304 1.602 1.602 
NM_014314 DDX58 NM_014314 0.0034 1.602 1.602 
NM_021249 SNX6 NM_021249 0.0374 1.603 1.603 
AI934828 
  
0.0484 1.603 1.603 
AI819043 CREB5 NM_001011666 0.0475 1.604 1.604 
AW263542 
  
0.0078 1.614 1.614 




0.0073 1.616 1.616 
AI335509 
  
0.0439 1.621 1.621 
AF059274 CSPG5 NM_006574 0.0361 1.622 1.622 
U80737 NCOA3 NM_006534 0.0228 1.622 1.622 
BG432350 C20orf108 NM_080821 0.0016 1.622 1.622 
AA166617 WDR37 NM_014023 0.0202 1.623 1.623 
AA992936 
  
0.0089 1.624 1.624 
NM_003447 ZNF165 NM_003447 0.0240 1.626 1.626 
BC005832 KIAA0101 NM_001029989 0.0059 1.626 1.626 
BC004973 STAT6 NM_003153 0.0232 1.627 1.627 
AA812232 TXNIP NM_006472 0.0305 1.627 1.627 
NM_032763 MGC16142 
 
0.0149 1.627 1.627 
AL121936 BTN2A1 NM_007049 0.0500 1.627 1.627 
AI928037 RUNDC3B NM_138290 0.0134 1.630 1.630 
BE562742 
  
0.0027 1.631 1.631 
N48315 PPARA NM_001001928 0.0029 1.631 1.631 
AB040883 KIAA1450 NM_020840 0.0027 1.631 1.631 
NM_022840 METTL4 NM_022840 0.0150 1.632 1.632 
AI263909 RHOB NM_004040 0.0401 1.633 1.633 
AL080081 DNAJB9 NM_012328 0.0060 1.633 1.633 
AL031714 UBE2I NM_003345 0.0257 1.633 1.633 
AB047006 PCGF6 NM_001011663 0.0161 1.637 1.637 
NM_016217 HECA NM_016217 0.0380 1.638 1.638 
AW242220 EIF4E2 NM_004846 0.0370 1.639 1.639 
AW515645 FRMD4A NM_018027 0.0088 1.639 1.639 
NM_018665 DDX43 NM_018665 0.0413 1.640 1.640 
NM_017917 PPP2R3C NM_017917 0.0091 1.643 1.643 
D80480 TMTC4 NM_001079669 0.0139 1.645 1.645 
AI979261 LOC202451 XM_928403 0.0069 1.645 1.645 
AL136944 SLC40A1 NM_014585 0.0288 1.647 1.647 
NM_018336 
  
0.0128 1.648 1.648 
BE439987 GAS7 NM_003644 0.0239 1.649 1.649 
AA160474 C20orf111 NM_016470 0.0140 1.650 1.650 
NM_014278 HSPA4L NM_014278 0.0364 1.650 1.650 
BC001188 TFRC NM_003234 0.0041 1.653 1.653 
AF115515 C3orf33 NM_173657 0.0344 1.654 1.654 
N51479 ATXN3 NM_001024631 0.0340 1.655 1.655 
AB051511 SELI NM_033505 0.0058 1.656 1.656 
AU144102 SNRPE NM_003094 0.0337 1.657 1.657 
AB037741 HACE1 NM_020771 0.0013 1.658 1.658 
AI335267 
  
0.0216 1.658 1.658 
AW511135 NUDT4 NM_019094 0.0245 1.658 1.658 
BE880245 GNS NM_002076 0.0286 1.659 1.659 
AF060922 BNIP3L NM_004331 0.0240 1.660 1.660 
AI652845 LRRC51 NM_145309 0.0389 1.667 1.667 
BE855799 KIAA1211 NM_020722 0.0292 1.668 1.668 
AI978623 OBSL1 NM_015311 0.0433 1.669 1.669 
AI797063 KIAA1377 NM_020802 0.0051 1.671 1.671 
M80536 DPP4 NM_001935 0.0138 1.674 1.674 
BF970855 MED12L NM_053002 0.0389 1.676 1.676 
AA764787 METTL4 NM_022840 0.0197 1.676 1.676 
AV727336 LOC401152 NM_001001701 0.0296 1.678 1.678 
AF126163 HHLA3 NM_001031693 0.0068 1.678 1.678 
BC000586 SCLY NM_016510 0.0336 1.678 1.678 
NM_014762 DHCR24 NM_014762 0.0345 1.679 1.679 
AW080025 
  
0.0221 1.679 1.679 
AU146105 ATXN3 NM_001024631 0.0234 1.679 1.679 
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AA573449 MTRF1 NM_004294 0.0230 1.682 1.682 
BG028320 
  
0.0019 1.682 1.682 
D83768 UBXD6 NM_005671 0.0419 1.682 1.682 
AV704962 SC4MOL NM_001017369 0.0392 1.684 1.684 
NM_006536 CLCA2 NM_006536 0.0175 1.685 1.685 
BC001305 ELOVL6 NM_024090 0.0024 1.686 1.686 
AA708470 
  
0.0408 1.687 1.687 
BC005247 IDI1 NM_004508 0.0015 1.688 1.688 
BC034316 
  
0.0493 1.693 1.693 
AW298070 
  
0.0297 1.695 1.695 
NM_002130 HMGCS1 NM_001098272 0.0067 1.696 1.696 
BC034248 NBR2 NM_005821 0.0048 1.699 1.699 
NM_173503 EFCAB3 NM_173503 0.0493 1.699 1.699 
AL136597 KLHL7 NM_001031710 0.0243 1.700 1.700 
AA779795 TEF NM_003216 0.0235 1.702 1.702 
BE645222 ZSWIM7 NM_001042697 0.0463 1.702 1.702 
NM_005896 IDH1 NM_005896 0.0263 1.702 1.702 
AA083483 FTH1 NM_002032 0.0124 1.702 1.702 
NM_005044 PRKX /// PRKY NM_002760 0.0147 1.703 1.703 
NM_022157 RRAGC NM_022157 0.0063 1.704 1.704 
AI972146 LOC401577 XM_379694 0.0440 1.705 1.705 
NM_005346 HSPA1B NM_005346 0.0397 1.705 1.705 
NM_024589 ROGDI NM_024589 0.0443 1.708 1.708 
L14611 RORA NM_002943 0.0062 1.709 1.709 
AA628398 STARD4 NM_139164 0.0394 1.709 1.709 
AF112204 ATP6V1H NM_015941 0.0223 1.712 1.712 
BC001727 ANKRD10 NM_017664 0.0275 1.713 1.713 
W93847 MUC15 NM_145650 0.0454 1.713 1.713 
NM_022912 REEP1 NM_022912 0.0006 1.716 1.716 
NM_003620 PPM1D NM_003620 0.0300 1.716 1.716 
AA886870 ANKRD37 NM_181726 0.0444 1.718 1.718 
AL359652 LOC92497 XM_931850 0.0187 1.718 1.718 
NM_144707 PROM2 NM_144707 0.0109 1.719 1.719 
CA313430 
  
0.0239 1.723 1.723 
Y13786 ADAM19 NM_023038 0.0246 1.723 1.723 
AA284532 C9orf19 NM_022343 0.0268 1.723 1.723 
AI439556 TXNIP NM_006472 0.0024 1.725 1.725 
AV686514 EMP2 NM_001424 0.0176 1.726 1.726 
AW138827 TAF5 NM_006951 0.0122 1.726 1.726 
NM_006350 FST NM_006350 0.0146 1.727 1.727 
NM_024094 DCC1 NM_024094 0.0079 1.728 1.728 
AI863954 
  
0.0142 1.730 1.730 
AF216962 CNNM2 NM_017649 0.0478 1.733 1.733 
BE550599 CACNA1D NM_000720 0.0163 1.735 1.735 
AI305170 SLC25A16 NM_152707 0.0394 1.740 1.740 
AB037791 KIAA1370 NM_019600 0.0008 1.741 1.741 
AI923944 
  
0.0119 1.741 1.741 
AW241813 H2AFJ NM_018267 0.0220 1.744 1.744 
AA770596 MARCKS NM_002356 0.0297 1.746 1.746 
AI273692 
  
0.0378 1.746 1.746 
AI671172 TMEM68 NM_152417 0.0270 1.746 1.746 
NM_003864 SAP30 NM_003864 0.0079 1.747 1.747 
AF116709 GAPDH 
 
0.0405 1.749 1.749 
AI932618 
  
0.0490 1.752 1.752 
AL049215 DST NM_001723 0.0486 1.752 1.752 
AI810767 
  
0.0320 1.754 1.754 
AI361034 
  




0.0178 1.755 1.755 
AI122770 FBXL20 NM_032875 0.0255 1.756 1.756 
NM_001458 FLNC NM_001458 0.0155 1.763 1.763 
AL524643 TMEM198 NM_001005209 0.0180 1.763 1.763 
AK002152 STAU2 NM_014393 0.0053 1.769 1.769 
NM_024578 OCEL1 NM_024578 0.0011 1.773 1.773 
AI925316 
  
0.0327 1.774 1.774 
NM_017729 EPS8L1 NM_017729 0.0066 1.779 1.779 
AI632214 
  
0.0190 1.779 1.779 
NM_017818 WDR8 NM_017818 0.0492 1.780 1.780 
AL138431 MTHFR NM_005957 0.0210 1.780 1.780 
AK023754 HES2 NM_019089 0.0414 1.784 1.784 
AU145356 AGPAT5 NM_018361 0.0261 1.785 1.785 
AI146450 NANP NM_152667 0.0083 1.792 1.792 
AI817041 CXCR7 NM_020311 0.0477 1.797 1.797 
BC001282 HMGN4 NM_006353 0.0042 1.800 1.800 
AI743092 
  
0.0068 1.801 1.801 
AI141670 FAM131A NM_144635 0.0022 1.803 1.803 
AI810669 
  
0.0191 1.805 1.805 
NM_018370 DRAM NM_018370 0.0067 1.809 1.809 
M68956 MARCKS NM_002356 0.0457 1.814 1.814 
NM_019081 KIAA0430 NM_014647 0.0222 1.815 1.815 
AA649070 DKFZp667E0512 
 
0.0266 1.820 1.820 
NM_004403 DFNA5 NM_004403 0.0005 1.822 1.822 
AA551090 AP1S2 NM_003916 0.0004 1.825 1.825 
AL136820 FAM135A NM_001105531 0.0089 1.826 1.826 
AB040875 SLC7A11 NM_014331 0.0195 1.827 1.827 
AI028528 
  
0.0485 1.828 1.828 
AF251050 TIGD7 NM_033208 0.0259 1.829 1.829 
BF516341 
  
0.0002 1.833 1.833 
AA702248 UCA1 
 
0.0285 1.837 1.837 
NM_014454 SESN1 NM_014454 0.0196 1.841 1.841 
NM_015385 SORBS1 NM_001034954 0.0446 1.842 1.842 
NM_004772 C5orf13 NM_004772 0.0345 1.845 1.845 
NM_018267 H2AFJ NM_018267 0.0263 1.846 1.846 
BC016828 ASAH1 NM_004315 0.0222 1.848 1.848 
BC043594 TCTE3 NM_174910 0.0111 1.850 1.850 
AI991328 CHKA NM_001277 0.0023 1.851 1.851 
BC005202 NIPSNAP3B NM_018376 0.0488 1.852 1.852 
AA573901 CCDC57 /// LOC732476 NM_198082 0.0211 1.854 1.854 
NM_015515 KRT23 NM_015515 0.0106 1.855 1.855 
AL132665 BNIP3L NM_004331 0.0221 1.859 1.859 
BC003073 ARHGEF10L NM_001011722 0.0013 1.859 1.859 
AV703731 
  
0.0045 1.864 1.864 
AV648364 CBX7 NM_175709 0.0482 1.872 1.872 
AL558164 TMEM143 NM_018273 0.0417 1.872 1.872 
AI803010 
  
0.0062 1.875 1.875 
AI014470 LOC728485 XM_001130518 0.0015 1.876 1.876 
NM_005689 ABCB6 NM_005689 0.0020 1.876 1.876 
NM_024090 ELOVL6 NM_024090 0.0218 1.877 1.877 
AI761748 NCOA3 NM_006534 0.0002 1.881 1.881 
BE858194 
  
0.0198 1.883 1.883 
AI538394 NSUN7 NM_024677 0.0067 1.889 1.889 
NM_014155 ZBTB44 NM_014155 0.0420 1.890 1.890 
NM_004508 IDI1 NM_004508 0.0061 1.891 1.891 
AK001947 RP5-1022P6.2 NM_019593 0.0041 1.894 1.894 
AF019214 HBP1 NM_012257 0.0039 1.906 1.906 
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NM_000389 CDKN1A NM_000389 0.0138 1.906 1.906 
H27948 MGC33894 NM_152914 0.0040 1.907 1.907 
BF569051 H19 NR_002196 0.0146 1.911 1.911 
NM_004849 ATG5 NM_004849 0.0373 1.913 1.913 
AW241910 COL22A1 NM_152888 0.0304 1.915 1.915 
NM_006763 BTG2 NM_006763 0.0101 1.917 1.917 
AA401492 GNAS NM_000516 0.0268 1.917 1.917 
NM_024702 ZNF750 NM_024702 0.0135 1.921 1.921 
AA776810 ZNF610 NM_173530 0.0027 1.926 1.926 
AI758317 
  
0.0149 1.926 1.926 
AI817264 SP6 NM_199262 0.0056 1.931 1.931 
AI242583 MYCT1 NM_025107 0.0164 1.931 1.931 
BC039154 C16orf79 NM_182563 0.0281 1.932 1.932 
AI817388 GNPDA2 NM_138335 0.0288 1.935 1.935 
NM_018593 SLC16A10 NM_018593 0.0195 1.935 1.935 
AF147782 ETV7 NM_016135 0.0035 1.937 1.937 
BC024748 
  
0.0258 1.937 1.937 
AL133001 SULF2 NM_018837 0.0050 1.938 1.938 
BG031897 AMN1 NM_207337 0.0221 1.938 1.938 
AI553933 SLC30A1 NM_021194 0.0173 1.940 1.940 
BC003177 CALCOCO1 NM_020898 0.0442 1.947 1.947 
AI738556 TNFRSF10D NM_003840 0.0050 1.947 1.947 
AW006935 ATP10B NM_025153 0.0351 1.948 1.948 
AI188653 MXD1 NM_002357 0.0066 1.952 1.952 
H63435 C11orf54 NM_014039 0.0094 1.959 1.959 
AW235548 MYO5A NM_000259 0.0073 1.963 1.963 
NM_003234 TFRC NM_003234 0.0001 1.964 1.964 
AA502768 C5orf34 NM_198566 0.0284 1.968 1.968 
BE540552 FADS1 NM_013402 0.0037 1.975 1.975 
NM_018050 MANSC1 NM_018050 0.0125 1.979 1.979 
NM_003151 STAT4 NM_003151 0.0167 1.986 1.986 
AA669336 COCH NM_004086 0.0074 1.989 1.989 
NM_014398 LAMP3 NM_014398 0.0242 2.002 2.002 
BF001786 SCML1 NM_001037535 0.0306 2.004 2.004 
BF438173 FST NM_006350 0.0180 2.009 2.009 
AA811371 
  
0.0441 2.014 2.014 
NM_025001 MTHFD2L NM_001004346 0.0021 2.016 2.016 
BC040700 
  
0.0292 2.020 2.020 
AL042588 PEG3 NM_006210 0.0207 2.022 2.022 
AI440495 LOC284702 
 
0.0492 2.023 2.023 
AI934569 ASAH1 NM_004315 0.0110 2.025 2.025 
BE513006 PROM2 NM_144707 0.0115 2.026 2.026 
M76742 CEACAM1 NM_001024912 0.0088 2.026 2.026 
AL571684 LOC401152 NM_001001701 0.0158 2.029 2.029 
AK096683 ZNF33B NM_006955 0.0035 2.036 2.036 
AL136680 GBP3 NM_018284 0.0265 2.040 2.040 
AA135522 GPD1L NM_015141 0.0063 2.045 2.045 
BF970044 
  
0.0035 2.047 2.047 
U47674 ASAH1 NM_004315 0.0424 2.051 2.051 
BG165833 FADS1 NM_013402 0.0002 2.052 2.052 
AA088177 TMEM200A NM_052913 0.0111 2.052 2.052 
BF063271 GALNT3 NM_004482 0.0028 2.058 2.058 
AI075407 IFIT3 NM_001031683 0.0080 2.060 2.060 
AI004453 TRIML1 NM_178556 0.0385 2.062 2.062 
NM_024519 FAM65A NM_024519 0.0264 2.062 2.062 
AK095151 UBR5 NM_015902 0.0068 2.065 2.065 
N49935 RASSF4 NM_032023 0.0143 2.067 2.067 
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AF070673 SNN NM_003498 0.0088 2.068 2.068 
AI432195 
  
0.0059 2.069 2.069 
AK026736 ITGB6 
 
0.0014 2.072 2.072 
AF131801 SPG3A NM_015915 0.0057 2.077 2.077 
AB051846 RAP1A NM_001010935 0.0397 2.080 2.080 
NM_016323 HERC5 NM_016323 0.0007 2.083 2.083 
AW237462 MAP7D2 NM_152780 0.0325 2.089 2.089 
N21320 SLC12A6 NM_001042494 0.0293 2.089 2.089 
N74607 AQP3 NM_004925 0.0333 2.089 2.089 
AB037810 SIPA1L2 NM_020808 0.0017 2.094 2.094 
AI650582 FAM118A NM_001104595 0.0204 2.105 2.105 
AA946876 
  
0.0363 2.109 2.109 
NM_003823 RTEL1 /// TNFRSF6B NM_003823 0.0476 2.109 2.109 
BC032952 MEX3C NM_016626 0.0319 2.111 2.111 
AL574184 HPGD NM_000860 0.0446 2.112 2.112 
AF280094 SP110 NM_004509 0.0318 2.113 2.113 
BC004907 EPS8L1 NM_017729 0.0199 2.115 2.115 
AA166895 NHLH2 NM_001111061 0.0005 2.126 2.126 
AB037797 ARRDC3 NM_020801 0.0161 2.129 2.129 
AW511227 MIB2 NM_080875 0.0425 2.131 2.131 
S69232 ETFDH NM_004453 0.0349 2.134 2.134 
N22849 
  
0.0074 2.140 2.140 
AW611550 MFSD8 NM_152778 0.0030 2.145 2.145 
AI884906 RNF182 NM_152737 0.0041 2.146 2.146 
AI743534 ARHGAP24 NM_001025616 0.0074 2.154 2.154 
AL117607 LOC203274 
 
0.0165 2.155 2.155 
NM_001277 CHKA /// LOC650122 NM_001277 0.0192 2.157 2.157 
BC020812 LOC389072 NM_001080475 0.0197 2.160 2.160 
NM_005410 SEPP1 NM_001085486 0.0145 2.163 2.163 
U46006 CSRP2 NM_001321 0.0215 2.170 2.170 
AL120021 KLHL24 NM_017644 0.0190 2.175 2.175 
BF512388 C10orf58 NM_032333 0.0004 2.176 2.176 
NM_024581 C6orf60 NM_001100411 0.0016 2.193 2.193 
NM_017786 GOLSYN NM_001099743 0.0069 2.193 2.193 
NM_013409 FST NM_006350 0.0341 2.195 2.195 
R12665 PATL2 XR_015470 0.0163 2.197 2.197 
AL109698 
  
0.0190 2.204 2.204 
AW402635 POLR2J2 /// POLR2J3 /// POLR2J4 NM_001015884 0.0271 2.206 2.206 
U77914 JAG1 NM_000214 0.0077 2.207 2.207 
AL512760 FADS1 NM_013402 0.0121 2.214 2.214 
AW071793 MXD1 NM_002357 0.0104 2.220 2.220 
NM_004509 SP110 NM_004509 0.0068 2.223 2.223 
BC030754 
  
0.0255 2.228 2.228 
AI435399 SLFN5 NM_144975 0.0187 2.229 2.229 
AW204518 ZNF341 NM_032819 0.0229 2.237 2.237 
NM_020632 ATP6V0A4 NM_020632 0.0251 2.255 2.255 
W73230 C7orf41 NM_152793 0.0143 2.262 2.262 
AI991103 C5orf39 NM_001014279 0.0081 2.279 2.279 
AK022852 SIPA1L2 NM_020808 0.0001 2.280 2.280 
AA860341 MORN3 NM_173855 0.0308 2.284 2.284 
BF109592 C11orf54 NM_014039 0.0245 2.286 2.286 
BC006472 DCAKD NM_024819 0.0351 2.293 2.293 
NM_003813 ADAM21 NM_003813 0.0198 2.305 2.305 
AU157271 LOC731450 XM_001133142 0.0057 2.315 2.315 
U73936 JAG1 NM_000214 0.0101 2.319 2.319 
AJ247087 MLCK NM_182493 0.0061 2.321 2.321 
BC005871 C10orf58 NM_032333 0.0113 2.327 2.327 
162 
AW301218 THAP9 NM_024672 0.0067 2.336 2.336 
AI822125 DUSP27 NM_001080426 0.0013 2.343 2.343 
NM_001321 CSRP2 NM_001321 0.0127 2.347 2.347 
AA565499 NLRP7 NM_139176 0.0151 2.347 2.347 
AW162015 ZNF143 NM_003442 0.0204 2.352 2.352 
AW134535 CCNG2 NM_004354 0.0120 2.357 2.357 
AA543084 
  
0.0263 2.357 2.357 
AL575306 H19 NR_002196 0.0296 2.400 2.400 
N47725 IFIT5 NM_012420 0.0407 2.429 2.429 
NM_006536 CLCA2 NM_006536 0.0276 2.450 2.450 
AA400206 FAM65A NM_024519 0.0033 2.454 2.454 
AA131041 IFIT2 NM_001547 0.0418 2.456 2.456 
AW293316 
  
0.0081 2.469 2.469 
AB046817 SYTL2 NM_032379 0.0114 2.469 2.469 
AV716964 ATF7IP2 NM_024997 0.0262 2.484 2.484 
NM_002356 MARCKS NM_002356 0.0089 2.492 2.492 
AA485440 SPHK2 NM_020126 0.0334 2.506 2.506 
AI827820 MBD2 NM_003927 0.0034 2.525 2.525 
W57613 
  
0.0318 2.532 2.532 
Z98884 CAMTA1 NM_015215 0.0026 2.542 2.542 
AI890761 TMEM68 NM_152417 0.0012 2.552 2.552 
NM_052889 CASP1 /// COP1 NM_001017534 0.0360 2.580 2.580 
AI686890 
  
0.0042 2.604 2.604 
AW341649 TP53INP1 NM_033285 0.0189 2.610 2.610 
AB051846 RAP1A NM_001010935 0.0383 2.616 2.616 
BE552414 TMEM52 NM_178545 0.0152 2.633 2.633 
AI826268 SLC25A29 NM_001039355 0.0037 2.636 2.636 
NM_006472 TXNIP NM_006472 0.0087 2.636 2.636 
AA911561 
  
0.0292 2.649 2.649 
BF002104 GDAP1 NM_001040875 0.0166 2.669 2.669 
AI928764 LOC154761 
 
0.0161 2.687 2.687 
NM_018095 KBTBD4 /// PTPMT1 NM_016506 0.0003 2.698 2.698 
BC005286 EPM2A NM_001018041 0.0158 2.723 2.723 
NM_004354 CCNG2 NM_004354 0.0359 2.762 2.762 
AI572938 
  
0.0184 2.792 2.792 
NM_004780 TCEAL1 NM_001006639 0.0229 2.810 2.810 
AI827820 MBD2 NM_003927 0.0066 2.824 2.824 
AW474434 TNFSF10 NM_003810 0.0070 2.838 2.838 
NM_024786 ZDHHC11 NM_024786 0.0054 2.851 2.851 
D63807 LSS NM_001001438 0.0037 2.891 2.891 
AI348159 REEP6 NM_138393 0.0035 2.897 2.897 
AI446414 KITLG NM_000899 0.0126 2.929 2.929 
AL117598 
  
0.0244 2.957 2.957 
BE268538 DENND4A NM_005848 0.0268 2.987 2.987 
NM_006746 SCML1 NM_001037535 0.0211 3.009 3.009 
NM_003810 TNFSF10 NM_003810 0.0005 3.048 3.048 
AI709406 MARCKS NM_002356 0.0011 3.101 3.101 
BF114815 MLCK NM_182493 0.0008 3.112 3.112 
NM_025155 PAAF1 NM_025155 0.0481 3.244 3.244 
L49506 CCNG2 NM_004354 0.0033 3.344 3.344 
AV720803 
  
0.0125 3.346 3.346 
NM_005670 EPM2A NM_001018041 0.0017 3.372 3.372 
BC035640 AP3B2 NM_004644 0.0010 3.401 3.401 
AU156189 
  
0.0037 3.580 3.580 
AF003934 GDF15 NM_004864 0.0073 3.594 3.594 
NM_024626 VTCN1 NM_024626 0.0000 3.603 3.603 
AI286239 LOC440731 XM_933693 0.0000 3.699 3.699 
163 
NM_001717 BNC1 NM_001717 0.0480 3.836 3.836 
NM_024703 SMPD3 NM_018667 0.0133 4.093 4.093 
AI376549 MLCK NM_182493 0.0090 4.153 4.153 
AF007162 CRYAB NM_001885 0.0043 4.560 4.560 
AF267859 ZDHHC11 NM_024786 0.0242 4.590 4.590 






Supplemental Table 2. Primers used for qPCR analysis.  
Table shows amplicon size and annealing temperature used for each gene in 
real-time quantitative RT-PCR. 
  Gene 
Accession 











CCDC88A NM_001135597 CTC TGC CAG AAT GTA CCG AGA ATT TAT CAG AAC GAG CAC GAG T 221 57 
CCND1 NM_053056 ACG AAG GTC TGC GCG TGT T  CCG CTG GCC ATG AAC TAC CT  320 58 
CCNG2 NM_004354 GAG CTG CCA ACG ATA CCT G TCT AAG ATG GAA AGC ACA GTG 172 58 
CDK6 NM_001145306 CGA GTA GTG CAT CGC GAT CTA A GGT CTT TGC CTA GTT CAT CGA T 407 58 
CDKN1A NM_000389 CGA AGT CAG TTC CTT GTG GAG CAT GGG TTC TGA CGG ACA T 111 57 
CRYAB NM_001885 CAC CCA GCT GGT TTG ACA CT TGA CAG AGA ACC TGT CCT TCT  63 57 
GDF15 NM_004864 CCG GAT ACT CAC GCC AGA  AGA GAT ACG CAG GTG CAG  63 58 
IGF1R NM_000875 CTC AAA AGT TAT CTC CGG TCT TTT GAC TGT GAA ATC TTC GGC TA  192 57 
IGFBP3 NM_000598 CAT CAT CAA GAA AGG GCA T  GCT GCC CAT ACT TAT CCA C  293 57 
JAG1 NM_000214 CAA ACC TTG TGT AAA CGC CAA ACC ATT AAC CAA ATC CCG ACA  157 58 
LIFR NM_001127671 CCC CAA CAT GAC TTG CGA CT CTG TAT AGG CTC GCA AGA CCA  497 58 
MCAM NM_006500    TCA AGG AGA GGA AGG TGT GG  ACT CGC TGT GGA TCT TGG TC  136 58 
MXD1 NM_001202513 GAC AGA AAA GCC GTT CAC C CTC GTC AGA GTC GCT CAC A 228 57 
MYC NM_002467  CCT ACC CTC TCA ACG ACA GC  CTC TGA CCT TTT GCC AGG AG  247 58 
OVOL2 NM_021220 CAC CTC AAG TGC CAC AAC CAG  TGT AGC CGC AAT CCT CGC AGA  256 58 
PTEN NM_000314 CAC CGC CAA ATT TAA TTG CAG CCC CGA TGT AAT AAA TAT GCA CA 198 57 
PXN NM_001080855 CTG AGC CTT CAC CCA CCG TA CCG CTT AGG CTT CTC TTT CGT 233 58 
RPS15 NM_001018 TTC CGC AAG TTC ACC TAC C CGG GCC GGC CAT GCT TTA CG 361 60 
SOCS2 NM_003877 TCT CTG CCA CCA TTT CGG ACA GTC CAA TCT GAA TTT TCC GTC T 452 58 
TFPI2 NM_006528  TCT GCC AAT GTG ACT CGC TA  ATT CTA CTG GCA AAG CGA AG  179 58 
TNFSF10 NM_001190942 TAC GTG TAC TTT ACC AAC GAG GAG TTG CCA CTT GAC TTG C  150 60 






GAPDH NM_001190390             TAC TGG CAA AGT GGA CAT CGT T TTG ATG ACG AGC TTC CCG TTC 138 58 
GDF15 NM_001206298 CCG GCA GCA CCA CAT CGC TCT TCC CAC GAG CTC CAC GCC TTC 398 60 
 
 
 
 
 
